Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors

Description

PRIORITY TO RELATED APPLICATIONS

This application claims the benefit of European Application No. 05111560.8, filed Dec. 1, 2005, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The invention is concerned with novel substituted piperidine derivatives of the formula (I)
embedded image

and pharmaceutically acceptable salts and esters thereof.

Further, the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.

All documents cited or relied upon below are expressly incorporated herein by reference.

BACKGROUND

High levels of free fatty acids (FFA) lead to an increase of liver mitochondrial β-oxidation, which is crucial to drive efficient gluconeogenesis. The mitochondrial oxidation of long-chain FFA requires the intervention of two membrane-bound carnitine-dependent palmitoyltransferases (CPTs). CPT1, the outer mitochondrial membrane enzyme, catalyzes the formation of long-chain acylcarnitines. Liver (L-CPT1) and muscle (M-CPT1) CPT1 isoforms are encoded by two different genes and inhibited by malonyl-CoA. The N-ter domain of L-CPT1 confers its lower sensitivity to malonyl CoA. CPT2, the inner mitochondrial membrane enzyme, reconverts long-chain acylcarnitines into long-chain acyl CoA esters. Long-chain acyl-CoAs are then β-oxidized to acetyl-CoA, which activates the pyruvate carboxylase and gluconeogenesis. According to the mechanism of action described above, pharmaceutically active substances which inhibit L-CPT1 reduce liver β-oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia.

SUMMARY OF THE INVENTION

In an embodiment of the present invention, provided is a compound of formula (I):
embedded image

wherein:

X is C(R⁸R⁹), NR¹⁰, O, S, S(O), S(O₂);
R¹is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and CN;
R²is hydrogen or lower-alkyl;
R³and R⁴independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R³and R⁴together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁵and R⁶independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R⁵and R⁶together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁷is an oxadiazolyl or triazolyl, which oxadiazolyl or triazolyl is substituted with R¹¹and optionally substituted with R¹²;
R⁸and R⁹independently from each other are hydrogen, halogen, hydroxy, lower-alkyl, lower-alkoxy; or
R⁸and R⁹are bound together and —R⁸—R⁹— is —(CH₂)_2-7— to form a ring together with the carbon atom to which they are attached;
R¹⁰is hydrogen, lower-alkyl, lower-alkyl-carbonyl or lower-alkyl-sulfonyl;
R¹¹is aryl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl, imidazopyridinyl, triazolepyridinyl, tetrazolepyridinyl, benzimidazolyl, 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy, B(OH)₂, carboxy-lower-alkoxy, carbamoyl-lower-alkoxy, cyano, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O₂)R¹³, C(O)R¹⁴, NO₂, NR¹⁵R¹⁶, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, phenyl-lower-alkoxy, [1,3,4]oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, which imidazolyl is optionally substituted with lower-alkyl, and which phenyl-lower-alkoxy is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl, and which pyrazolyl is optionally substituted with lower-alkyl, and which isoxazolyl is optionally substituted with lower-alkyl;
R¹²is hydrogen or lower-alkyl;
R¹³is lower-alkyl, NR¹⁷R¹⁸or fluoro-lower-alkyl;
R¹⁴is OH, NR¹⁹R²⁰, lower-alkoxy, lower-alkenyl-oxy or lower-alkyl;
R¹⁵and R¹⁶independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO₂, lower-alkenyl-oxy-carbonyl, NH₂-carbonyl, lower-alkyl-NH-carbonyl, (lower-alkyl)₂N-carbonyl or phenyl-lower-alkyl, which phenyl-lower-alkyl is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl; or
NR¹⁵R¹⁶is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl, pyrrolidinyl, 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl;
R¹⁷and R¹⁸independently from each other are hydrogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or
NR¹⁷R¹⁸is morpholinyl;
R¹⁹and R²⁰independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, (lower-alkyl)₂N-lower-alkyl, pyridinyl-lower-alkyl or cyano-lower-alkyl; or
NR¹⁹R²⁰is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl, which heterocyclyl is optionally substituted with hydroxy, lower-alkyl-S(O₂), lower-alkyl, lower-alkyl-carbonyl, carboxy, carbamoyl, lower-alkoxy-carbonyl, cyano, phenyl, pyridinyl or lower-alkoxy;

and pharmaceutically acceptable salts and esters thereof.

In another embodiment of the present invention, provided is a process for the manufacture of a compound according to formula (I), comprising the step of reacting a compound of formula (II)
embedded image

with a compound of formula (III)

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and X are as defined in the compound of formula (I) and L is halogen.

In a further embodiment of the present invention, provided is a pharmaceutical composition, comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier and/or adjuvant.

In a still another embodiment of the present invention, provided is a method for the treatment of diseases which are modulated by L-CPT1 inhibitors, comprising the step of administering a therapeutically effective amount of a compound according to formula (I) to a human being or animal in need thereof.

DETAILED DESCRIPTION

The present invention relates to novel compounds which inhibit liver carnitine palmitoyl transferase 1 (L-CPT1) activity. The compounds of the present invention can be used as pharmaceutically active agents which are useful in the prevention and/or treatment of diseases which are modulated by L-CPT1 inhibitors, particularly diseases which are related to hyperglycemia and/or glucose tolerance disorders. Such diseases include e.g. diabetes and associated pathologies, non insulin dependent diabetes mellitus (also referred to as diabetes type II), obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

In this specification the term “lower” is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).

The term “halogen” refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.

The term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.

The term “lower-alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like. The term “hydroxy-lower-alkyl” refers to a lower-alkyl group which is substituted with hydroxy.

The term “fluoro-lower-alkyl” refers to lower-alkyl groups which are mono- or multiply substituted with fluorine. Examples of fluoro-lower-alkyl groups are e.g. CFH₂, CF₂H, CF₃, CF₃CH₂, CF₃(CH₂)₂, (CF₃)₂CH and CF₂H—CF₂.

The term “alkoxy” refers to the group R′—O—, wherein R′ is an alkyl. The term “lower-alkoxy” refers to the group R′—O—, wherein R′ is a lower-alkyl.

The term “fluoro-lower-alkoxy” refers to the group R″—O—, wherein R″ is fluoro-lower-alkyl.

Examples of fluoro-lower-alkoxy groups are e.g. CFH₂—O, CF₂H—O, CF₃—O, CF₃CH₂—O, CF₃(CH₂)₂—O, (CF₃)₂CH—O, and CF₂H—CF₂—O.

The term “alkenyl”, alone or in combination with other groups, stands for a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms. The term “lower-alkenyl” refers to a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.

The term “alkinyl”, alone or in combination with other groups, stands for a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 20, preferably up to 16 carbon atoms. The term “lower-alkinyl” refers to a straight-chain or branched hydrocarbon residue comprising a triple bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propinyl.

The term “alkylene” refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower-alkylene groups as described below also are preferred alkylene groups.

The term “lower-alkylene” refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.

The term “cycloalkyl” refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

The term “aryl”, alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 5, preferably 1 to 3, substituents independently selected from the group consisting of halogen, hydroxy, amino, NO₂, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy, carboxy, carboxy-lower-alkyl, lower-alkoxy-carbonyl, lower-alkoxy-carbonyl-lower-alkyl, lower-alkylcarbonyl, lower-alkylcarbonyloxy, lower-alkylcarbonyl-NH, H₂NC(O), (H,lower-alkyl)NC(O), (lower-alkyl)₂NC(O), H₂NC(O)-lower-alkyl, (H,lower-alkyl)NC(O)-lower-alkyl, (lower-alkyl)₂NC(O)-lower-alkyl, fluoro-lower-alkyl, fluoro-lower-alkoxy, H₂N-lower-alkyl, (H,lower-alkyl)N-lower-alkyl, (lower-alkyl)₂N-lower-alkyl, lower-alkyl-SO₂, lower-alkyl-SO₂O, lower-alkyl-SO₂—NH, lower-alkyl-SO₂—N(lower-alkyl), H₂NSO₂, (H,lower-alkyl)NSO₂, (lower-alkyl)₂NSO₂, dioxo-lower-alkylene (forming e.g. a benzodioxyl group), cyano, heteroaryl, cycloalkyl, lower-alkoxy-lower-alkyl, lower-alkenyl, lower-alkinyl, phenyl and phenyloxy. Of the above mentioned substituents, halogen, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and fluoro-lower-alkoxy are preferred. Furthermore and more preferably, aryl groups can be substituted as described in the description below.

The term “heteroaryl” refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzimidazolyl, indolyl, indazolyl, benzoisothiazolyl, benzoxazolyl, benzoisoxazolyl, pyridinyl-2-one, oxadiazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl, imidazopyridinyl, triazolepyridinyl and tetrazolepyridinyl. Other possible heteroaryl are 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one. A heteroaryl group may optionally have a substitution pattern as described earlier in connection with the term “aryl”. Furthermore, heteroaryl groups can preferably be substituted as described in the description below.

The term “heterocyclyl” refers to 5 to 6 membered monocyclic ring or 8 to 14, preferably 8 to 10, membered bi- or tricyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl and pyrrolidinyl. Other possible heterocyclyl are 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one, 1,3-dihydro-imidazol-2-one, thiazolidinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl. A heterocyclyl may optionally have a substitution pattern as described earlier in connection with the term “aryl”. Furthermore, heterocyclyl groups can preferably be substituted as described in the description below.

Compounds of formula (I) wherein an amino group is present can form pharmaceutically acceptable acid addition salts. Examples of such pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. The term “pharmaceutically acceptable salts” refers to such salts. Compounds of formula (I) in which a COOH group is present can further form salts with bases. Examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na—, K—, Ca— and Trimethylammonium salt. The term “pharmaceutically acceptable salts” also refers to such salts. Salts obtained by the addition of an acid are preferred.

The term “pharmaceutically acceptable esters” embraces derivatives of the compounds of formula (I), in which a carboxy group has been converted to an ester. Lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, amino-lower-alkyl, mono- or di-lower-alkyl-amino-lower-alkyl, morpholino-lower-alkyl, pyrrolidino-lower-alkyl, piperidino-lower-alkyl, piperazino-lower-alkyl, lower-alkyl-piperazino-lower-alkyl and aralkyl esters are examples of suitable esters. The methyl, ethyl, propyl, butyl and benzyl esters are preferred esters. The term “pharmaceutically acceptable esters” furthermore embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.

In detail, the present invention relates to compounds of formula (I)
embedded image

wherein

X is C(R⁸R⁹), NR¹⁰, O, S, S(O), S(O₂);
R¹is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and CN;
R²is hydrogen or lower-alkyl;
R³and R⁴independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R³and R⁴together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁵and R⁶independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R⁵and R⁶together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁷is an oxadiazolyl or triazolyl, which oxadiazolyl or triazolyl is substituted with R¹¹and optionally substituted with R¹²;
R⁸and R⁹independently from each other are hydrogen, halogen, hydroxy, lower-alkyl, lower-alkoxy; or
R⁸and R⁹are bound together and —R⁸—R⁹— is —(CH₂)_2-7— to form a ring together with the carbon atom to which they are attached;
R¹⁰is hydrogen, lower-alkyl, lower-alkyl-carbonyl or lower-alkyl-sulfonyl;
R¹¹is aryl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl, imidazopyridinyl, triazolepyridinyl,tetrazolepyridinyl, benzimidazolyl, 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy, B(OH)₂, carboxy-lower-alkoxy, carbamoyl-lower-alkoxy, cyano, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O₂)R¹³, C(O)R¹⁴, NO₂, NR¹⁵R¹⁶, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, phenyl-lower-alkoxy, [1,3,4]oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, which imidazolyl is optionally substituted with lower-alkyl, and which phenyl-lower-alkoxy is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl, and which pyrazolyl is optionally substituted with lower-alkyl, and which isoxazolyl is optionally substituted with lower-alkyl;
R¹²is hydrogen or lower-alkyl;
R¹³is lower-alkyl, NR¹⁷R¹⁸or fluoro-lower-alkyl;
R¹⁴is OH, NR¹⁹R²⁰, lower-alkoxy, lower-alkenyl-oxy or lower-alkyl;
R¹⁵and R¹⁶independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO₂, lower-alkenyl-oxy-carbonyl, NH₂-carbonyl, lower-alkyl-NH-carbonyl, (lower-alkyl)₂N-carbonyl or phenyl-lower-alkyl, which phenyl-lower-alkyl is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl; or
NR¹⁵R¹⁶is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl, pyrrolidinyl, 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl;
R¹⁷and R¹⁸independently from each other are hydrogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or
NR¹⁷R¹⁸is morpholinyl;
R¹⁹and R²⁰independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, (lower-alkyl)₂N-lower-alkyl, pyridinyl-lower-alkyl or cyano-lower-alkyl; or
NR¹⁹R²⁰is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl, which heterocyclyl is optionally substituted with hydroxy, lower-alkyl-S(O₂), lower-alkyl, lower-alkyl-carbonyl, carboxy, carbamoyl, lower-alkoxy-carbonyl, cyano, phenyl, pyridinyl or lower-alkoxy;

and pharmaceutically acceptable salts and esters thereof.

Compounds of formula (I) are individually preferred and physiologically acceptable salts thereof are individually preferred and pharmaceutically acceptable esters thereof are individually preferred, with the compounds of formula (I) being particularly preferred.

The compounds of formula (I) can have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, mixture of stereoisomers or as optically pure compounds.

Preferred compounds of formula (I) as described above are those, wherein

X is C(R⁸R⁹), NR¹⁰, O, S, S(O), S(O₂);
R¹is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and CN;
R²is hydrogen or lower-alkyl;
R³and R⁴independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R³and R⁴together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁵and R⁶independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R⁵and R⁶together are ═O to form a carbonyl group together with the carbon atom to which they are attached;
R⁷is an oxadiazolyl or triazolyl, which oxadiazolyl or triazolyl is substituted with R¹¹and optionally substituted with R¹²;
R⁸and R⁹independently from each other are hydrogen, halogen, hydroxy, lower-alkyl, lower-alkoxy; or
R⁸and R⁹are bound together and —R⁸—R⁹— is —(CH₂)_2-7— to form a ring together with the carbon atom to which they are attached;
R¹⁰is hydrogen, lower-alkyl, lower-alkyl-carbonyl or lower-alkyl-sulfonyl;
R¹¹is aryl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl, imidazopyridinyl, triazolepyridinyl,tetrazolepyridinyl and benzimidazolyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O₂)R¹³, C(O)R¹⁴, NO₂, NR¹⁵R¹⁶, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower-alkoxy, which imidazolyl is optionally substituted with lower-alkyl and which phenyl-lower-alkoxy is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl;
R¹²is hydrogen or lower-alkyl;
R¹³is lower-alkyl, NR¹⁷R¹⁸or fluoro-lower-alkyl;
R¹⁴is OH, NR¹⁹R²⁰, lower-alkoxy or lower-alkenyl-oxy;
R¹⁵and R¹⁶independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO₂, lower-alkenyl-oxy-carbonyl, NH₂-carbonyl, lower-alkyl-NH-carbonyl, (lower-alkyl)₂N-carbonyl or phenyl-lower-alkyl, which phenyl-lower-alkyl is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl; or
NR¹⁵R¹⁶is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl and pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl;
R¹⁷and R¹⁸independently from each other are hydrogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or
NR¹⁷R¹⁸is morpholinyl;
R¹⁹and R²⁰independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl or lower-alkoxy-lower-alkyl; or
NR¹⁹R²⁰is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl and 8-oxa-3-aza-bicyclo[3.2.1]octyl, which heterocyclyl is optionally substituted with hydroxy or lower-alkyl-S(O₂);

and pharmaceutically acceptable salts and esters thereof.

Preferred compounds of formula (I) as described above are those, wherein R¹is phenyl optionally substituted with halogen, hydroxy, hydroxy-lower-alkyl or CN, more preferably those wherein R¹is phenyl.

Other preferred compounds are those, wherein R²is hydrogen. Further preferred compounds are those, wherein R³is hydrogen. Still other preferred compounds are those, wherein R⁴is hydrogen. Other preferred compounds are those, wherein R⁵is hydrogen. Compounds wherein R⁶is hydrogen are alo preferred.

Preferably, R⁷which are an oxadiazolyl are not substituted with R¹². In a preferred embodiment of the present invention, R⁷is
embedded image

wherein R¹¹and R¹²are as defined above. Preferably, R⁷is

wherein R¹¹and R¹²are as defined in claim 1.

Furthermore, it is preferred that R⁷is
embedded image

wherein R¹¹is as defined above.

Preferred compounds of formula (I) as described above are those, wherein X is C(R⁸R⁹), NR¹⁰, O or S, wherein R⁸, R⁹and R¹⁰are as defined above. Preferably, X is C(R⁸R⁹) or NR¹⁰, wherein R⁸, R⁹and R¹⁰are as defined above.

In the compounds as defined above, it is preferred that R⁸is hydrogen. Preferably, R⁹is hydrogen. It is also preferred, that R¹⁰is hydrogen.

Another preferred embodiment of the present invention refers to compounds as defined above, wherein R¹¹is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O₂)R¹³, C(O)R¹⁴, NO₂, NR¹⁵R¹⁶, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower-alkoxy, which imidazolyl is optionally substituted with lower-alkyl, wherein R¹³, R¹⁴, R¹⁵and R¹⁶are as defined above.

Preferably, R¹¹is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of fluoro-lower-alkyl, halogen, C(O)R¹⁴and NR¹⁵R¹⁶, wherein R¹⁴, R¹⁵and R¹⁶are as defined above.

More preferably, R¹¹is 1H-Indazol-5-yl, 1H-Indazol-6-yl, 1,3-dihydro-indol-2-one-6-yl, 1,3-dihydro-benzoimidazol-2-one-5-yl, 1,3-dihydro-indol-2-one-5-yl, 1H-Benzotriazol-5-yl, 1H-Benzoimidazol-5-yl, 1H-pyridin-2-one-4-yl, 4-Fluoro-phenyl, 3-trifluoromethyl-phenyl, 1H-Benzoimidazol-5-yl, 3-benzamide, 5-nicotinamide, 3-(N-acetamide)-phenyl or 3-(N-methanesulfonamide)-phenyl.

Another preferred embodiment of the present invention refers to compounds as defined above, wherein R¹¹is phenyl or a heteroaryl selected from the group consisting of 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, which phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, B(OH)₂, carboxy-lower-alkoxy, carbamoyl-lower-alkoxy, cyano, [1,3,4]oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, which pyrazolyl is optionally substituted with lower-alkyl, and which isoxazolyl is optionally substituted with lower-alkyl.

Preferably, R¹¹is phenyl or a heteroaryl selected from the group consisting of pyridinyl, 1,3-dihydro-indol-2-one, 1H-benzimidazolyl, 3H-pyrimidin-4-one, 1H-pyrazolyl, isoxazolyl and 4H-benzo[1,4]oxazin-3-one, which phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy, halogen and NR¹⁵R¹⁶, wherein R¹⁴and R¹⁵are as defined in claim 1.

More preferably, R¹¹is 2-methyl-3H-pyrimidin-4-one, 5-methyl-isoxazol-3-yl, 1H-pyrazol-3-yl, 6-amino-pyridin-3-yl, 1,3-dihydro-indol-2-one, 2-amino-pyridin-4-yl, 4H-benzo[1,4]oxazin-3-one, 1H-benzimidazol-5-yl, 3-(N-acetamide)-4-fluoro-phenyl or 2-hydroxy-pyridin-4-yl.

Preferably, R¹²is hydrogen. Compounds as defined above, wherein R¹³is lower-alkyl are also preferred. Other preferred compounds are those, wherein R¹⁴is NR¹⁹R²⁰, wherein R¹⁹and R²⁰are as defined above. Other preferred compounds are those, wherein R¹⁴is lower-alkyl.

Another preferred embodiment of the present invention refers to compounds as defined above, wherein R¹⁵and R¹⁶independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO₂, lower-alkenyl-oxy-carbonyl or lower-alkyl-NH-carbonyl; or NR¹⁵R¹⁶is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, piperazinyl and pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl. More preferably, R¹⁵and R¹⁶independently from each other are hydrogen, lower-alkyl-carbonyl or lower-alkyl-SO₂.

Other preferred compounds are those, wherein NR¹⁵R¹⁶is a heterocyclyl selected from the group consisting of 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl.

Other preferred compounds are those, wherein R¹⁷and R¹⁸independently from each other are hydrogen or lower-alkyl; or NR¹⁷R¹8 is morpholinyl.

Further preferred compounds as defined above are those, wherein R¹⁹and R²⁰independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or NR¹⁹R²⁰is a heterocyclyl selected from the group consisting of morpholinyl or pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy or lower-alkyl-S(O₂). More preferably, R¹⁹and R²⁰are hydrogen.

Other preferred compounds are those, wherein R¹⁹and R²⁰independently from each other are (lower-alkyl)₂N-lower-alkyl, pyridinyl-lower-alkyl or cyano-lower-alkyl; or NR¹⁹R²⁰is a heterocyclyl selected from the group consisting of piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl, which heterocyclyl is optionally substituted with hydroxy, lower-alkyl-S(O₂), lower-alkyl, lower-alkyl-carbonyl, carboxy, carbamoyl, lower-alkoxy-carbonyl, cyano, phenyl, pyridinyl or lower-alkoxy.

Preferred compounds of formula (I) as defined above are those, which are R-isomers and which are characterised by formula (Ia)
embedded image

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷and X are as defined above.

In particular, preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts as well as pharmaceutically acceptable esters thereof.

Preferred compounds of formula (I) are those selected from the group consisting of:

(R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-3-(2-{2-[3-(4-Methoxy-phenyl)[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-oxo-ethoxy)benzonitrile,
(R) 1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-propan-1-one,
(R)-1-{2-[3-(4-Bromo-phenyl)[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-2-(4-Hydroxy-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-(4-Chloro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-(4-Hydroxymethyl-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-(3-Chloro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-(4-Fluoro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Methane-sulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-2-(4-Fluoro-phenoxy)-1-[2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid methyl ester,
(R)-1-{2-[3-(3-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-2-Phenoxy-1-[2-(3-pyrazin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone,
(R)-1-(2-{3-[4-(Morpholine-4-sulfonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(3-Hydroxymethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid allyl ester,
(R)-1-{2-[3-(4-Imidazol-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[3-(4-trifluoromethanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-Phenoxy-1-{2-[3-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-1-{2-[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide,
(R)-1-{2-[3-(3-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Methoxy-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-N-(2-Hydroxy-ethyl)-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
(R)-1-{2-[3-(2-Morpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[3-(3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-2-Phenoxy-1-{2-[3-(2-thiomorpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-1-{2-[3-(2-Diethylamino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethyl ester,
(R)-1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-{2-[3-(2-Imidazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-piperidin-2-one,
(R)-1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[4-(2-Methyl-imidazol-1-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[3-(2-pyrazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
(R)-4-(5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-piperazin-2-one,
(R)-2-Phenoxy-1-(2-{3-[4-(1H-tetrazol-5-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-ethanone,
(R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Indazol-6-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Fluoro-3-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
(R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-(2-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide,
(R)-1-{2-[3-(6-Benzyloxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid ethyl ester,
(R)-4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
(R)-2-Phenoxy-1-[2-(5-phenyl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone,
(R)-1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(3,4-Dimethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(3,4-Dichloro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxyethanone,
(R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-ethanone,
(R)-1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(3-Nitro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid methyl ester,
(R)-1-{2-[5-(4-Fluoro-3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one,
1-{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone,
1-{3-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone,
4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
1-(3-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-morpholin-4-yl)-2-phenoxy-ethanone,
N-(4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide,
1-{3-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-morpholin-4-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{3-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-morpholin-4-yl}-ethanone,
(R)-4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
1-{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-thiomorpholin-4-yl}-2-phenoxy-ethanone,
1-{3-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-thiomorpholin-4-yl}-2-phenoxy-ethanone,
4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
2-Phenoxy-1-[3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-thiomorpholin-4-yl]-ethanone,
1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
N-(5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide,
1-{2-[3-(2-Imidazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
1-{2-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-ethanone,
1-{2-[3-(2,4-Dichloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[2-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-ethanone,
2-Phenoxy-1-[2-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperazin-2-yl]-ethanone,
1-{2-[3-(4-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(3-Hydroxymethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(4-Diethylamino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-(2-{3-[4-(Morpholine-4-sulfonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
1-{2-[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
N-(4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide,
4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid allyl ester,
1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(4-Methoxy-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[3-(4-Chloro-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
3-Fluoro-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid methyl ester,
4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethyl ester,
2-Phenoxy-1-{2-[3-(4-piperidin-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone,
1-{2-[3-(4-Morpholin-4-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-(2-{3-[4-(2-Methyl-imidazol-1-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
4-(5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-piperazin-2-one,
1-{2-[3-(6-Imidazol-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
2-Phenoxy-1-{2-[3-(4-pyrrol-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone,
2-Phenoxy-1-{2-[3-(4-trifluoromethanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone,
1-{2-[3-(2-Morpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{2-[3-(2-thiomorpholin-4-yl-pyridin-4-yl)-[1,2,41oxadiazol-5-yl]-piperazin-1-yl}-ethanone,
1-(2-{3-[6-(3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
(R)-1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide,
(R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Morpholin-4-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[6-(3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide hydrochloride,
(R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone hydrochloride,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one,
(R)-1-(2-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone hydrochloride,
(R)-1-{2-[3-(3-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
1-{4-Acetyl-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{4-Acetyl-2-[3-(4-methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
4-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide,
1-[4-Acetyl-2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-2-phenoxy-ethanone,
1-{4-Methanesulfonyl-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone,
1-{2-[5-(4-Fluoro-3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone,
2-Phenoxy-1-[2-(5-p-tolyl-2H-[1,2,4]triazol-3-yl)-piperazin-1-yl]-ethanone,
2-Phenoxy-1-{2-[5-(4-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone,
1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(3,4-Dimethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(3,4-Dichloro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
1-{2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-1-{2-[3-(1H-Indazol-5yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-5-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
(R)-5-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one,
(R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{4-Methyl-2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid methyl ester,
(R)-N-(3-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1 H-[1,2,4]triazol-3-yl}-phenyl)-acetamide,
(R)-N-(3-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-methanesulfonamide,
(R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
(R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid,
(R)-2-Fluoro-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid,
3-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
3-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-4-yl}-benzamide,
3-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
4-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid,
(R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid,
1-(2-{3-[4-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[4-(3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Ethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Cyclopropyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-(2-Hydroxy-ethyl)-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N,N-Dimethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Ethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Cyclopropyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-(2-Hydroxy-ethyl)-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-(2-Methoxy-ethyl)-N-methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-1-(2-{3-[3-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[3-(3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-N,N-Diethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid methylamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid dimethylamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethylamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid diethylamide,
(R)-1-(2-{3-[2-(Morpholine-4-carbonyl)-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-1-(2-{3-[2-(3-Methanesulfonyl-pyrrolidine-1-carbonyl)-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid methylamide,
(R)-N-Methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
1N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
1-(2-{3-[4-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone,
N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-N-Methyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-Ethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-Diethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-Diethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-(2-Hydroxy-ethyl)-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-(2-Methoxy-ethyl)-N-methyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl][1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-Cyclopropyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-1-(2-{3-[5-(3-Hydroxy-pyrrolidine-1-carbonyl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid amide,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3yl]-[1,2,4]oxadiazol-3yl}-benzamide,
4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-1-{2-[3-(3-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(4-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[5-(3-Amino-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide,
(R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide,
(R)-N-(5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-methanesulfonamide,
(R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-methanesulfonamide,
(R)-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-carbamic acid allyl ester,
(R)-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-carbamic acid allyl ester,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-methanesulfonamide,
(R)-1-Ethyl-3-(3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-urea,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzonitrile, and
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinonitrile,

and pharmaceutically acceptable salts and esters thereof.

Particularly preferred compounds of formula (I) are those selected from the group consisting of:

(R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Indazol-6-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one,
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
(R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-4-{5-(4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
(R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
(R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-ethanone,
(R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide,
5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide,
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, and
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-methanesulfonamide,

and pharmaceutically acceptable salts and esters thereof.

Other preferred compounds of formula (I) are those selected from the group consisting of:

1-{(R)-2-[3-(2-Methyl-1H-benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[3-(3-Hydroxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
4-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one,
1-{(R)-2-[3-(4-Hydroxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenylboronic acid,
4-(2-Oxo-2-{(R)-2-[3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethoxy)-benzonitrile,
4-(2-{(R)-2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-oxo-ethoxy)-benzonitrile,
2-Methyl-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-3H-pyrimidin-4-one,
1-[(R)-2-(3-Furan-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-[(R)-2-(3-Imidazo[1,2-a]pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-{(R)-2-[3-(4-Methyl-[1,2,3]thiadiazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[3-(2,5-Dimethyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
1-{(R)-2-[3-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyrimidine-2,4-dione,
1-{(R)-2-[3-(6-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-[(R)-2-(3-Imidazo[1,2-a]pyridin-6-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-4H-benzo[1,4]oxazin-3-one,
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one,
1-((R)-2-{3-[3-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-pyrrolidin-2-one,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-imidazolidine-2,4-dione,
4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one,
1-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-pyrrolidine-2,5-dione,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one,
1-{(R)-2-[5-(1H-Indazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(1H-Indol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(3H-Benzotriazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-benzoimidazol-2-one,
1-{(R)-2-[5-(2-Methyl-1H-benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
5-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-3H-[1,3,4]oxadiazol-2-one,
1-{(R)-2-[5-(3-[1,3,4]Oxadiazol-2-yl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenylboronic acid,
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one,
1-[(R)-2-(5-Imidazo[1,2-a]pyridin-6-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-{(R)-2-[5-(6-Amino-pyridin-3-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[(R)-2-(5-pyridin-3-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone,
1-{(R)-2-[5-(3,5-Dimethyl-isoxazol-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[(R)-2-(5-thiophen-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone,
2-Phenoxy-1-[(R)-2-(5-pyrimidin-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone,
1-{(R)-2-[5-(4-Methyl-oxazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[(R)-2-(5-pyrazin-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone,
1-{(R)-2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(3,5-Difluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2-Methyl-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(3-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(3,4-Difluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one,
7-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-3,4-dihydro-1H-quinazolin-2-one,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-imidazolidine-2,4-dione,
1-{(R)-3-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone,
1-{(R)-3-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone,
1-{(R)-2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one,
1-{(R)-2-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone,
(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetic acid,
2-Phenoxy-1-((R)-2-{5-[3-(piperidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone,
1-((R)-2-{5-[3-(Morpholine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-((R)-2-{5-[3-(4-Methyl-piperazine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperazin-one,
N-(2-Methoxy-ethyl)-N-methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
1-((R)-2-{5-[3-(4-Acetyl-piperazine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperidine-4-carboxylic acid,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperidine-4-carboxylic acid amide,
2-Phenoxy-1-((R)-2-{5-[3-(thiazolidine-3-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone,
N-(2-Dimethylamino-ethyl)-N-methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
2-Phenoxy-1-((R)-2-{5-[3-(thiomorpholine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone,
4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperazine-1-carboxylic acid ethyl ester,
N-(2-Hydroxy-ethyl)-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
N-Methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-N-(2-pyridin-2-yl-ethyl)-benzamide,
N-(2-Cyano-ethyl)-N-cyclopropyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-4-phenyl-piperidine-4-carbonitrile,
1-((R)-2-{5-[3-(4-Hydroxy-piperidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
8-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione,
1-(2-{5-[3-(Spiro(1-Phtalan)-piperidine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
2-Phenoxy-1-((R)-2-{5-[3-(3-pyridin-4-yl-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone,
1-((R)-2-{5-[3-(3-Methanesulfonyl-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-((R)-2-{5-[3-((S)-3-Ethoxy-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-((R)-2-{5-[3-((S)-3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-nicotinamide,
2-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetamide,
N-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide,
N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide,
N-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-propionamide,
N-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-isobutyramide,
N-(4-Fluoro-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide,
N-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide,
N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide,
N-(4-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-pyridin-2-yl)-acetamide,
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-azetidin-2-one,
1-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-pyrrolidine-2,5-dione,
2-Phenoxy-1-[(R)-2-(5-pyridazin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone,
4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-benzonitrile,
1-{(R)-2-[5-(3-Amino-pyrazin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-benzonitrile,
1-{(R)-2-[5-(2-Hydroxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(5-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2-Hydroxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2-Hydroxy-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(4-Hydroxy-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2-Amino-5-chloro-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[(R)-2-(5-pyrazin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone,
2-Phenoxy-1-{(R)-2-[5-(4-[1,2,4]triazol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone,
2-Phenoxy-1-{(R)-2-[5-(4-tetrazol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone,
1-{(R)-2-[5-(1H-Benzoimidazol-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(4-Acetyl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(6-Hydroxy-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(5-Methyl-pyrazin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-[(R)-2-(5-quinoxalin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone,
1-{(R)-2-[5-(3-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(6-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-[(R)-2-(5-Benzothiazol-6-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
2-Phenoxy-1-{(R)-2-[5-(2,4,5-trifluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone,
2-Phenoxy-1-{(R)-2-[5-(6-trifluoromethyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone,
1-[(R)-2-(5-Benzo[1,2,3]thiadiazol-5-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-[(R)-2-(5-[1,8]Naphthyridin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-[(R)-2-(5-[1,6]Naphthyridin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-[(R)-2-(5-Cinnolin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone,
1-{(R)-2-[5-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(3,6-Dichloro-pyridazin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-4H-benzo[1,4]oxazin-3-one,
1-{(R)-2-[5-(3H-Imidazo[4,5-b]pyridin-6-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
N-(4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-pyridin-2-yl)-acetamide,
1-{(R)-2-[5-(6-Chloro-3-hydroxy-pyridazin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-1,4-dihydro-quinoxaline-2,3-dione,
1-{(R)-2-[5-(6-Hydroxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
7-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-3,4-dihydro-1H-quinoxalin-2-one,
1-{(R)-2-[5-(6-Amino-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-nicotinonitrile,
5-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-pyridine-2-carbonitrile,
4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-1,2-dihydro-indazol-3-one,
1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(6-Hydroxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
4-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one,
1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-imidazolidine-2,4-dione,
1-((R)-2-{5-[3-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-phenyl]-[1,2,4]oxadiazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone,
1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-pyrrolidin-2-one,
1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-1,3-dihydro-imidazol-2-one,
3-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-imidazolidine-2,4-dione,
1-{(R)-2-[5-(1-Methyl-1H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{(R)-2-[5-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone,
1-{(R)-2-[5-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(2,5-Dimethyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(5-Methyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, and
1-{(R)-2-[5-(3-Methyl-isoxazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,

and pharmaceutically acceptable salts and esters thereof.

Other particularly preferred compounds of formula (I) are those selected from the group consisting of:

2-Methyl-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-3H-pyrimidin-4-one,
1-{(R)-2-[3-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone,
1-{(R)-2-[3-(6-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one,
1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one,
1-{(R)-2-[5-(6-Amino-pyridin-3-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,
N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, and
1-{(R)-2-[5-(2-Hydroxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone,

and pharmaceutically acceptable salts and esters thereof.

It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.

The invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises reacting a compound of formula (II)
embedded image

with a compound of formula (III)

wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and X are as defined in any of claims 1-22 and L is halogen.

The reaction of a compound of formula (II) with a compound of formula (III) can be carried out under conditions well known to the person skilled in the art. Such reactions can conveniently be carried out for example by mixing a compound of formula (II) with e.g. an acid chloride of formula (III) or alternatively with an activated ester thereof a compound of formula (III) in a solvent such as e.g. DMF at appropriate temperatures between 25° C. and 120° C., optionally in the presence of diisopropylethylamine. Preferably, L is Cl. Alternatively, L can be an active ester. Such active esters as well as their use to form amide bonds are well known to the person skilled in the art.

The present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.

The compounds of formula (I), (II) and (III) can be prepared by methods known in the art or as described below or in analogy thereto. Unless otherwise indicated, R¹, R², R³, R⁴, R⁵, R⁶, R⁷and X are as described above.

Compounds of formula (I), can be prepared according to the following general methods.
embedded image

Compounds of general formula 1 are dissolved preferably in DMF and 1 equivalent of activation reagent such as TBTU is added. The reaction is stirred at room temperature for 10 min and the corresponding hydroxyamidine (compound 2) added to result in compounds of general formula 3. The reaction mixture is heated to 80° C. and stirred overnight of treated under microwave conditions at 120° C. for 15-30 minutes to result in 4. After evaporation of the solvent and extracted from ethylactate/water the crude material is treated with neat trifluoroacetic acid or 4N HCL in Dioxan to result in compounds of general formula 5. The final product is obtained by treating these intermediates either with phenoxyl chloride and derivatives thereof or its corresponding active esters.

The corresponding N-methylpiperazine derivatives were generated from the piperazines as indicated in scheme 2.
embedded image

Compounds of type 1 are dissolved preferably in DMF and treated with an excess of formaldehyde and catalytic amount of acetic acid. The reaction mixture is stirred at room temperature for 30 minutes and 1 equivalent of NaBH3CN added. The reaction is stirred at room temperature for 16 h and the product isolated by chromatography.

The carboxylic acid analogues were generated from the corresponding esters through classical saponification with NaOH or LiOH or by catalytic debenzylation procedures where the starting material is typically dissolved in methanol and an aqueous solution of NaOH or LiOH is added.

The reaction is stirred preferably for 2 h at room temperature and the product extracted form ethylacetate/water after acidification of the reaction mixture.

The carboxyamide analogues were generated from the corresponding carboxylates by preactivation with reagents such as TBTU in DMF. The reaction mixtures are usually stirred at room temperature overnight.

The primary carboxyamide analogues were generated from the corresponding carboxylates through coupling on Rink-resin and subsequent cleavage with TFA by preactivating the starting material with reagents such as TBTU. The reaction mixture is usually stirred at room temperature overnight. After excessive washing of the resins with solvents such as DMF, methanol and methylenchloride the solid phase material is treated with TFA at room temperature for 2 h. After evaporation the product is isolated by chromatography.

The amino derivatives were generated from the corresponding nitro analogues through a Zink mediated reduction where the starting material is dissolved preferably in ethanol and saturated aqueous ammonium chloride. An excess of zinc powder is added, the reaction briefly heated to reflux and then stirred at room temperature for 16 h. The product is isolated by extraction from ethylacetate/water and final chromatography

The following N-amides, -sulfonamides, -carbamates and -ureas were all generated from the corresponding amino-derivatives where the amino-derivatives are dissolved preferably in DMF and the corresponding acetyl chlorides or activate esters, sulfonyl chlorides or isocyanates are added. The reactions proceed at room temperature. The products are isolated by chromatography.

The benzonitriles were generated from the corresponding primary benzamides by treatment of the latter with neat trifluoroacetic anhydride at room temperature for preferably 16 h.

The non-commercially available aminoacids were generated from Piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester by coupling with either acetyl chloride or methylsulfonyl chloride in THF at room temperature followed by saponification as described above.

The non-commercially available hydroxyamidines were generated from the corresponding nitriles by the addition of 5 equivalents of hydroxylamine mono hydrochloride and 2.5 equivanents sodium carbonate in a mixture of ethanol/water (7:3). The reaction mixture was heated to 80° C. for usually 2 h. The product was isolated by extraction from ethylacetate/water.

The non-commercially available sulfonamido hydroxyamidines were generated by coupling of 4-cyanobenzen-1-sulfonylchloride with 2 equivalents of the corresponding amine in THF at room temperature for 16 h. After evaporation of the solvent the product is extracted from ethylacetate/water. The crude nitril is treated with hydrazine as described above.

The non-commercially available 2-aminopyridino hydroxyamidines were generated from the corresponding nitrites as described above. The nitriles were obtained from the corresponding chlorocyanopyridines after dissolving in DMF and adding 2 equivalents of the amine. The reaction mixture was heated to 120° C. under microwave conditions usually for 30 min. The product was isolated by extraction from ethylacetate/water after evaporation of the reaction solvent.

The aminoamidines were generated from the corresponding imidoethers by addition of 1 equivalent of hydrazine monohydrate in methanol. The product was isolated by precipitation when adding 1.25M HCl/methanol. The iminoethers were obtained from the corresponding nitriles after suspending in methylenchloride and saturation with HCl gas at 0° C. for 30 min. The reaction mixture was stirred for 16 h at room temperature and the product filtered off after addition of diethylether.

The non-commercially available nitrites were generated from the corresponding primary amides by the addition of neat trifluoroaceticacid anhydride at room temperature preferably for 16 h.
embedded image

Furthermore, as outlined in scheme 3, compounds of general formula 1 can be dissolved preferably in DMF and 1 equivalent of activation reagent such as TBTU is added in addition to 1 equivalent of a base such as DIPEA. The reaction is cooled to 0° C. and an excess of hydrazine added. The reaction is warmed up and stirred at ambient temperature to result in compound 2. After evaporation of the solvent and extraction from ethylactate/water the crude material is treated with 1 equivalent of the corresponding amidine in DMF. Catalytic amount of acetic acid is added and the reaction heated to 120° C. overnight to result in compounds of general formula 4. After evaporation of the solvent and extraction from ethylactate/water neat trifluoroacetic acid or 4N HCL in Dioxan is added to generate compounds of general formula 5. The final product is obtained by treating these intermediates either with phenoxyacetyl chloride and derivatives thereof or its corresponding active esters.
embedded image

Furthermore, as outlined in scheme 4, compound 1 can be dissolved preferably in aqueous ethanol and treated with an excess of hydrazine hydrochloride and a base such as sodium carbonate to result in compound 2. This intermediate can be coupled with 1 equivalent of pre-activated carboxylates or their corresponding acetyl chlorides in solvents such as DMF to result in compounds with the general formula 3. Cyclisation to the corresponding oxadiazole occurs under elevated temperature either using conventional or microwave heating. Boc cleavage is usually performed using either neat TFA or 4N HCl in Dioxan to result in compounds of general formula 5. The final product is obtained by treating these intermediates either with phenoxyacetyl chloride and derivatives thereof or its corresponding active esters.

The corresponding salts can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula(I) in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid. The products can usually be isolated by filtration or by chromatography.

The conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable carboxy group present in the molecule with a suitable alcohol using e.g. a condensating reagent such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N,N-dicyclohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) or O-(1,2-dihydro-2-oxo-1-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU). Pharmaceutically acceptable esters can furthermore be prepared by treatment of a suitable hydroxy group present in the molecule with a suitable acid, optionally or if necessary in the presence of a condensating agent as described above.

Insofar as their preparation is not described in the examples, the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto.

As described above, the novel compounds of the present invention have been found to inhibit liver carnitine palmitoyl transferase 1 (L-CPT1) activity. The compounds of the present invention can therefore be used in the treatment and/or prophylaxis of diseases which are modulated by L-CPT1 inhibitors, particularly diseases which are related to hyperglycemia and/or glucose tolerance disorders. Such diseases include e.g. diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

The invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by L-CPT1 inhibitors, particularly as therapeutically active substances for the treatment and/or prophylaxis of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

In another preferred embodiment, the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure, which method comprises administering a compound as defined above to a human being or animal.

The invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

The invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by L-CPT1 inhibitors, particularly for the therapeutic and/or prophylactic treatment of hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure. Such medicaments comprise a compound as described above.

Prevention and/or treatment of hyperglycemia and non insulin dependent diabetes mellitus is the preferred indication.

The following tests were carried out in order to determine the activity of the compounds of the present invention. Background information on the performed assays can be found in: Jackson et al., 1999, Biochem. J. 341, 483-489 and Jackson et al., 2000, J. Biol. Chem. 275, 19560-19566.

Human liver and muscle CPT1 cDNAs and rat CPT2 cDNA were subcloned in pGAPZB or pGAPZA, respectively. These plasmids were used to transform P. pastoris strain X-33 via electroporation after the preparation of electrocompetent cells. High copy number clones were selected where necessary using 0.5 or 1 mg/ml Zeocin. Cultures for activity measurements were induced for 16 h in YPD medium (1% yeast extract, 2% peptone, 2% glucose). Crude cell extracts were prepared by disrupting the cells with glass beads or French Press, depending on fermenter sizes. After centrifugation, the cell-free extracts were resuspended in cell breaking buffer (50 mM Tris, pH7.4, 100 mM KCl, 1 mM EDTA) in the presence of a protease inhibitor cocktail, before aliquoting and freezing at −20° C.

CPT activity was measured using a spectrophotometric assay using 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTNB) also called Ellman's reagent. The HS-CoA released on the formation of acylcarnitine from carnitine (500 μM) and palmitoyl-CoA (80 μM) reduced DTNB (300 μM) forming 5-mercapto-(2-nitrobenzoic acid) which absorbed at 410 nm with a molar coefficient extinction of 13600 M⁻¹.cm⁻¹. The assay buffer contained 120 mM KCl, 25 mM Tris, pH 7.4, 1 mM EDTA. This assay was used for the identification of selective inhibitors of the liver CPT1 isoform versus the muscle CPT1 and CPT2 isoforms.

The compounds according to formula (I) preferably have an IC50 value below 10 μM, preferably 10 nM to 10 μM, more preferably 10 nM to 5 μM. The following table shows data for some examples.

L-CPT1 inhibitionExampleIC₅₀[μmol/l]10.066100.2601720.242

The compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.

The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 2000 mg, especially about 1 to 500 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.

The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-200 mg, of a compound of formula I.

The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

EXAMPLES
Example 1
(R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone

Step 1:

(R)-2-{[Hydroxyimino-(4-methoxy-phenyl)-methyl]-carbamoyl}-piperidine-1-carboxylic acid tert-butyl ester

23 mg (0.1 mmol) of Boc-D-Pipecolic Acid were treated with 0.1 mmol [Dimethylamino-([1,2,3]triazolo[4,5-b]pyridin-3-yloxy)-methylene]-dimethyl-ammonium hexafluorophosphate (HATU) and Diisopropylamine (DIPEA) in 1 ml Dimethylforamide (DMF) for 10 min. 17 mg (0.1 mmol) of N-Hydroxy-4-methoxy-benzamidine were added and the reaction stirred at room temperature for 20 min. The product was not further characterized.

Step 2:

(R)-2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester

Crude material from step 1 was either treated at 80° C. for 16 h or briefly heated to 120° C. under microwave conditions (10 min). The DMF was evaporated and the product extracted from ethylacetate/water. The product was not further characterized.

Step 3:

(R)-2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine trifluoroacetate

Crude material from step 2 was treated with neat trifluoroacetic acid (TFA) at room temperature for 1 h. The TFA was evaporated. The crude product not further characterized.

Step 4:

(R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone

Crude material from step 3 was dissolved in 1 ml DMF and 0.1 mmol DIPEA. Either 0.1 mmol phenoxyacetyl chloride were added and the reaction stirred at room temperature for 30 min, or the corresponding phenoxyacetic acid derivatives were pre-activated with HATU/DIPEA in DMF for lOmin and added to the crude material from step 3. The product was isolated via preparative high performance liquid chromatography (HPLC).

MS(ISO): 394.4 (MH+)

The following compounds were prepared in analogy.

TABLE 1MH⁺ExampleCompound nameStarting materials(found)2(R)-3-(2-{2-[3-(4-Methoxy-Boc-D-Pipecolic Acid, N-419.5phenyl)[1,2,4]oxadiazol-5-yl]-Hydroxy-4-methoxy-piperidin-1-yl}-2-oxo-ethoxy)benzamidine and 3-benzonitrileCyanophenoxy-acetyl chloride3(R)-1-{2-[3-(4-Methoxy-Boc-D-Pipecolic Acid, N-408.5phenyl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-methoxy-piperidin-1-yl}-2-phenoxy-benzamidine and 2-Phenoxy-propan-1-onepropionic acid4(R)-1-{2-[3-(4-Bromo-phenyl)Boc-D-Pipecolic Acid, N-442.2[1,2,4]oxadiazol-5-yl]-Hydroxy-4-bromo-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone5(R)-2-(4-Hydroxy-phenoxy)-Boc-D-Pipecolic Acid, N-410.51-{2-[3-(4-methoxy-phenyl)-Hydroxy-4-methoxy-[1,2,4]oxadiazol-5-yl]-benzamidine and 4-Hydroxy-piperidin-1-yl}-ethanonephenoxyacetic acid6(R)-2-(4-Chloro-phenoxy)-1-Boc-D-Pipecolic Acid, N-428.5{2-[3-(4-methoxy-phenyl)-Hydroxy-4-methoxy-[1,2,4]oxadiazol-5-yl]-benzamidine and 4-piperidin-1-yl}-ethanoneChlorophenoxy-acetic acid7(R)-2-(4-Hydroxymethyl-Boc-D-Pipecolic Acid, N-424.2phenoxy)-1-{2-[3-(4-methoxy-Hydroxy-4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-benzamidine and 4-piperidin-1-yl}-ethanoneHydroxymethylphenoxy-aceticacid8(R)-2-(3-Chloro-phenoxy)-1-Boc-D-Pipecolic Acid, N-428.5{2-[3-(4-methoxy-phenyl)-Hydroxy-4-methoxy-[1,2,4]oxadiazol-5-yl]-benzamidine and 3-piperidin-1-yl}-ethanoneChlorophenoxy-acetic acid9(R)-2-(4-Fluoro-phenoxy)-1-Boc-D-Pipecolic Acid, N-412.4{2-[3-(4-methoxy-phenyl)-Hydroxy-4-methoxy-[1,2,4]oxadiazol-5-yl]-benzamidine and 4-piperidin-1-yl}-ethanoneFluorophenoxy-acetic acid10(R)-1-{2-[3-(4-Fluoro-Boc-D-Pipecolic Acid, N-382.5phenyl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-fluoro-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone11(R)-1-{2-[3-(4-Methane-Boc-D-Pipecolic Acid, N-442.5sulfonyl-phenyl)-Hydroxy-4-methane-[1,2,4]oxadiazol-5-yl]-sulfonylbenzamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetyl chlorideethanone12(R)-4-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-443.5acetyl)-piperidin-2-yl]-Hydroxy-4-sulfamoyl-[1,2,4]oxadiazol-3-yl}-benzamidine and phenoxyacetylbenzenesulfonamidechloride13(R)-2-(4-Fluoro-phenoxy)-1-Boc-D-Pipecolic Acid, N-383.4[2-(3-pyridin-4-yl-Hydroxy-isonicotinamidine and[1,2,4]oxadiazol-5-yl)-phenoxyacetyl chloridepiperidin-1-yl]-ethanone14(R)-3-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, 3-(N-422.5acetyl)-piperidin-2-yl]-Hydroxycarbam-imidoyl)-[1,2,4]oxadiazol-3-yl}-benzoicbenzoic acid methyl ester andacid methyl esterphenoxyacetyl chloride15(R)-1-{2-[3-(3-Nitro-phenyl)-Boc-D-Pipecolic Acid, N-409.5[1,2,4]oxadiazol-5-yl]-Hydroxy-3-nitro-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone16(R)-1-{2-[3-(4-Nitro-phenyl)-Boc-D-Pipecolic Acid, N-409.5[1,2,4]oxadiazol-5-yl]-Hydroxy-4-nitro-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone17(R)-3-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-443.5acetyl)-piperidin-2-yl]-Hydroxy-3-sulfamoyl-[1,2,4]oxadiazol-3-yl}-benzamidine and phenoxyacetylbenzenesulfonamidechloride18(R)-2-Phenoxy-1-[2-(3-Boc-D-Pipecolic Acid, N-366.5pyrazin-2-yl-[1,2,4]oxadiazol-Hydroxy-pyrazine-2-5-yl)-piperidin-1-yl]-ethanonecarboxamidine andphenoxyacetyl chloride19(R)-1-(2-{3-[4-(Morpholine-4-Boc-D-Pipecolic Acid, N-513.6sulfonyl)-phenyl]-Hydroxy-4-N-acetyl-[1,2,4]oxadiazol-5-yl}-benzamidine and phenoxyacetylpiperidin-1-yl)-2-phenoxy-chlorideethanone20(R)-1-{2-[3-(6-Methoxy-Boc-D-Pipecolic Acid, N-395.5pyridin-3-yl)-[1,2,4]oxadiazol-Hydroxy-6-methoxy-5-yl]-piperidin-1-yl}-2-nicotinamidine andphenoxy-ethanonephenoxyacetyl chloride21(R)-1-{2-[3-(3-Boc-D-Pipecolic Acid, N-394.5Hydroxymethyl-phenyl)-Hydroxy-3-hydroxymethyl[1,2,4]oxadiazol-5-yl]-benzamidine and phenoxyacetylpiperidin-1-yl}-2-phenoxy-chlorideethanone22(R)-6-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, 6-(N-449.1acetyl)-piperidin-2-yl]-Hydroxycarb-amimidoyl)-[1,2,4]oxadiazol-3-yl}-nicotinic acid allyl ester andnicotinic acid allyl esterphenoxyacetyl chloride23(R)-1-{2-[3-(4-Imidazol-1-yl-Boc-D-Pipecolic Acid, N-430.5phenyl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-imidazol-1-yl-piperidin-1-yl}-2-phenoxy-benzamidine and phenoxyacetylethanonechloride24(R)-N-Methyl-4-{5-[1-(2-Boc-D-Pipecolic Acid, N-457.5phenoxy-acetyl)-piperidin-2-Hydroxy-4-methylsulfamoyl-yl]-[1,2,4]oxadiazol-3-yl}-benzamidine and phenoxyacetylbenzenesulfonamidechloride25(R)-1-{2-[3-(6-Morpholin-4-Boc-D-Pipecolic Acid, N-450.5yl-pyridin-3-yl)-Hydroxy-6-morpholin-4-yl-[1,2,4]oxadiazol-5-yl]-nicotinamidine and phenoxy-piperidin-1-yl}-2-phenoxy-acetyl chlorideethanone26(R)-2-Phenoxy-1-{2-[3-(4-Boc-D-Pipecolic Acid, N-496.5trifluoromethanesulfonyl-Hydroxy-4-phenyl)-[1,2,4]oxadiazol-5-yl]-trifluoromethanesulfonyl-piperidin-1-yl}-ethanonebenzamidine and phenoxyacetylchloride27(R)-2-Phenoxy-1-{2-[3-(4-Boc-D-Pipecolic Acid, N-432.5trifluoromethyl-phenyl)-Hydroxy-4-trifluoromethyl-[1,2,4]oxadiazol-5-yl]-benzamidine and phenoxyacetylpiperidin-1-yl}-ethanonechloride28(R)-1-{2-[3-(4-Chloro-Boc-D-Pipecolic Acid, N-398.4phenyl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-chloro-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone29(R)-N-(4-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-[4-(N-489.5acetyl)-piperidin-2-yl]-Hydroxycarb-amimidoyl)-2-[1,2,4]oxadiazol-3-yl}-2-trifluoro-methyl-phenyl]-trifluoromethyl-phenyl)-acetamide and phenoxyacetylacetamidechloride30(R)-1-{2-[3-(3-Boc-D-Pipecolic Acid, N-442.5Methanesulfonyl-phenyl)-Hydroxy-3-methanesulfonyl-[1,2,4]oxadiazol-5-yl]-benzamidine and phenoxyacetylpiperidin-1-yl}-2-phenoxy-chlorideethanone31(R)-1-{2-[3-(4-Methyl-3-Boc-D-Pipecolic Acid, N-423.5nitro-phenyl)-Hydroxy-4-methyl-3-nitro-[1,2,4]oxadiazol-5-yl]-benzamidine and phenoxyacetylpiperidin-1-yl}-2-phenoxy-chlorideethanone32(R)-1-{2-[3-(4-Methoxy-3-Boc-D-Pipecolic Acid, N-439.5nitro-phenyl)-Hydroxy-4-methoxy-3-nitro-[1,2,4]oxadiazol-5-yl]-benzamidine and phenoxyacetylpiperidin-1-yl}-2-phenoxy-chlorideethanone33(R)-N-(2-Hydroxy-ethyl)-4-Boc-D-Pipecolic Acid, N-487.5{5-[1-(2-phenoxy-acetyl)-Hydroxy-4-(2-hydroxy-piperidin-2-yl]-ethylsulfamoyl)-benzamidine[1,2,4]oxadiazol-3-yl}-and phenoxyacetyl chloridebenzenesulfonamide34(R)-N-(2-Methoxy-ethyl)-N-Boc-D-Pipecolic Acid, N-515.5methyl-4-{5-[1-(2-phenoxy-Hydroxy-4-[(2-methoxy-ethyl)-acetyl)-piperidin-2-yl]-methyl-suifamoyl]-benzamidine[1,2,4]oxadiazol-3-yl}-and phenoxyacetyl chloridebenzenesulfonamide35(R)-N,N-Dimethyl-4-{5-[1-(2-Boc-D-Pipecolic Acid, 4-471.5phenoxy-acetyl)-piperidin-2-Dimethylsulfamoyl-N-hydroxy-yl]-[1,2,4]oxadiazol-3-yl}-benzamidine and phenoxyacetylbenzenesulfonamidechloride36(R)-N,N-Diethyl-4-{5-[1-(2-Boc-D-Pipecolic Acid, 4-499.6phenoxy-acetyl)-piperidin-2-Diethylsulfamoyl-N-hydroxy-yl]-(1,2,4]oxadiazol-3-yl}-benzamidine and phenoxyacetylbenzenesulfonamidechloride37(R)-1-{2-[3-(2-Morpholin-4-Boc-D-Pipecolic Acid, N-450.5yl-pyridin-4-yl)-Hydroxy-2-morpholin-4-yl-[1,2,4]oxadiazol-5-yl]-isonicotinamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetyl chlorideethanone38(R)-2-Phenoxy-1-{2-[3-Boc-D-Pipecolic Acid, N-448.5(3,4,5,6-tetrahydro-2H-Hydroxy-3,4,5,6-tetrahydro-[1,2′]bipyridinyl-4′-yl)-2H-[1,2′]bipyridinyl-4′-[1,2,4]oxadiazol-5-yl]-carboxamidine andpiperidin-1-yl}-ethanonephenoxyacetyl chloride39(R)-2-Phenoxy-1-{2-[3-(2-Boc-D-Pipecolic Acid, N-466.5thiomorpholin-4-yl-pyridin-4-Hydroxy-2-thiomorpholin-4-yl-yl)-[1,2,4]oxadiazol-5-yl]-isonicotinamidine andpiperidin-1-yl}-ethanonephenoxyacetyl chloride40(R)-1-{2-[3-(2-Diethylamino-Boc-D-Pipecolic Acid, 2-436.5pyridin-4-yl)-[1,2,4]oxadiazol-Diethylamino-N-hydroxy-5-yl]-piperidin-1-yl}-2-isonicotin amidine andphenoxy-ethanonephenoxyacetyl chloride41(R)-4-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, 4-(N-437.5acetyl)-piperidin-2-yl]-Hydroxycarbamimidoyl)-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethylpyridine-2-carboxylic acidesterand phenoxyacetyl chlorideethyl ester42(R)-1-(2-{3-[6-(4-Acetyl-Boc-D-Pipecolic Acid, 6-(4-491.5piperazin-1-yl)-pyridin-3-yl]-Acetyl-piperazin-1yl)-N-[1,2,4]oxadiazol-5-yl}-hydroxy-nicotinamidine andpiperidin-1-yl)-2-phenoxy-phenoxyacetyl chlorideethanone43(R)-1-{2-[3-(2-Imidazol-1-yl-Boc-D-Pipecolic Acid, N-431.5pyridin-4-yl)-[1,2,4]oxadiazol-Hydroxy-2-imidazol-1-yl5-yl]-piperidin-1-yl}-2-isonicotinamidine andphenoxy-ethanonephenoxyacetyl chloride44(R)-1-(3-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-461.5acetyl)-piperidin-2-y]-Hydroxy-3-(2-oxo-piperidin-1-[1,2,4]oxadiazol-3-yl}-phenyl)-yl)-benzamidine and phenoxy-piperidin-2-oneacetyl chloride45(R)-1-(2-{3-[4-(3H-Imidazol-Boc-D-Pipecolic Acid, N-430.54-yl)-phenyl]-[1,2,4]oxadiazol-Hydroxy-4-(3H-imidazol-4-yl)-5-yl}-piperidin-1-yl)-2-benzamidine and phenoxy-phenoxy-ethanoneacetyl chloride46(R)-1-(2-{3-[4-(2-Methyl-Boc-D-Pipecolic Acid, N-444.5imidazol-1-yl)-phenyl]-Hydroxy-4-(2-methyl-imidazol-[1,2,4]oxadiazol-5-yl}-1-yl)-benzamidine andpiperidin-1-yl)-2-phenoxy-phenoxy-acetyl chlorideethanone47(R)-2-Phenoxy-1-{2-[3-(2-Boc-D-Pipecohc Acid, N-431.5pyrazol-1-yl-pyridin-4-yl)-Hydroxy-2-pyrazol-1-yl-[1,2,4]oxadiazol-5-yl]-isonicotin amidine andpiperidin-1-yl}-ethanonephenoxy-acetyl chloride48(R)-4-(5-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-463.5acetyl)-piperidin-2-yl]-Hydroxy-6-(3-oxo-piperazin-1-[1,2,4]oxadiazol-3-yl}-pyridin-yl)-nicotinamidine and2-yl)-piperazin-2-onephenoxyacetyl chloride49(R)-2-Phenoxy-1-(2-{3-[4-Boc-D-Pipecolic Acid, N-430.1(M − H+)(1H-tetrazol-5-yl)-phenyl]-Hydroxy-4-(1H-tetrazol-5-yl)-[1,2,4]oxadiazol-5-yl}-benzamidine and phenoxyacetylpiperidin-1-yl)-ethanonechloride50(R)-1-{2-[3-(1H-Indazol-5-Boc-D-Pipecolic Acid, N-404.5yl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-1H-indazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride51(R)-1-{2-[3-(1H-Indazol-6-Boc-D-Pipecolic Acid, N-404.1yl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-1H-indazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride52(R)-1-{2-[3-(4-Fluoro-3-Boc-D-Pipecolic Acid, 4-450.4trifluoromethyl-phenyl)-Fluoro-N-hydroxy-3-[1,2,4]oxadiazol-5-yl]-trifluoromethyl-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetyl chlorideethanone53(R)-6-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-419.3acetyl)-piperidin-2-yl]-Hydroxy-2-oxo-2,3-dihydro-[1,2,4]oxadiazol-3-yl}-1,3-1H-indole-6-carboxamidinedihydro-indol-2-oneand phenoxyacetyl chloride54(R)-5-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-420.4acetyl)-piperidin-2-yl]-Hydroxy-2-oxo-2,3-dihydro-[1,2,4]oxadiazol-3-yl}-1,3-1H-benzoimidazole-5-dihydro-benzoimidazol-2-onecarboxamidine andphenoxyacetyl chloride55(R)-5-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-419.4acetyl)-piperidin-2-yl]-Hydroxy-2-oxo-2,3-dihydro-[1,2,4]oxadiazol-3-yl}-1,3-1H-indole-5-carboxamidinedihydro-indol-2-oneand phenoxyacetyl chloride56(R)-1-{2-[3-(1H-Benzotriazol-Boc-D-Pipecolic Acid, N-405.45-yl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-1H-benzotriazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride57(R)-1-{2-[3-(1H-Boc-D-Pipecolic Acid, N-404.5Benzoimidazol-5-yl)-Hydroxy-1H-benzoimidazole-5-[1,2,4]oxadiazol-5-yl]-carboxamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetyl chlorideethanone58(R)-1-(2-{3-[6-(1,1-Dioxo-Boc-D-Pipecolic Acid, 6-(1,1-498.5thiomorpholin-4-yl)-pyridin-Dioxo-thiomorpholin-4-yl)-N-3-yl]-[1,2,4]oxadiazol-5-yl}-hydroxy-nicotinamidine andpiperidin-1-yl)-2-phenoxy-phenoxyacetyl chlorideethanone59(R)-N-(4-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-[4-(N-422.5acetyl)-piperidin-2-yl]-Hydroxy-carbamimidoyl)-[1,2,4]oxadiazol-3-yl}-pyridin-pyridin-2-yl]-acetamide and2-yl)-acetamidephenoxyacetyl chloride60(R)-1-{2-[3-(6-Benzyloxy-Boc-D-Pipecolic Acid, 6-470.8pyridin-3-yl)-[1,2,4]oxadiazol-Benzyloxy-N-hydroxy-5-yl]-piperidin-1-yl}-2-nicotinamidine andphenoxy-ethanonephenoxyacetyl chloride61(R)-5-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, 5-(N-337.5acetyl)-piperidin-2-yl]-Hydroxy-carbamimidoyl)-[1,2,4]oxadiazol-3-yl}-nicotinic acid ethyl ester andnicotinic acid ethyl esterphenoxyacetyl chloride62(R)-4-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-381.5acetyl)-piperidin-2-yl]-Hydroxy-2-oxo-1,2-dihydro-[1,2,4]oxadiazol-3-yl}-1H-pyridine-4-carboxamidine andpyridin-2-onephenoxyacetyl chloride63(R)-5-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-381.5acetyl)-piperidin-2-yl]-Hydroxy-6-oxo-1,6-dihydro-[1,2,4]oxadiazol-3-yl}-1H-pyridine-3-carboxamidine andpyridin-2-onephenoxyacetyl chloride64(R)-2-Phenoxy-1-[2-(5-Boc-D-Pipecolic Acid, N-363.5phenyl-2H-[1,2,4]triazol-3-yl)-Amino-benzamidine andpiperidin-1-yl]-ethanonephenoxyacetic acid65(R)-1-{2-[5-(4-Boc-D-Pipecolic Acid, N-441.5Methanesulfonyl-phenyl)-2H-Amino-4-methanesulfonyl-[1,2,4]triazol-3-yl]-piperidin-benzamidine and phenoxyaceticl-yl}-2-phenoxy-ethanoneacid66(R)-1-{2-[5-(3,4-Dimethoxy-Boc-D-Pipecolic Acid, N-423.5phenyl)-2H-[1,2,4]triazol-3-Amino-3,4-Dimethoxy-yl]-piperidin-1-yl}-2-phenoxy-benzamidine and phenoxyaceticethanoneacid67(R)-1-{2-[5-(3,4-Dichloro-Boc-D-Pipecolic Acid, N-431.4phenyl)-2H-[1,2,4]triazol-3-Amino-3,4-Dichloro-yl]-piperidin-1-yl}-2-benzamidine and phenoxyaceticphenoxyethanoneacid68(R)-1-{2-[5-(4-Fluoro-Boc-D-Pipecolic Acid, N-381.5phenyl)-2H-[1,2,4]triazol-3-Amino-4-Fluoro-benzamidineyl]-piperidin-1-yl}-2-phenoxy-and phenoxyacetic acidethanone69(R)-2-Phenoxy-1-{2-[5-(3-Boc-D-Pipecolic Acid, N-431.5trifluoromethyl-phenyl)-2H-Amino-3-Trifluoromethyl-[1,2,4]triazol-3-yl]-piperidin-benzamidine and phenoxyacetic1-yl}-ethanoneacid70(R)-1-{2-[5-(4-Methoxy-Boc-D-Pipecolic Acid, N-393.5phenyl)-2H-[1,2,4]triazol-3-Amino-4-Methoxy-yl]-piperidin-1-yl}-2-phenoxy-benzamidine and phenoxyaceticethanoneacid71(R)-1-{2-[5-(3-Nitro-phenyl)-Boc-D-Pipecolic Acid, N-408.52H-[1,2,4]triazol-3-yl]-Amino-3-Nitro-benzamidinepiperidin-1-yl}-2-phenoxy-and phenoxyacetic acidethanone72(R)-3-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-421.5acetyl)-piperidin-2-yl]-1H-Amino-3-Benzoic[1,2,4]triazol-3-yl}-benzoicAcidmethylester-benzamidineacid methyl esterand phenoxyacetic acid73(R)-1-{2-[5-(4-Fluoro-3-Boc-D-Pipecolic Acid, N-449.0trifluoromethyl-phenyl)-2H-Amino-4-Fluoro-3-[1,2,4]triazol-3-yl]-piperidin-trifluoromethyl-benzamidine1-yl}-2-phenoxy-ethanoneand phenoxyacetic acid74(R)-6-{5-[1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-418.5acetyl)-piperidin-2-yl]-1H-Amino-2-Oxo-2,3-dihydro-1H-[1,2,4]triazol-3-yl}-1,3-indole-6-carboxamidinedihydro-indol-2-onebenzamidine and phenoxyaceticacid751-{3-[3-(4-Methoxy-phenyl)-Morpholine-3,4-dicarboxylic396.4[1,2,4]oxadiazol-5-yl]-acid 4-tert-butyl ester, N-morpholin-4-yl}-2-phenoxy-Hydroxy-4-methoxy-ethanonebenzamidine and phenoxyacetylchloride761-{3-[3-(4-Methanesulfonyl-Morpholine-3,4-dicarboxylic444.5phenyl)-[1,2,4]oxadiazol-5-yl]-acid 4-tert-butyl ester, N-morpholin-4-yl}-2-phenoxy-Hydroxy-4-methanesulfonyl-ethanonebenzamidine and phenoxyacetylchloride774-{5-[4-(2-Phenoxy-acetyl)-Morpholine-3,4-dicarboxylic445.5morpholin-3-yl]-acid 4-tert-butyl ester, N-[1,2,4]oxadiazol-3-yl}-Hydroxy-4-sulfamoyl-benzenesulfonamidebenzamidine and phenoxyacetylchloride781-(3-{3-[6-(1,1-Dioxo-Morpholine-3,4-dicarboxylic500.5thiomorpholin-4-yl)-pyridin-acid 4-tert-butyl ester, 6-(1,1-3-yl]-[1,2,4]oxadiazol-5-yl}-Dioxo-thiomorpholin-4-yl)-N-morpholin-4-yl)-2-phenoxy-hydroxy-nicotinamidine andethanonephenoxyacetyl chloride79N-(4-{5-[4-(2-Phenoxy-Morpholine-3,4-dicarboxylic424.6acetyl)-morpholin-3-yl]-acid 4-tert-butyl ester, N-[4-(N-[1,2,4]oxadiazol-3-yl}-pyridin-Hydroxycarbamimidoyl)-2-yl)-acetamidepyridin-2-yl]-acetamide andphenoxyacetyl chloride801-{3-[5-(4-Methanesulfonyl-Morpholine-3,4-dicarboxylic443.4phenyl)-2H-[1,2,4]triazol-3-acid 4-tert-butyl ester, 4-yl]-morpholin-4-yl}-2-Methanesulfonyl-N-amino-phenoxy-ethanonebenzamidine and phenoxyacetylchloride812-Phenoxy-1-{3-[5-(3-Morpholine-3,4-dicarboxylic433.4trifluoromethyl-phenyl)-2H-acid 4-tert-butyl ester, 3-[1,2,4]triazol-3-yl]-morpholin-Trifluoromethyl-N-amino-4-yl}-ethanonebenzamidine and phenoxyacetylchloride82(R)-4-{5-[4-(2-Phenoxy-(R)-Morpholine-3,4-383.4acetyl)-morpholin-3-yl]-dicarboxylic acid 4-tert-butyl[1,2,4]oxadiazol-3-yl}-1H-ester, N-Hydroxy-2-oxo-1,2-pyridin-2-onedihydro-pyridine-4-carboxamidine andphenoxyacetyl chloride831-{3-[3-(4-Methoxy-phenyl)-4-(2-tert-Butoxy-acetyl)-412.5[1,2,4]oxadiazol-5-yl]-thiomorpholine-3-carboxylicthiomorpholin-4-yl}-2-acid, N-Hydroxy-4-methoxy-phenoxy-ethanonebenzamidine and phenoxyacetylchloride841-{3-[3-(4-Methanesulfonyl-4-(2-tert-Butoxy-acetyl)-460.4phenyl)-[1,2,4]oxadiazol-5-yl]-thiomorpholine-3-carboxylicthiomorpholin-4-yl}-2-acid, N-Hydroxy-4-methane-phenoxy-ethanonesulfonyl-benzamidine andphenoxyacetyl chloride854-{5-[4-(2-Phenoxy-acetyl)-4-(2-tert-Butoxy-acetyl)-461.4thiomorpholin-3-yl]-thiomorpholine-3-carboxylic[1,2,4]oxadiazol-3-yl}-acid, N-Hydroxy-4-sulfamoyl-benzenesulfonamidebenzamidine and phenoxyacetylchloride862-Phenoxy-1-[3-(3-pyridin-4-4-(2-tert-Butoxy-acetyl)-383.4yl-[1,2,4]oxadiazol-5-yl)-thiomorpholine-3-carboxylicthiomorpholin-4-yl]-ethanoneacid, N-Hydroxy-isonicotinamidineand phenoxyacetylchloride871-{2-[3-(4-Methoxy-phenyl)-Piperazine-1,3-dicarboxylic acid395.5[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-methoxy-benzamidine andethanonephenoxyacetic acid88N-(5-{5-[1-(2-Phenoxy-Piperazine-1,3-dicarboxylic acid423.5acetyl)-piperazin-2-yl]-1-tert-butyl ester, N-[5-(N-[1,2,4]oxadiazol-3-yl}-pyridin-Hydroxycarbamimidoyl)-2-yl)-acetamidepyridin-2-yl]-acetamide andphenoxyacetic891-{2-[3-(2-Imidazol-1-yl-Piperazine-1,3-dicarboxylic acid432.5pyridin-4-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-2-2-imidazol-1-yl-phenoxy-ethanoneisonicotinamidine andphenoxyacetic90N,N-Diethyl-4-{5-[1-(2-Piperazine-1,3-dicarboxylic acid500.5phenoxy-acetyl)-piperazin-2-1-tert-butyl ester, 4-yl]-[1,2,4]oxadiazol-3-yl}-Diethylsulfamoyl-N-benzenesulfonamidehydroxybenzamidine andphenoxyacetic acid91N,N-Dimethyl-4-{5-[1-(2-Piperazine-1,3-dicarboxylic acid472.5phenoxy-acetyl)-piperazin-2-1-tert-butyl ester, 4-yl]-[1,2,4]oxadiazol-3-yl}-Dimethylsulfamoyl-N-benzenesulfonamidehydroxybenzamidine andphenoxyacetic acid924-{5-[1-(2-Phenoxy-acetyl)-Piperazine-1,3-dicarboxylic acid444.4piperazin-2-yl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-3-yl}-4-sulfamoyl-benzamidine andbenzenesulfonamidephenoxyacetic acid931-{2-[3-(4-Methanesulfonyl-Piperazine-1,3-dicarboxylic acid443.5phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-methane-sulfonyl-ethanonebenzamidine and phenoxyaceticacid942-Phenoxy-1-[2-(3-pyridin-4-Piperazine-1,3-dicarboxylic acid366.4yl-[1,2,4]oxadiazol-5-yl)-1-tert-butyl ester, N-piperazin-1-yl]-ethanoneHydroxyisonicotin-amidine andphenoxyacetic acid951-{2-[3-(2,4-Dichloro-phenyl)-Piperazine-1,3-dicarboxylic acid433.3[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, 2,4-Dichloro-piperazin-1-yl}-2-phenoxy-N-hydroxy-benzamidine andethanonephenoxyacetic acid962-Phenoxy-1-[2-(3-pyridin-2-Piperazine-1,3-dicarboxylic acid366.4yl-[1,2,4]oxadiazol-5-yl)-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl]-ethanonepyridine-2-carboxamidine andphenoxyacetic acid972-Phenoxy-1-[2-(3-pyridin-2-Piperazine-1,3-dicarboxylic acid366.4yl-[1,2,4]oxadiazol-5-yl)-1-tert-butyl ester, N-Hydroxy-piperazin-2-yl]-ethanonepyridine-3-carboxamidine andphenoxyacetic acid981-{2-[3-(4-Nitro-phenyl)-Piperazine-1,3-dicarboxylic acid410.4[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-nitro-benzamidine ndethanonephenoxyacetic acid991-{2-[3-(6-Methoxy-pyridin-3-Piperazine-1,3-dicarboxylic acid396.4yl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-6-methoxy-nicotinamidine andethanonephenoxyacetic acid1001-{2-[3-(6-Morpholin-4-yl-Piperazine-1,3-dicarboxylic acid451.5pyridin-3-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-2-6-morpholin-4-yl-phenoxy-ethanonenicotinamidine and phenoxyacetic acid1011-{2-[3-(6-Morpholin-4-yl-Piperazine-1,3-dicarboxylic acid367.4pyridin-3-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-2-pyrazine-2-carboxamidine andphenoxy-ethanonephenoxy-acetic acid1021-{2-[3-(3-Hydroxymethyl-Piperazine-1,3-dicarboxylic acid395.4phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-3-hydroxy-methyl-benzamidineethanoneand phenoxy-acetic acid1031-{2-[3-(4-Diethylamino-Piperazine-1,3-dicarboxylic acid436.5phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, 4-piperazin-1-yl}-2-phenoxy-Diethylamino-N-hydroxy-ethanonebenzamidine and phenoxy-acetic acid1041-(2-{3-[4-(Morpholine-4-Piperazine-1,3-dicarboxylic acid514.6sulfonyl)-phenyl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-5-yl}-4-(morpholine-4-sulfonyl)-piperazin-1-yl)-2-phenoxy-benzamidine and phenoxyaceticethanoneacid105N-Methyl-4-{5-[1-(2-phenoxy-Piperazine-1,3-dicarboxylic acid458.4acetyl)-piperazin-2-yl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-3-yl}-4-methylsulfamoyl-benzenesulfonamidebenzamidine and phenoxyaceticacid106N-(2-Methoxy-ethyl)-N-Piperazine-1,3-dicarboxylic acid516.4methyl-4-{5-[1-(2-phenoxy-1-tert-butyl ester, N-Hydroxy-acetyl)-piperazin-2-yl]-4-[(2-methoxy-ethyl)-methyl-[1,2,4]oxadiazol-3-yl}-sulfamoyl]-benzamidine andbenzenesulfonamidephenoxy-acetic acid1071-{2-[3-(4-Chloro-phenyl)-Piperazine-1,3-dicarboxylic acid399.3[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, 4-Chloro-N-piperazin-1-yl}-2-phenoxy-hydroxy-benzamidine andethanonephenoxyacetic acid108N-(4-{5-[1-(2-Phenoxy-Piperazine-1,3-dicarboxylic acid490.4acetyl)-piperazin-2-yl]-1-tert-butyl ester, N-[4-(N-[1,2,4]oxadiazol-3-yl}-2-Hydroxycarbamimidoyl)-2-trifluoromethyl-phenyl)-trifluoro-methyl-phenyl]-acetamideacetamide and phenoxyaceticacid1094-{5-[1-(2-Phenoxy-acetyl)-Piperazine-1,3-dicarboxylic acid449.4piperazin-2-yl]-1-tert-butyl ester, 4-(N-[1,2,4]oxadiazol-3-yl}-benzoicHydroxycarbamimidoyl)-acid allyl esterbenzoic acid allyl ester andphenoxyacetic acid1101-{2-[3-(4-Methyl-3-nitro-Piperazine-1,3-dicarboxylic acid424.4phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-methyl-3-nitro-benzamidineethanoneand phenoxyacetic acid1111-{2-[3-(4-Methoxy-3-nitro-Piperazine-1,3-dicarboxylic acid440.4phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-methoxy-3-nitro-ethanonebenzamidine and phenoxyaceticacid1121-{2-[3-(4-Chloro-3-nitro-Piperazine-1,3-dicarboxylic acid444.8phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, 4-Chloro-N-piperazin-1-yl}-2-phenoxy-hydroxy-3-nitro-benzamidineethanoneand phenoxyacetic acid1133-Fluoro-4-{5-[1-(2-phenoxy-Piperazine-1,3-dicarboxylic acid441.4acetyl)-piperazin-2-yl]-1-tert-butyl ester, 3-Fluoro-4-[1,2,4]oxadiazol-3-yl}-benzoic(N-hydroxy-carbamimidoyl)-acid methyl esterbenzoic acid methyl ester andphenoxyacetic acid1144-{5-[1-(2-Phenoxy-acetyl)-Piperazine-1,3-dicarboxylic acid438.4piperazin-2-yl]-1-tert-butyl ester, 4-(N-[1,2,4]oxadiazol-3-yl}-Hydroxycarbamimidoyl)-pyridine-2-carboxylic acidpyridine-2-carboxylic acid ethylethyl esterester and phenoxyacetic acid1152-Phenoxy-1-{2-[3-(4-Piperazine-1,3-dicarboxylic acid448.5piperidin-1-yl-phenyl)-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-5-yl]-4-piperidin-1-yl-benzamidinepiperazin-1-yl}-ethanoneand phenoxyacetic acid1161-{2-[3-(4-Morpholin-4-yl-Piperazine-1,3-dicarboxylic acid450.4phenyl)-[1,2,4]oxadiazol-5-yl]-1-tert-butyl ester, N-Hydroxy-piperazin-1-yl}-2-phenoxy-4-morpholin-4-yl-benzamidineethanoneand phenoxyacetic acid1171-(2-{3-[4-(2-Methyl-Piperazine-1,3-dicarboxylic acid445.4imidazol-1-yl)-phenyl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-5-yl}-4-(2-methyl-imidazol-1-yl)-piperazin-1-yl)-2-phenoxy-benzamidine and phenoxyaceticethanoneacid1181-(2-{3-[4-(3H-Imidazol-4-Piperazine-1,3-dicarboxylic acid431.4yl)-phenyl]-[1,2,4]oxadiazol-5-1-tert-butyl ester, N-Hydroxy-yl}-piperazin-1-yl)-2-phenoxy-4-(3H-imidazol-4-yl)-ethanonebenzamidine and phenoxyaceticacid1194-(5-{5-[1-(2-Phenoxy-acetyl)-Piperazine-1,3-dicarboxylic acid464.4piperazin-2-yl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-3-yl}-pyridin-6-(3-oxo-piperazin-1-yl)-2-yl)-piperazin-2-onenicotinamidine andphenoxyacetic acid1201-{2-[3-(6-Imidazol-1-yl-Piperazine-1,3-dicarboxylic acid432.4pyridin-3-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-2-6-imidazol-1-yl-nicotinamidinephenoxy-ethanoneand phenoxyacetic acid1211-(2-{3-[6-(4-Acetyl-Piperazine-1,3-dicarboxylic acid492.4piperazin-1-yl)-pyridin-3-yl]-1-tert-butyl ester, 6-(4-Acetyl-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-N-hydroxy-piperazin-1-yl)-2-phenoxy-nicotinamidine andethanonephenoxyacetic acid1222-Phenoxy-1-{2-[3-(4-pyrrol-Piperazine-1,3-dicarboxylic acid430.41-yl-phenyl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-ethanone4-pyrrol-1-yl-benzamidine andphenoxyacetic acid1232-Phenoxy-1-{2-[3-(4Piperazine-1,3-dicarboxylic acid497.4trifluoromethanesulfonyl-1-tert-butyl ester, N-Hydroxy-phenyl)-[1,2,4]oxadiazol-5-yl]-4-trifluoromethane-sulfonyl-piperazin-1-yl}-ethanonebenzamidine and phenoxyaceticacid1241-{2-[3-(2-Morpholin-4-yl-Piperazine-1,3-dicarboxylic acid451.4pyridin-4-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, N-Hydroxy-5-yl]-piperazin-1-yl}-2-2-morpholin-4-yl-phenoxy-ethanoneisonicotinamidine andphenoxyacetic acid1252-Phenoxy-1-{2-[3-(2-Piperazine-1,3-dicarboxylic acid467.4thiomorpholin-4-yl-pyridin-4-1-tert-butyl ester, N-Hydroxy-yl)-[1,2,4]oxadiazol-5-yl]-2-thiomorpholin-4-yl-piperazin-1-yl}-ethanoneisonicotinamidine andphenoxyacetic acid1261-(2-{3-[6-(3-Hydroxymethyl-Piperazine-1,3-dicarboxylic acid465.4pyrrolidin-1-yl)-pyridin-3-yl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-5-yl}-6-(3-hydroxymethyl-pyrrolidin-piperazin-1-yl)-2-phenoxy-1-yl)-nicotinamidine andethanonephenoxyacetic acid127(R)-1-{2-[3-(6-Methoxy-D-Piperazine-1,3-dicarboxylic396.4pyridin-3-yl)-[1,2,4]oxadiazol-acid 1-tert-butyl ester, N-5-yl]-piperazin-1-yl}-2-Hydroxy-6-methoxy-phenoxy-ethanonenicotinamidine andphenoxyacetic acid128(R)-1-{2-[3-(6-Morpholin-4-D-Piperazine-1,3-dicarboxylic451.4yl-pyridin-3-yl)-acid 1-tert-butyl ester, N-[1,2,4]oxadiazol-5-yl]-Hydroxy-6-morpholin-4-yl-piperazin-1-yl}-2-phenoxy-nicotinamidine andethanonephenoxyacetic acid129(R)-N-(4-{5-[1-(2-Phenoxy-D-Piperazine-1,3-dicarboxylic490.4acetyl)-piperazin-2-yl]-acid 1-tert-butyl ester, N-[4-(N-[1,2,4]oxadiazol-3-yl}-2-Hydroxycarbamimidoyl)-2-trifluoromethyl-phenyl)-trifluoromethyl-phenyl]-acetamideacetamide and phenoxyaceticacid130(R)-1-{2-[3-(4-Methyl-3-D-Piperazine-1,3-dicarboxylic424.4nitro-phenyl)-acid 1-tert-butyl ester, N-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-methyl-3-nitro-piperazin-1-yl}-2-phenoxy-benzamidine and phenoxyaceticethanoneacid131(R)-1-{2-[3-(4-Methyl-3-D-Piperazine-1,3-dicarboxylic440.4nitro-phenyl)-acid 1-tert-butyl ester, 1-{2-[3-[1,2,4]oxadiazol-5-yl]-(4-Methoxy-3-nitro-phenyl)-piperazin-1-yl}-2-phenoxy-[1,2,4]oxadiazol-5-yl]-ethanonepiperazin-1-yl}-2-phenoxy-ethanone and phenoxyaceticacid132(R)-1-{2-[3-(4-Morpholin-4-D-Piperazine-1,3-dicarboxylic450.4yl-phenyl)-[1,2,4]oxadiazol-5-acid 1-tert-butyl ester, N-yl]-piperazin-1-yl}-2-phenoxy-Hydroxy-4-morpholin-4-yl-ethanonebenzamidine and phenoxyaceticacid133(R)-1-(2-{3-[4-(3H-Imidazol-D-Piperazine-1,3-dicarboxylic431.44-yl)-phenyl]-[1,2,4]oxadiazol-acid 1-tert-butyl ester, N-5-yl}-piperazin-1-yl)-2-Hydroxy-4-(3H-imidazol-4-yl)-phenoxy-ethanonebenzamidine and phenoxyaceticacid134(R)-1-(2-{3-[6-(3-D-Piperazine-1,3-dicarboxylic465.4Hydroxymethyl-pyrrolidin-1-acid 1-tert-butyl ester, N-yl)-pyridin-3-yl]-Hydroxy-6-(3-hydroxymethyl-[1,2,4]oxadiazol-5-yl}-pyrrolidin-1-yl)-nicotinamidinepiperazin-1-yl)-2-phenoxy-and phenoxyacetic acidethanone135(R)-1-(2-{3-[6-(4-Acetyl-D-Piperazine-1,3-dicarboxylic492.5piperazin-1-yl)-pyridin-3-yl]-acid 1-tert-butyl ester, 6-(4-[1,2,4]oxadiazol-5-yl}-Acetyl-piperazin-1-yl)-N-piperazin-1-yl)-2-phenoxy-hydroxy-nicotinamidine andethanonephenoxyacetic acid136(R)-N-(3-{5-[1-(2-Phenoxy-D-Piperazine-1,3-dicarboxylic422.4acetyl)-piperazin-2-yl]-acid 1-tert-butyl ester, N-[3-(N-[1,2,4]oxadiazol-3-yl}-phenyl)-Hydroxycarbamimidoyl)-acetamide hydrochloridephenyl]-acetamide andphenoxyacetic acid137(R)-1-{2-[3-(1H-D-Piperazine-1,3-dicarboxylic405.5Benzoimidazol-5-yl)-acid 1-tert-butyl ester, N-[1,2,4]oxadiazol-5-yl]-Hydroxy-1H-benzoimidazole-5-piperazin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid138(R)-1-{2-[3-(1H-Benzotriazol-D-Piperazine-1,3-dicarboxylic406.45-yl)-[1,2,4]oxadiazol-5-yl]-acid 1-tert-butyl ester, N-piperazin-1-yl}-2-phenoxy-Hydroxy-1H-benzotriazole-5-ethanonecarboxamidine andphenoxyacetic acid139(R)-1-{2-[3-(1H-Indazol-5-D-Piperazine-1,3-dicarboxylic405.4yl)-[1,2,4]oxadiazol-5-yl]-acid 1-tert-butyl ester, N-piperazin-1-yl}-2-phenoxy-Hydroxy-1H-indazole-5-ethanone hydrochloridecarboxamidine andphenoxyacetic acid140(R)-5-{5-[1-(2-Phenoxy-D-Piperazine-1,3-dicarboxylic421.5acetyl)-piperazin-2-yl]-acid 1-tert-butyl ester, N-[1,2,4]oxadiazol-3-yl}-1,3-Hydroxy-2-oxo-2,3-dihydro-dihydro-benzoimidazol-2-one1H-benzoimidazole-5-carboxamidine andphenoxyacetic acid141(R)-1-(2-{3-[6-(1,1-Dioxo-D-Piperazine-1,3-dicarboxylic499.1thiomorpholin-4-yl)-pyridin-acid 1-tert-butyl ester, 6-(1,1-3-yl]-[1,2,4]oxadiazol-5-yl}-Dioxo-thiomorpholin-4-yl)-N-piperazin-1-yl)-2-phenoxy-hydroxy-nicotinamidine andethanone hydrochloridephenoxyacetic acid142(R)-1-{2-[3-(3-Nitro-phenyl)-D-Piperazine-1,3-dicarboxylic410.1[1,2,4]oxadiazol-5-yl]-acid 1-tert-butyl ester, N-piperazin-1-yl}-2-phenoxy-Hydroxy-3-nitro-benzamidineethanoneand phenoxyacetic acid143(R)-1-{2-[3-(4-Fluoro-D-Piperazine-1,3-dicarboxylic383.4phenyl)-[1,2,4]oxadiazol-5-yl]-acid 1-tert-butyl ester, 4-Fluoro-piperazin-1-yl}-2-phenoxy-N-hydroxy-benzamidine andethanonephenoxyacetic acid144(R)-4-{5-[1-(2-Phenoxy-D-Piperazine-1,3-dicarboxylic382.4acetyl)-piperazin-2-yl]-acid 1-tert-butyl ester, N-[1,2,4]oxadiazol-3-yl}-1H-Hydroxy-2-oxo-1,2-dihydro-pyridin-2-onepyridine-4-carboxamidine andphenoxyacetic acid1451-{4-Acetyl-2-[3-(4-methoxy-4-Acetyl-piperazine-1,2-437.5phenyl)-[1,2,4]oxadiazol-5-yl]-dicarboxylic acid 1-tert-butylpiperazin-1-yl}-2-phenoxy-ester, N-Hydroxy-4-methoxy-ethanonebenzamidine and phenoxyaceticacid1461-{4-Acetyl-2-[3-(4-4-Acetyl-piperazine-1,2-485.5methanesulfonyl-phenyl)-dicarboxylic acid 1-tert-butyl[1,2,4]oxadiazol-5-yl]-ester, N-Hydroxy-4-piperazin-1-yl}-2-phenoxy-methanesulfonyl-benzamidineethanoneand phenoxyacetic acid1474-{5-[4-Acetyl-1-(2-phenoxy-4-Acetyl-piperazine-1,2-486.5acetyl)-piperazin-2-yl]-dicarboxylic acid 1-tert-butyl[1,2,4]oxadiazol-3-yl}-ester, N-Hydroxy-4-sulfamoyl-benzenesulfonamidebenzamidine and phenoxyaceticacid1481-[4-Acetyl-2-(3-pyridin-4-yl-4-Acetyl-piperazine-1,2-408.5[1,2,4]oxadiazol-5-yl)-dicarboxylic acid 1-tert-butylpiperazin-1-yl]-2-phenoxy-ester, N-Hydroxy-ethanoneisonicotinamidine andphenoxyacetic acid1491-{4-Methanesulfonyl-2-[3-(4-4-Methanesulfonyl-piperazine-473.2methoxy-phenyl)-1,2-dicarboxylic acid 1-tert-[1,2,4]oxadiazol-5-yl]-butyl ester, N-Hydroxy-4-piperazin-1-yl}-2-phenoxy-Methoxy-benzamidine andethanonephenoxyacetic acid150(R)-1-{2-[5-(4-Fluoro-D-Piperazine-1,3-dicarboxylic382.4phenyl)-2H-[1,2,4]triazol-3-acid 1-tert-butyl ester, 4-Fluoro-yl]-piperazin-1-yl}-2-phenoxy-N-amino-benzamidine andethanonephenoxyacetic acid151(R)-2-Phenoxy-1-{2-[5-(3-D-Piperazine-1,3-dicarboxylic432.4trifluoromethyl-phenyl)-2H-acid 1-tert-butyl ester, 3-[1,2,4]triazol-3-yl]-piperazin-Trifluoromethyl-N-amino-1-yl}-ethanonebenzamidine and phenoxyaceticacid1521-{2-[5-(4-Fluoro-3-Piperazine-1,3-dicarboxylic acid450.4trifluoromethyl-phenyl)-2H-1-tert-butyl ester, 4-Fluoro-3-[1,2,4]triazol-3-yl]-piperazin-trifluoromethyl-N-amino-1-yl}-2-phenoxy-ethanonebenzamidine and phenoxyaceticacid1531-{2-[5-(4-Methanesulfonyl-Piperazine-1,3-dicarboxylic acid442.4phenyl)-2H-[1,2,4]triazol-3-1-tert-butyl ester, 4-yl]-piperazin-1-yl}-2-phenoxy-Methanesulfonyl-N-amino-ethanonebenzamidine and phenoxyaceticacid1542-Phenoxy-1-{2-[5-(3-Piperazine-1,3-dicarboxylic acid432.4trifluoromethyl-phenyl)-2H-1-tert-butyl ester, 3-[1,2,4]triazol-3-yl]-piperazin-Trifluoromethyl-N-amino-1-yl}-ethanonebenzamidine and phenoxyaceticacid1552-Phenoxy-1-[2-(5-p-tolyl-2H-Piperazine-1,3-dicarboxylic acid378.4[1,2,4]triazol-3-yl)-piperazin-1-tert-butyl ester, 4-Methyl-N-1-yl]-ethanoneamino-benzamidine andphenoxyacetic acid1562-Phenoxy-1-{2-[5-(4Piperazine-1,3-dicarboxylic acid432.4trifluoromethyl-phenyl)-2H-1-tert-butyl ester, 4-[1,2,4]triazol-3-yl]-piperazin-Trifluoromethyl-N-amino-1-yl}-ethanonebenzamidine and phenoxyaceticacid1571-{2-[5-(4-Methoxy-phenyl)-Piperazine-1,3-dicarboxylic acid394.42H-[1,2,4]triazol-3-yl]-1-tert-butyl ester, 4-Methoxy-piperazin-1-yl}-2-phenoxy-N-amino-benzamidine andethanonephenoxyacetic acid1581-{2-[5-(4-Fluoro-phenyl)-2H-Piperazine-1,3-dicarboxylic acid382.4[1,2,4]triazol-3-yl]-piperazin-1-tert-butyl ester, 4-Fluoro-N-1-yl}-2-phenoxy-ethanoneamino-benzamidine andphenoxyacetic acid1591-{2-[5-(4-Fluoro-phenyl)-2H-Piperazine-1,3-dicarboxylic acid400.4[1,2,4]triazol-3-yl]-piperazin-1-tert-butyl ester, 2,4-Difluoro-1-yl}-2-phenoxy-ethanoneN-amino-benzamidine andphenoxyacetic acid1601-{2-[5-(3,4-Dimethoxy-Piperazine-1,3-dicarboxylic acid424.4phenyl)-2H-[1,2,4]triazol-3-1-tert-butyl ester, 3,4-yl]-piperazin-1-yl}-2-phenoxy-Dimethoxy-N-amino-ethanonebenzamidine and phenoxyaceticacid1611-{2-[5-(3,4-Dichloro-phenyl)-Piperazine-1,3-dicarboxylic acid432.42H-[1,2,4]triazol-3-yl]-1-tert-butyl ester, 3,4-Dichioro-piperazin-1-yl}-2-phenoxy-N-amino-benzamidine andethanonephenoxyacetic acid1621-{2-[5-(2-Fluoro-phenyl)-2H-Piperazine-1,3-dicarboxylic acid382.4[1,2,4]triazol-3-yl]-piperazin-1-tert-butyl ester, 3-Fluoro-N-1-yl}-2-phenoxy-ethanoneamino-benzamidine andphenoxyacetic acid1631-{2-[5-(2-Fluoro-phenyl)-2H-Piperazine-1,3-dicarboxylic acid382.4[1,2,4]triazol-3-piperazin-1-tert-butyl ester, 2-Fluoro-N-1-yl}-2-phenoxy-ethanoneamino-benzamidine andphenoxyacetic acid

Example 164
4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide

0.1 mmol of 4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide are dissolved in 1 ml DMF and 1 eq. DIPEA and Na₂CO₃added. To the suspension 1 eq. of MeI is added and the reaction stirred at room temperature overnight. The product is isolated via preparative HPLC.

MS(ISO): 422.4 (MH+)

The following compounds have been prepared in analogy:

TABLE 2MH⁺ExampleCompound nameStarting material(found)165(R)-1-{2-[3-(1H-Indazol-5yl)-(R)-1-{2-[3-(1H-Indazol-5 yl)-419.5[1,2,4]oxadiazol-5-yl]-4-[1,2,4]oxadiazol-5 yl]-methyl-piperazin-1-yl}-2-piperazin-1-yl}-2-phenoxy-phenoxy-ethanoneethanone166(R)-1-{2-[3-(4-Fluoro-phenyl)-(R)-1-{2-[3-(4-Fluoro-397.4[1,2,4]oxadiazol-5-yl]-4-phenyl)-[1,2,4]oxadiazol-5-yl]-methyl-piperazin-1-yl}-2-piperazin1-yl}-2-phenoxy-phenoxy-ethanoneethanone167(R)-5-{5-[4-Methyl-1-(2-(R)-5-{5-[1-(2-Phenoxy-434.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-yl]-[1,2,4]oxadiazol-3-yl}-1,3-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-onedihydro-indol-2-one168(R)-5-{5-[4-Methyl-1-(2-(R)-5-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-yl]-[1,2,4]oxadiazol-3-yl}-1,3-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-onedihydro-benzoimidazol-2-one169(R)-1-{2-[3-(1H-(R)-1-{2-[3-(1H-419.5Benzoimidazol-5-yl)-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-4-[1,2,4]oxadiazol-5-yl]-methyl-piperazin-1-yl}-2-piperazin-1-yl}-2-phenoxy-phenoxy-ethanoneethanone170(R)-1-{2-[3-(1H-Benzotriazol-(R)-1-{2-[3-(1H-Benzotriazol-420.55-yl)-[1,2,4]oxadiazol-5-yl]-4-5-yl)-[1,2,4]oxadiazol-5-yl]-methyl-piperazin-1-yl}-2-piperazin-1-yl}-2-phenoxy-phenoxy-ethanoneethanone171(R)-1-{4-Methyl-2-[5-(3-(R)-2-Phenoxy-1-{2-[5-(3-446.4trifluoromethyl-phenyl)-2H-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-[1,2,4]triazol-3-yl]-piperazinyl}-2-phenoxy-ethanone1-yl}-ethanone172(R)-1-{2-[5-(4-Methoxy-(R)-1-{2-[5-(4-Methoxy-408.4phenyl)-2H-[1,2,4]triazol-3-yl]-phenyl)-2H-[1,2,4]triazol-3-4-methyl-piperazin-1-yl}-2-yl]-piperazin}-yl}-2-phenoxy-phenoxy-ethanoneethanone173(R)-1-{2-[5-(4-Fluoro-phenyl)-(R)-1-{2-[5-(4-Fluoro-396.42H-[1,2,4]triazol-3-yl]-4-phenyl)-2H-[1,2,4]triazol-3-methyl-piperazin-1-yl}-2-yl]-piperazin1-yl}-2-phenoxy-phenoxy-ethanoneethanone174(R)-1-{2-[5-(4-(R)-1-{2-[5-(4-456.4Methanesulfonyl-phenyl)-2H-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-[1,2,4]triazol-3-yl]-piperazin-piperazin-1-yl}-2-phenoxy-1-yl}-2-phenoxy-ethanoneethanone175(R)-4-{5-[4-Methyl-1-(2-(R)-4-{5-[1-(2-Phenoxy-436.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-benzoicbenzoic acid methyl esteracid methyl ester176(R)-N-(3-{5-[4-Methyl-1-(2-(R)-N-(3-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-phenyl)-phenyl)-acetamideacetamide177(R)-N-(3-{5-[4-Methyl-1-(2-(R)-N-(3-{5-[1-(2-Phenoxy-471.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-phenyl)phenyl)-methanesulfonamidemethanesulfonamide178(R)-4-{5-[4-Methyl-1-(2-(R)-4-{5-[1-(2-Phenoxy-421.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-benzamidebenzamide

Example 179
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid

4 mmol of (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid benzyl ester were dissolved in MeOH and treated with Pd/C and flushed with hydrogen (3 bar) and stirred for 30 min. The catalyst was filtered off and the solvent evaporated. After extraction from ethylacetate/water the resulting oil was purified via preperative HPLC. The corresponding alkylesters were treated with aq. 2N NaOH or LiOH in methanol at room temperature. The allylester can be cleaved using Pd(Ph3)4 as catalyst and morpholine as a nucleophile.

MS(ISO): 408.5 (MH+)

The following compounds have been prepared in analogy:

TABLE 3MH⁺ExampleCompound nameStarting material(found)180(R)-3-{5-[1-(2-Phenoxy-(R)-3-{5-[1-(2-Phenoxy-408.5acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-benzoicacidacid methyl ester181(R)-6-{5-[1-(2-Phenoxy-(R)-6-{5-[1-(2-Phenoxy-409.4acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic[1,2,4]oxadiazol-3-yl}-nicotinicacidacid methylester182(R)-2-Fluoro-4-{5-[1-(2-(R)-2-Fluoro-4-{5-[1-(2-426.5phenoxy-acetyl)-piperidin-2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acidbenzoic acid methyl ester183(R)-5-{5-[1-(2-Phenoxy-(R)-5-{5-[1-(2-Phenoxy-409.4acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-[1,2,4]oxadiazol-3-yl}-2-carboxylic acidpyridine-2-carboxylic acidmethyl ester184(R)-4-{5-[1-(2-Phenoxy-(R)-4-{5-[1-(2-Phenoxy-409.4acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-[1,2,4]oxadiazol-3-yl}-2-carboxylic acidpyridine-2-carboxylic acid ethylester185(R)-3-{5-[1-(2-Phenoxy-(R)-3-{5-[1-(2-Phenoxy-407.4acetyl)-piperidin-2-yl]-1H-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid[1,2,4]triazol-3-yl}-benzoic acidmethyl ester1863-{5-[4-(2-Phenoxy-acetyl)-3-{5-[4-(2-Phenoxy-acetyl)-410.5morpholin-3-yl]-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-benzoicacidacid methyl ester1873-{5-[4-(2-Phenoxy-acetyl)-3-{5-[4-(2-Phenoxy-acetyl)-410.5morpholin-3-yl]-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-benzoicacidacid methyl ester1884-{5-[4-(2-Phenoxy-acetyl)-4-{5-[4-(2-Phenoxy-acetyl)-426.4thiomorpholin-3-yl]-thiomorpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzamidebenzamide methyl ester1894-{5-[4-(2-Phenoxy-acetyl)-4-{5-[4-(2-Phenoxy-acetyl)-426.4thiomorpholin-3-yl]-thiomorpholin-3-yl}-[1,2,4]oxadiazol-4-yl}-[1,2,4]oxadiazol-4-yl}-benzamidebenzamide methyl ester1903-{5-[4-Acetyl-1-(2-phenoxy-3-{5-[4-Acetyl-1-(2-phenoxy-451.5acetyl)-piperazin-2-yl]-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-benzoicacidacid methyl ester1914-{5-[4-Acetyl-1-(2-phenoxy-4-{5-[4-Acetyl-1-(2-phenoxy-451.5acetyl)-piperazin-2-yl]-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-benzoicacidacid methyl ester192(R)-4-{5-[4-Methyl-1-(2-(R)-4-{5-[1-(2-Phenoxy-422.5phenoxy-acetyl)-piperazin-2-acetyl)-piperazin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-benzoic acidbenzoic acidmethyl ester193(R)-5-{5-[1-(2-Phenoxy-(R)-5-{5-[1-(2-Phenoxy-409.5acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic[1,2,4]oxadiazol-3-yl}-nicotinicacidacid ethyl ester

Example 194
(R)-1-(2-{3-[4-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone

0.07 mmol of (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid were treated with 1 eq. of TBTU/DIPEA in 1 ml DMF for 10 min and 2 eq. of Morpholine added. Ther reaction is stirred overnight at room temperature and the product isolated via preperative HPLC.

MS(ISO): 477.6 (MH+)

The following compounds have been prepared in analogy:

TABLE 4MH⁺ExampleCompound nameStarting material(found)195(R)-1-(2-{3-[4-(3-Hydroxy-(R)-4-{5-[1-(2-Phenoxy-477.6pyrrolidine-1-carbonyl)-acetyl)-piperidin-2-yl]-phenyl]-[1,2,4]oxadiazol-5-yl}-[1,2,4]oxadiazol-3-yl}-benzoicpiperidin-1-yl)-2-phenoxy-acid and pyrrolidin-3-olethanone196(R)-N,N-Diethyl-4-{5-[1-(2-(R)-4-{5-[1-(2-Phenoxy-463.6phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and diethylamine197(R)-N-Methyl-4-{5-[1-(2-(R)-4-{5-[1-(2-Phenoxy-421.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and methylamine198(R)-N,N-Dimethyl-4-{5-[1-(2-(R)-4-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and dimethylamine199(R)-N-Ethyl-4-{5-[1-(2-(R)-4-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and ethylamine200(R)-N-Cyclopropyl-4-{5-[1-(2-(R)-4-{5-[1-(2-Phenoxy-447.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and cyclopropylamine201(R)-N-(2-Hydroxy-ethyl)-4-{5-(R)-4-{5-[1-(2-Phenoxy-451.5[1-(2-phenoxy-acetyl)-acetyl)-piperidin-2-yl]-piperidin-2-yl]-[1,2,4]oxadiazol-[1,2,4]oxadiazol-3-yl}-benzoic3-yl}-benzamideacid and ethanolamine202(R)-N-(2-Methoxy-ethyl)-N-(R)-4-{5-[1-(2-Phenoxy-479.5methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-acid and (2-methoxy-ethyl)-benzamidemethyl-amine203(R)-N-Methyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-421.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and methylamine204(R)-N,N-Dimethyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and dimethylamine205(R)-N-Ethyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-435.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and ethylamine206(R)-N-Cyclopropyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-447.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and cyclopropylamine207(R)-N-(2-Hydroxy-ethyl)-3-{5-(R)-3-{5-[1-(2-Phenoxy-451.5[1-(2-phenoxy-acetyl)-acetyl)-piperidin-2-yl]-piperidin-2-yl]-[1,2,4]oxadiazol-[1,2,4]oxadiazol-3-yl}-benzoic3-yl}-benzamideacid and ethanolamine208(R)-N-(2-Methoxy-ethyl)-N-(R)-3-{5-[1-(2-Phenoxy-479.5methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic[1,2,4]oxadiazol-3-yl}-acid and (2-methoxy-ethyl)-benzamidemethyl-amine209(R)-1-(2-{3-[3-(Morpholine-4-(R)-3-{5-[1-(2-Phenoxy-477.6carbonyl)-phenyl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-[1,2,4]oxadiazol-3-yl}-benzoic1-yl)-2-phenoxy-ethanoneacid and morpholine210(R)-1-(2-{3-[3-(3-Hydroxy-(R)-3-{5-[1-(2-Phenoxy-477.6pyrrolidine-1-carbonyl)-acetyl)-piperidin-2-yl]-phenyl]-[1,2,4]oxadiazol-5-yl}-[1,2,4]oxadiazol-3-yl}-benzoicpiperidin-1-yl)-2-phenoxy-acid and pyrrolidin-3-olethanone211(R)-N,N-Diethyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-463.6phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-benzoicbenzamideacid and diethylamine212(R)-4-{5-[1-(2-Phenoxy-acetyl)-(R)-4-{5-[1-(2-Phenoxy-422.5piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-methylamidepyridine-2-carboxylic acid andmethylamine213(R)-4-{5-[1-(2-Phenoxy-acetyl)-(R)-4-{5-[1-(2-Phenoxy-436.5piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-dimethylamidepyridine-2-carboxylic acid anddimethylamine214(R)-4-{5-[1-(2-Phenoxy-acetyl)-(R)-4-{5-[1-(2-Phenoxy-436.5piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-ethylamidepyridine-2-carboxylic acid andethylamine215(R)-4-{5-[1-(2-Phenoxy-acetyl)-(R)-4-{5-[1-(2-Phenoxy-464.5piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-diethylamidepyridine-2-carboxylic acid anddiethylamine216(R)-1-(2-{3-[2-(Morpholine-4-(R)-4-{5-[1-(2-Phenoxy-478.5carbonyl)-pyridin-4-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-[1,2,4]oxadiazol-3-yl}-1-yl)-2-phenoxy-ethanonepyridine-2-carboxylic acid andmorpholine217(R)-1-(2-{3-[2-(3-(R)-4-{5-[1-(2-Phenoxy-540.5Methanesulfonyl-pyrrolidine-1-acetyl)-piperidin-2-yl]-carbonyl)-pyridin-4-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-5-yl}-piperidin-pyridine-2-carboxylic acid and1-yl)-2-phenoxy-ethanone3-methanesulfonyl-pyrrolidine218(R)-5-{5-[1-(2-Phenoxy-acetyl)-(R)-5-{5-[1-(2-Phenoxy-422.4piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-methylamidepyridine-2-carboxylic acid andmethylamine219(R)-N-Methyl-3-{5-[1-(2-(R)-3-{5-[1-(2-Phenoxy-420.4phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-1H-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-benzoicbenzamideacid and methylamine2201N,N-Diethyl-4-{5-[1-(2-3-[3-(4-Carboxy-phenyl)-464.3phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-5-yl]-4-(2-[1,2,4]oxadiazol-3-yl}-phenoxy-acetyl)-piperazine-1-benzamidecarboxylic acid tert-butyl esterand diethylamine2211-(2-{3-[4-(Morpholine-4-3-[3-(4-Carboxy-phenyl)-478.0carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl]-4-(2-[1,2,4]oxadiazol-5-yl}-piperazin-phenoxy-acetyl)-piperazine-1-1-yl)-2-phenoxy-ethanonecarboxylic acid tert-butyl esterand morpholine222N-Methyl-4-{5-[1-(2-phenoxy-3-[3-(4-Carboxy-phenyl)-422.4acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-5-yl]-4-(2-[1,2,4]oxadiazol-3-yl}-phenoxy-acetyl)-piperazine-1-benzamidecarboxylic acid tert-butyl esterand methylamine223(R)-N-Methyl-5-{5-[1-(2-(R)-5-{5-[1-(2-Phenoxy-422.4phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicnicotinamideacid and methylamine224(R)-N-Ethyl-5-{5-[1-(2-(R)-5-{5-[1-(2-Phenoxy-436.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicnicotinamideacid and ethylamine225(R)-N-Diethyl-5-{5-[1-(2-(R)-5-{5-[1-(2-Phenoxy-436.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicnicotinamideacid and diethylamine226(R)-N-Diethyl-5-{5-[1-(2-(R)-5-{5-[1-(2-Phenoxy-464.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicnicotinamideacid and diethylamine227(R)-N-(2-Hydroxy-ethyl)-5-{5-(R)-5-{5-[1-(2-Phenoxy-452.5[1-(2-phenoxy-acetyl)-acetyl)-piperidin-2-yl]-piperidin-2-yl]-[1,2,4][1,2,4]oxadiazol-3-yl}-nicotinicoxadiazol-3-yl}-nicotinamideacid and aminoethanol228(R)-N-(2-Methoxy-ethyl)-N-(R)-5-{5-[1-(2-Phenoxy-480.6methyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic[1,2,4]oxadiazol-3-yl}-acid and (2-Methoxy-ethyl)-nicotinamidemethyl-amine229(R)-N-Cyclopropyl-5-{5-[1-(2-(R)-5-{5-[1-(2-Phenoxy-448.5phenoxy-acetyl)-piperidin-2-yl]-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicnicotinamideacid and cyclopropylamine230(R)-1-(2-{3-[5-(3-Hydroxy-(R)-5-{5-[1-(2-Phenoxy-478.5pyrrolidine-1-carbonyl)-pyridin-acetyl)-piperidin-2-yl]-3-yl]-[1,2,4]oxadiazol-5-yl}-[1,2,4]oxadiazol-3-yl}-nicotinicpiperidin-1-yl)-2-phenoxy-acid and Pyrrolidin-3-olethanone

Example 231
(R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide

34 mg of (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid were treated with 1 eq HATU/DIPEA in DMF and added to 1 eq of Rink-Resin. The reaction was shaken overnight at room temperature. The resin was washed with DMF, MeOH, DCM (3 times each) and then treated with TFA/DCM (1:1) for 2 h. The resulting yellow oil was purified via preparative HPLC.

MS(ISO): 407.5 (MH+)

The following compounds have been prepared in analogy:

TABLE 5MH⁺ExampleCompound nameStarting materials(found)232(R)-3-{5-[1-(2-Phenoxy-acetyl)-(R)-3-{5-[1-(2-Phenoxy-407.4piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-benzamide[1,2,4]oxadiazol-3-yl}-benzoicacid and Rink resin233(R)-4-{5-[1-(2-Phenoxy-acetyl)-(R)-4-{5-[1-(2-Phenoxy-408.4piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-pyridine-2-carboxylic acid[1,2,4]oxadiazol-3-yl}-amidepyridine-2-carboxylic acid andRink resin234(R)-3-{5-[1-(2-Phenoxy-acetyl)-(R)-3-{5-[1-(2-Phenoxy-406.4piperidin-2-yl]-1H-[1,2,4]triazol-acetyl)-piperidin-2-yl]-1H-3-yl}-benzamide[1,2,4]triazol-3-yl}-benzoicacid and Rink resin2354-{5-[4-(2-Phenoxy-acetyl)-4-{5-[4-(2-Phenoxy-acetyl)-409.5morpholin-3-yl]-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzamide[1,2,4]oxadiazol-3-yl}-benzoicacid and Rink resin2364-{5-[4-(2-Phenoxy-acetyl)-4-{5-[4-(2-Phenoxy-acetyl)-425.5thiomorpholin-3 yl]-thiomorpholin-3 yl]-[1,2,4]oxadiazol-3yl}-benzamide[1,2,4]oxadiazol-3yl}-benzoicacid and Rink resin2374-{5-[1-(2-Phenoxy-acetyl)-3-[3-(4-Carboxy-phenyl)-408.3piperazin-2-yl]-[1,2,4]oxadiazol-[1,2,4]oxadiazol-5-yl]-4-(2-3-yl}-benzamidephenoxy-acetyl)-piperazine-1-carboxylic acid tert-butyl esterand Rink resin238(R)-5-{5-[1-(2-Phenoxy-acetyl)-(R)-5-{5-[1-(2-Phenoxy-408.5piperidin-2-yl]-[1,2,4]oxadiazol-acetyl)-piperidin-2-yl]-3-yl}-nicotinamide[1,2,4]oxadiazol-3-yl}-nicotinicacid and Rink resin

Example 239
(R)-1-{2-[3-(3-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone

(R)-1-{2-[3-(3-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone were dissolved in 100 ml MeOH. 50 ml sat. NH₄Cl and Zn-powder were added. The suspension was briefly heated to reflux and stirred for 30 min. After filtration the MeOH was evaporated and the product isolated via extraction ethylacetate/water.

MS(ISO): 379.5 (MH+)

Example 240
(R)-1-{2-[3-(4-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone

(R)-1-{2-[3-(4-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone were dissolved in 100 ml MeOH. 50 ml sat. NH₄Cl and Zn-powder were added. The suspension was briefly heated to reflux and stirred for 30 min. After filtration the MeOH was evaporated and the product isolated via extraction ethylacetate/water.

MS(ISO): 379.5 (MH+)

Example 241
(R)-1-{2-[5-(3-Amino-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone

(R)-1-{2-[5-(3-Nitro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone were dissolved in 100 ml MeOH. 50 ml sat. NH₄Cl and Zn-powder were added. The suspension was briefly heated to reflux and stirred for 30 min. After filtration the MeOH was evaporated and the product isolated via extraction ethylacetate/water.

MS(ISO): 378.5 (MH+)

Example 242
(R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide

1 mmol (R)-1-{2-[3-(3-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy ethanone were dissolved in THF. 2 eq. of DIPEA were added. The reaction was cooled to 0° C. 1 eq. of acetylchloride in THF was added dropwise and the reaction stirred for 30 min. The product was isolated by extraction from ethylactetade/water and subsequent purification via preparative HPLC.

MS(ISO): 421.5 (MH+)

The following compounds have been generated in analogy by using either acetyl chloride, mesylchloride, chloroformic acid allyl ester or ethylisocyanate as the reagent:

TABLE 6MH⁺ExampleCompound nameStarting materials(found)243(R)-N-(4-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(4-Amino-phenyl)-421.5acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl]-piperidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1-yl}-2-phenoxy-ethanone andacetamideacetyl chloride244(R)-N-(5-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(6-Amino-pyridin-422.5acetyl)-piperidin-2-yl]-3-yl)-[1,2,4]oxadiazol-5-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-piperidin-1-yl}-2-phenoxy-2-yl)-acetamideethanone and acytyl chloride245(R)-N-(3-{5-[1-(2-Phenoxy-(R)-1-{2-[5-(3-Amino-phenyl)-420.5acetyl)-piperidin-2-yl]-1H-2H-[1,2,4]triazol-3-yl]-[1,2,4]triazol-3-yl}-phenyl)-piperidin-1-yl}-2-phenoxy-acetamideethanone and acytyl chloride246(R)-N-(3-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(3-Amino-phenyl)-457.4acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl]-piperidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1yl}-2 phenoxy-ethanone andmethanesulfonamidemesyl chloride247(R)-N-(4-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(4-Amino-phenyl)-457.4acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl]-piperidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1-yl}-2-phenoxy-ethanone andmethane-sulfonamidemesylchloride248(R)-(3-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(3-Amino-phenyl)-463.5acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl]-piperidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1yl}-2 phenoxy-ethanone acidcarbamic acid allyl esterallyl ester249(R)-(4-{5-[1-(2-Phenoxy-(R)-1-{2-[3-(4-Amino-phenyl)-463.5acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl]-piperidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1-yl}-2-phenoxy-ethanone andcarbamic acid allyl esterchloroformic acid allyl ester250(R)-N-(3-{5-[1-(2-Phenoxy-(R)-1-{2-[5-(3-Amino-phenyl)-456.5acetyl)-piperidin-2-yl]-1H-2H-[1,2,4]triazol-3-yl]-[1,2,4]triazol-3-yl}-phenyl)-piperidin-1-yl}-2-phenoxy-methanesulfonamideethanone and mesyl chloride251(R)-1-Ethyl-3-(3-{5-[1-(2-(R)-1-{2-[5-(3-Amino-phenyl)-449.5phenoxy-acetyl)-piperidin-2-2H-[1,2,4]triazol-3-yl]-yl]-1H-[1,2,4]triazol-3-yl}-piperidin-1-yl}-2-phenoxy-phenyl)-ureaethanone and ethylisocyanate

Example 252
(R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzonitrile

1.3 mmol (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide were treated with neat trifluoroacetic anhydride at room temperature overnight. The reaction was quenched with aqueous NaHCO₃and product extracted with ethylacetate twice. The organic layers were washed with water/NaCl, combined, dried over Na2SO4 and the solvent evaporated. The product was purified via preparative HPLC.

MS(ISO): 388.5 (MH+)

Example 253
(R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinonitrile

0.15 mmol of 5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide are treated with trifluoracetic anhydride at room temperature over night. The reaction was quenched with aqueous NaHCO₃and product extracted with ethylacetate twice. The organic layers were washed with water/NaCl, combined, dried over Na2SO4 and the solvent evaporated. The product was purified via preparative HPLC.

MS(ISO): 390.4 (MH+)

Example 254
4-Acetyl-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester

10 mmol of Piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester were dissolved in 20 ml methylenchloride. 1.05 eq of DIPEA and acetychloride were added. The reaction mixture was stirred at room temperature for 30 min. The product was extracted from etylacetate/water. The crude material was re-dissolved in methanol and treated with 2N NaOH. The reaction mixture was stirred at room temperature for 2 h. The mixture was neutralized with HCl and the product isolated via extraction from ethylacetate/water.

MS(ISO): 271.3 (M−H+)

Example 255
4-Methanesulfonyl-piperazine-1,2-dicarboxylic acid 1-tert-butyl ester

10 mmol of Piperazine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester were dissolved in 20 ml methylenchloride. 1.05 eq of DIPEA and mesylchloride were added. The reaction mixture was stirred at room temperature for 30 min. The product was extracted from etylacetate/water. The crude material was redissolved in methanol and treated with 2N NaOH. The reaction mixture was stirred at room temperature for 2 h. The mixture was neutralized with HCl and the product isolated via extraction from ethylacetate/water.

MS(ISO): 307.4 (M−H+)

Example 256
N-Hydroxy-4-sulfamoyl-benzamidine

1 mmol of 4-Cyano-benzenesulfonamide are dissolved in a mixture of ethanol/water (7:3) and 5 eq of hydroxylamine hydrochloride and 2.5 eq. Na2CO3 added. The suspension is heated to 80° C. for 2 h. After evaporation of the solvent mixture the resulting material is extracted from ethylacetate/water. The product was not further characterized.

MS(ISO): 216.3 (MH+)

All following compounds were prepared in analogy:

TABLE 7ExampleCompound nameStarting materials2573-(N-Hydroxy-carbamimidoyl)-3-Cyano-benzoic acid methyl esterbenzoic acid methyl esterand hydroxylamine2584-(N-Hydroxycarbamimidoyl)-4-Cyano-pyridine-2-carboxylic acidpyridine-2-carboxylic acid ethyl esterethyl ester2593-Fluoro-4-(N-4-Cyano-3-fluoro-benzoic acidhydroxycarbamimidoyl)-benzoic acidmethyl estermethyl ester260N-Hydroxy-4-nitro-benzamidine4-Nitro-benzonitrile andhydroxylamine261N-Hydroxy-3-sulfamoyl-benzamidine3-Cyano-benzenesulfonamide andhydroxylamine262N-Hydroxy-6-methoxy-6-Methoxy-nicotinonitrile andnicotinamidinehydroxylamine263N-Hydroxy-3-hydroxymethyl-3-Hydroxymethyl-benzonitrile andbenzamidinehydroxylamine264N-Hydroxy-4-imidazol-1-yl-4-Imidazol-1-yl-benzonitrile andbenzamidinehydroxylamine265N-Hydroxy-6-morpholin-4-yl-6-Morpholin-4-yl-nicotinonitrilenicotinamidineand hydroxylamine266N-Hydroxy-4-4-Trifluoromethanesulfonyl-trifluoromethanesulfonyl-benzonitrile and hydroxylaminebenzamidine267N-Hydroxy-4-trifluoromethyl-4-Trifluoromethyl-benzonitrile andbenzamidinehydroxylamine2684-Chloro-N-hydroxy-benzamidine4-Chloro-benzonitrile andhydroxylamine269N-[4-(N-Hydroxycarbamimidoyl)-2-N-(4-Cyano-2-trifluoromethyl-trifluoromethyl-phenyl]-acetamidephenyl)-acetamide andhydroxylamine270N-Hydroxy-3-methanesulfonyl-3-Methanesulfonyl-benzonitrilebenzamidineand hydroxylamine271N-Hydroxy-4-methyl-3-nitro-4-Methyl-3-nitro-benzonitrile andbenzamidinehydroxylamine272N-Hydroxy-4-methoxy-3-nitro-4-Methoxy-3-nitro-benzonitrilebenzamidineand hydroxylamine273N-Hydroxy-2-oxo-1,2-dihydro-2-Oxo-1,2-dihydro-pyridine-4-pyridine-4-carboxamidinecarbonitrile274N-Hydroxy-6-oxo-1,6-dihydro-6-Oxo-1,6-dihydro-pyridine-3-pyridine-3-carboxamidinecarbonitrile275N-Hydroxy-4-(1H-tetrazol-5-yl)-4-(1H-Tetrazol-5-yl)-benzonitrilebenzamidineand hydroxylamine276N-Hydroxy-1H-indazole-5-1H-Indazole-5-carbonitrile andcarboxamidinehydroxylamine277N-Hydroxy-1H-indazole-6-1H-Indazole-6-carbonitrile andcarboxamidinehydroxylamine2784-Fluoro-N-hydroxy-3-4-Fluoro-3-trifluoro-methyl-trifluoromethyl-benzamidinebenzonitrile and hydroxylamine279N-Hydroxy-2-oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-indole-6-indole-6-carboxamidinecarbonitrile and hydroxylamine280N-Hydroxy-2-oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-benzoimidazole-5-carboxamidinebenzoimidazole-5-carbonitrile andhydroxylamine281N-Hydroxy-2-oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-indole-5-indole-5-carboxamidinecarbonitrile and hydroxylamine282N-Hydroxy-pyridine-2-Pyridine-2-carbonitrile andcarboxamidinehydroxylamine283N-Hydroxy-pyridine-3-Pyridine-3-carbonitrile andcarboxamidinehydroxylamine2844-Diethylamino-N-hydroxy-4-Diethylamino-benzonitrile andbenzamidinehydroxylamine285N-[4-(N-Hydroxycarbamimidoyl)-2-N-(4-Cyano-2-trifluoromethyl-trifluoromethyl-phenyl]-acetamidephenyl)-acetamide andhydroxylamine2864-Chloro-N-hydroxy-3-nitro-4-Chloro-3-nitro-benzonitrile andbenzamidinehydroxylamine287N-Hydroxy-4-pyrrol-1yl-4-Pyrrol-1-yl-benzonitrile andbenzamidinehydroxylamine2882,4-Dichloro-N-hydroxy-2,4-Dichloro-benzonitrile andbenzamidinehydroxylamine289N-Hydroxy-3-(2-oxo-piperidin-1-yl)-3-(2-Oxo-piperidin-1-yl)-benzamidinebenzonitrile and hydroxylamine290N-Hydroxy-1H-benzoimidazole-5-1H-Benzoimidazole-5-carbonitrilecarboxamidine2916-(N-Hydroxy-carbamimidoyl)-6-Cyano-nicotinic acid allyl esternicotinic acid allyl esterand hydroxylamine2924-(N-Hydroxycarbamimidoyl)-4-Cyano-pyridine-2-carboxylic acidpyridine-2-carboxylic acid ethyl esterethyl ester and hydroxylamine2933-Fluoro-4-(N-4-Cyano-3-fluoro-benzoic acidhydroxycarbamimidoyl)-benzoic acidmethyl ester and bydroxylaminemethyl ester294N-Hydroxy-1H-benzotriazole-5-1H-Benzotriazole-5-carbonitrilecarboxamidine2946-Benzyloxy-N-hydroxy-6-Benzyloxy-nicotinonitrilenicotinamidine295N-[5-(N-Hydroxycarbamimidoyl)-N-(5-Cyano-pyridin-2-yl)-pyridin-2-yl]-acetamideacetamide296N-[4-(N-Hydroxycarbamimidoyl)-N-(4-Cyano-pyridin-2-yl)-pyridin-2-yl]-acetamideacetamide

Example 297
N-Hydroxy-4-methylsulfamoyl-benzamidine

5 mmol of 4-Cyano-benzenesulfonyl chloride were dissolved in 10 ml THF. 10 ml of a 2M methylamine/THF solution was added dropwise. The reaction was stirred at room temperature overnight. The solvent was evaporated and the product extracted from ethylacetate/water. The nitril obtained was treated analogously to example 231.

MS(ISO): 230.5 (MH+)

All following compounds were prepared in analogy:

TABLE 8ExampleCompound nameStarting materials298N-Hydroxy-4-(morpholine-4-4-Cyano-benzenesulfonyl chloride andsulfonyl)-benzamidinemorpholine299N-Hydroxy-4-(2-hydroxy-4-Cyano-benzenesulfonyl chlorideethylsulfamoyl)-benzamidineand ethanolamine300N-Hydroxy-4-[(2-methoxy-ethyl)-4-Cyano-benzenesulfonyl chloridemethyl-sulfamoyl]-benzamidineand (2-Methoxy-ethyl)-methylamine3014-Dimethylsulfamoyl-N-hydroxy-4-Cyano-benzenesulfonyl chloridebenzamidineand dimethylamine3024-Diethylsulfamoyl-N-hydroxy-4-Cyano-benzenesulfonyl chloridebenamidineand diethylamine

Example 303
6-(1,1-Dioxo-thiomorpholin-4-yl)-N-hydroxy-nicotinamidine

10 mmol of 6-Cl-4-CN-pyridine are dissolved in 10 ml DMF. 20 mmol of morpholine are added and the reaction heated to 120° C. under microwave conditions for 20 min. The DMF is evaporated and the crude extracted from ethylacetate/water. After evaporation the resulting solid was treated with 30 mmol of metha-chloroperbenzoic acid in DCM at room temperature overnight and the resulting precipitate filtered off and recrystalized from MeOH. The nitril obtained was treated analogously to example 231.

MS(ISO): 271.5 (MH+)

The following compounds were prepared in analogy.

TABLE 9ExampleCompound nameStarting materials304N-Hydroxy-2-morpholin-4-yl-2-Chloroisonicotinonitrile andisonicotinamidinemorpholin305N-Hydroxy-3,4,5,6-tetrahydro-2-Chloroisonicotinonitrile and2H-[1,2′]bipyridinyl-4′-piperidincarboxamidine306N-Hydroxy-2-thiomorpholin-4-yl-2-Chloroisonicotinonitrile andisonicotinamidinethiomorpholin3072-Diethylamino-N-hydroxy-2-Chloroisonicotinonitrile andisonicotinamidinediethylamine308N-Hydroxy-6-(3-oxo-piperazin-1-2-Chloronicotinonitrile and Piperazin-yl)-nicotinamidine2-one3096-(4-Acetyl-piperazin-1-yl)-N-2-Chloronicotinonitrile and 1-hydroxy-nicotinamidineacetylpiperazin310N-Hydroxy-6-(3-hydroxymethyl-2-Chloronicotinonitrile and Pyrrolidin-pyrrolidin-1-yl)-nicotinamidine3-yl-methanol311N-Hydroxy-6-morpholin-4-yl-2-Chloronicotinonitrile and morpholinnicotinamidine

Example 312
4-Fluoro-N-amino-benzamidine hydrochloride

82 mmol of 3-Cyano-benzoic acid methyl ester were dissolved in 50 m1 of an HCl-saturated methylenchloride solution and 50 ml of methanol. Under ice-bath cooling HCl-gas was bubbled through the solution to keep the temperature under 20° C. The reaction mixture was stirred overnight at room temperature. lOOml of diethylether were added and the resulting solid filtered off, washed with diethylether and dried under vaccum. The resulting imidoether was extracted from ethylacetate/aq. sodiumbicarbonate to result in an oily residue. This was taken up in 25 ml methanol and treated with 1 ml hydrazin monohydrate at room temperature overnight. The solution was slowly added to a cold solution of 4N HCl/dioxan. 80 ml of diethylether were added and the suspension stirred at room temperature for 30 min. The solid was filtered off and washed with diethylether and dried under vacuum. The product was confirmed by MS.

MS(ISO): 194.4 (MH+)

The following compounds were prepared in analogy:

TABLE 10ExampleCompound nameStarting materials3134-Fluoro-N-amino-3-4-Fluoro-3-trifluoromethyl-trifluoromethyl-benzamidinebenzonitrile and hydrazinehydrochloride314N-Amino-4-methanesulfonyl-4-Methanesulfonyl-benzonitril andbenzamidine hydrochloridehydrazine315N-Amino-3-trifluoromethyl-m-Trifluoromethyl-benzonitril and hydrazinebenzamidine hydrochloride316N-Amino-4-methyl-benzamidinep-Tolunitril and hydrazinehydrochloride317N-Amino-4-trifluoromethyl-p-Trifluoromethyl-benzonitril andbenzamidine hydrochloridehydrazine318N-Amino-4-methoxy-benzamidine4-Methoxybenzonitrile andhydrochloridehydrazine319N-Amino-2,4-difluoro-benzamidine2,4-Difluorobenzonitrile andhydrochloridehydrazine320N-Amino-3,4-dimethoxy-3,4-Dimethoxybenzonitrile andbenzamidine hydrochloridehydrazine321N-Amino-3,4-dichloro-benzamidine3,4-Dichlorobenzonitrile andhydrochloridehydrazine322N-Amino-benzamidine hydrochlorideBenzonitrile and hydrazine323N-Amino-3-Nitro-benzamidine3-Nitrobenzonitrile and hydrazinehydrochloride324N-Amino-3-methylester-benzamidine3-Cyano-benzoic acid methyl esterhydrochlorideand hydrazine325N-Amino-2-oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-indole-6-indole-6-carboxamidinecarbonitrile and hydrazine326N-Amino-2-fluoro-benzamidine2-Fluorobenzonitrile and hydrazinehydrochloride

Example 327
6-Cyano-nicotinic acid allyl ester

4 mmol of 6-Cyanonicotinic acid were dissolved in THF. 1.5 eq. of Cs2CO3 were added he reaction stirred for 10 min. 1.5 eq allylbromide and a catalytic amount of KI were added he reaction heated to 100° C. for 4 h. The product was isolated via extraction from cetate/water.

MS(ISO): 222.5 (MH+)

Example 328
1H-Benzotriazole-5-carbonitrile

10 mmol of 3,4-Diamino-benzonitrile were suspended in water/acetic acid (4:1) and cooled to 0° C. 1.05 eq of NaNO2 were dissolved in water and added inert 30 min. The reaction was stirred at room temperature overnight. The precipitate was filtered off, washed with ether and dried under vacuum. The intermediate was not further characterized.

Example 329
6-Benzyloxy-nicotinonitrile

20 mmol of 6-Chloro-nicotinonitrile were dissolved in THF. 1.1 eq. of benzyl alcohol were added. The reaction mixture was cooled to 0° C. and flushed with argon. 4 eq of NaH were added slowly. After 15 min the product was isolated via extraction from ethylacetate/water.

MS(ISO): 211.5 (MH+)

Example 330
N-(5-Cyano-pyridin-2-yl)-acetamide

8 mmol of 6-Amino-nicotinonitrile were dissolved in THF. 2 eq of DIPEA were added. The reaction mixture was cooled to 0° C. and 1.0 eq of acetylchloride in THF added dropwise and the reaction stirred for 2 h. The product was isolated by extraction from ethylacetate/water.

MS(ISO): 162.2 (MH+)

Example 331
N-(4-Cyano-pyridin-2-yl)-acetamide

8 mmol of 2-Amino-isonicotinonitrile were dissolved in THF. 2 eq of DIPEA were added. The reaction mixture was cooled to 0° C. and 1.0 eq of acetylchloride in THF added dropwise and the reaction stirred for 2 h. The product was isolated by extraction from ethylacetate/water.

MS(ISO): 162.2 (MH+)

The following compounds were generated in analogy to example 1

MH+ExampleCompound nameStarting materials(found)3321-{2-[3-(2-Methyl-1H-Boc-D-Pipecolic Acid, N-418.5benzoimidazol-5-yl)-Hydroxy-2-methyl-1H-[1,2,4]oxadiazol-5-yl]-benzoimidazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride3331-{2-[3-(2-Amino-pyridin-4-Boc-D-Pipecolic Acid, 2-380.5yl)-[1,2,4]oxadiazol-5-yl]-Amino-N-hydroxy-piperidin-1-yl}-2-phenoxy-isonicotinamidine andethanonephenoxyacetic acid3341-{2-[3-(3-Hydroxy-phenyl)-Boc-D-Pipecolic Acid, 3-N-380.5[1,2,4]oxadiazol-5-yl]-Dihydroxy-benzamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3354-{5-[1-(2-Phenoxy-acetyl)-Boc-D-Pipecolic Acid, 2,N-381.4piperidin-2-yl]-Dihydroxy-isonicotinamidine[1,2,4]oxadiazol-3-yl}-1H-and phenoxyacetyl chloridepyridin-2-one3361-{2-[3-(4-Hydroxy-phenyl)-Boc-D-Pipecolic Acid, 4-N-379.6[1,2,4]oxadiazol-5-yl]-Dihydroxy-benzamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3373-{5-[1-(2-Phenoxy-acetyl)-Boc-D-Pipecolic Acid, 3-(N-407.7piperidin-2-yl]-Hydroxycarbamidoyl)-[1,2,4]oxadiazol-3-yl}-phenylboronic acid andphenylboronic acidphenoxyacetyl chloride3384-(2-Oxo-2-{2-[3-(2-oxo-2,3-Boc-D-Pipecolic Acid, N-443.7dihydro-1H-indol-5-yl)-Hydroxy-2-oxo-2,3-dihydro-[1,2,4]oxadiazol-5-yl]-1H-indole-5-carboxamidinepiperidin-1-yl}-ethoxy)-and 4-cyanophenoxyacetic acidbenzonitrile3394-(2-{2-[3-(4-Methoxy-Boc-D-Pipecolic Acid, N-419.3phenyl)-[1,2,4]oxadiazol-5-yl]-Hydroxy-4-methoxy-piperidin-1-yl}-2-oxo-ethoxy)-benzamidine and 4-benzonitrilecyanophenoxyacetic acid3402-Methyl-5-{5-[1-(2-phenoxy-Boc-D-Pipecolic Acid, 4,N-396.2acetyl)-piperidin-2-yl]-Dihydroxy-2-methyl-[1,2,4]oxadiazol-3-yl}-3H-pyrimidine-5-carboxamidinepyrimidin-4-oneand phenoxyacetyl chloride3411-[(R)-2-(3-Furan-2-yl-Boc-D-Pipecolic Acid, N-354.2[1,2,4]oxadiazol-5-yl)-Hydroxy-furan-2-piperidin-1-yl]-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride3421-[(R)-2-(3-Imidazo[1,2-Boc-D-Pipecolic Acid, N-404.2a]pyridin-2-yl-Hydroxy-imidazo[1,2-[1,2,4]oxadiazol-5-yl)-a]pyridine-2-carboxamidinepiperidin-1-yl]-2-phenoxy-and phenoxyacetyl chlorideethanone3431-{(R)-2-[3-(4-Methyl-Boc-D-Pipecolic Acid, N-386.2[1,2,3]thiadiazol-5-yl)-Hydroxy-4-methyl-[1,2,4]oxadiazol-5-yl]-[1,2,3]thiadiazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetyl chloride3441-{(R)-2-[3-(2,5-Dimethyl-Boc-D-Pipecolic Acid, N-382.22H-pyrazol-3-yl)-Hydroxy-2,5-dimethyl-2H-[1,2,4]oxadiazol-5-yl]-pyrazole-3-carboxamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetyl chlorideethanone3452-Phenoxy-1-{(R)-2-[3-(1H-Boc-D-Pipecolic Acid, N-354.2pyrazol-4-yl)-[1,2,4]oxadiazol-Hydroxy-1H-pyrazole-4-5-yl]-piperidin-1-yl}-ethanonecarboxamidine andphenoxyacetyl chloride3461-{(R)-2-[3-(5-Methyl-Boc-D-Pipecolic Acid, N-369.2isoxazol-3-yl)-Hydroxy-5-methyl-isoxazole-3-[1,2,4]oxadiazol-5-yl]-carboxamidine andpiperidin-1-yl}-2-phenoxy-phenoxyacetyl chlorideethanone3472-Phenoxy-1-{(R)-2-[3-(1H-Boc-D-Pipecolic Acid, N-354.2pyrazol-3-yl)-[1,2,4]oxadiazol-Hydroxy-1H-pyrazole-3-5-yl]-piperidin-1-yl}-ethanonecarboxamidine andphenoxyacetyl chloride3485-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, 2,4,N-398.2acetyl)-piperidin-2-yl]-Trihydroxy-pyrimidine-5-[1,2,4]oxadiazol-3-yl}-1H-carboxamidine andpyrimidine-2,4-dionephenoxyacetyl chloride3491-{(R)-2-[3-(6-Amino-Boc-D-Pipecolic Acid, 6-380.5pyridin-3-yl)-[1,2,4]oxadiazol-Amino-N-hydroxy5-yl]-piperidin-1-yl}-2-nicotinamidine andphenoxy-ethanonephenoxyacetyl chloride3501-[(R)-2-(3-Imidazo[1,2-Boc-D-Pipecolic Acid, N-404.2a]pyridin-6-yl-Hydroxy-imidazo[1,2-[1,2,4]oxadiazol-5-yl)-a]pyridine-6-carboxamidinepiperidin-1-yl]-2-phenoxy-and phenoxyacetyl chlorideethanone3516-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-435.2acetyl)-piperidin-2-yl]-Hydroxy-3-oxo-3,4-dihydro-[1,2,4]oxadiazol-3-yl}-4H-2H-benzo[1,4]oxazine-6-benzo[1,4]oxazin-3-onecarboxamidine andphenoxyacetyl chloride3526-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-435.2acetyl)-piperidin-2-yl]-Hydroxy-2-oxo-1,4-dihydro-[1,2,4]oxadiazol-3-yl}-1,4-2H-benzo[d][1,3]oxazine-6-dihydro-benzo[d][1,3]oxazin-carboxamidine and2 onephenoxyacetyl chloride3531-((R)-2-{3-[3-(1,1-Dioxo-Boc-D-Pipecolic Acid, 3-(1,1-483.31$$6-isothiazolidin-2-yl)-Dioxo-1$$6-isothiazolidin-2-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-N-hydroxy-benzamidine andpiperidin-1-yl)-2-phenoxy-phenoxyacetyl chlorideethanone3541-(3-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-447.3acetyl)-piperidin-2-yl]-Hydroxy-3-(2-oxo-pyrrolidin-[1,2,4]oxadiazol-3-yl}-phenyl)-1-yl)-benzamidine andpyrrolidin-2-onephenoxyacetyl chloride3551-(3-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, 3-(2,4-462.5acetyl)-piperidin-2-yl]-Dioxo-imidazolidin-1-yl)-N-[1,2,4]oxadiazol-3-yl}-phenyl)-hydroxy-benzamidine andimidazolidine-2,4-dionephenoxyacetyl chloride3564-(3-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-447.5acetyl)-piperidin-2-yl]-Hydroxy-3-(5-oxo-1,5-dihydro-[1,2,4]oxadiazol-3-yl}-phenyl)-[1,2,4]triazol-4-yl)-benzamidine2,4-dihydro-[1,2,4]triazol-3-and phenoxyacetyl chlorideone3571-(3-Fluoro-5-{5-[(R)-1-(2-Boc-D-Pipecolic Acid, 3-(2,5-479.2phenoxy-acetyl)-piperidin-2-Dioxo-pyrrolidin-1-yl)-5-yl]-[1,2,4]oxadiazol-3-yl}-fluoro-N-hydroxy-benzamidinephenyl)-pyrrolidine-2,5-dioneand phenoxyacetyl chloride3585-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-418.5acetyl)-piperidin-2-yl]-1H-Amino-2-Oxo-2,3-dihydro-1H-[1,2,4]triazol-3-yl}-1,3-indole-5-carboxamidine anddihydro-indol-2-onephenoxyacetic acid3591-{(R)-2-[5-(1H-Indazol-5-Boc-D-Pipecolic Acid, N-403.5yl)-2H-[1,2,4]triazol-3-yl]-Amino-1H-Indazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid3601-{(R)-2-[5-(1H-Indol-5-yl)-Boc-D-Pipecolic Acid, N-402.52H-[1,2,4]triazol-3-yl]-Amino-1H-Indole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid3611-{(R)-2-[5-(3H-Benzotriazol-Boc-D-Pipecolic Acid, N-402.5(M − H+)5-yl)-2H-[1,2,4]triazol-3-yl]-Amino-3H-Benzotriazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid3625-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-419.5acetyl)-piperidin-2-yl]-1H-Amino-2-Oxo-2,3-dihydro-1H-[1,2,4]triazol-3-yl}-1,3-benzoimidazole-5-dihydro-benzoimidazol-2-onecarboxamidine andphenoxyacetic acid3631-{(R)-2-[5-(2-Methyl-1H-Boc-D-Pipecolic Acid, N-417.5benzoimidazol-5-yl)-2H-Amino-2-Methyl-1H-[1,2,4]triazol-3-yl]-piperidin-benzoimidazole-5-1-yl}-2-phenoxy-ethanonecarboxamidine andphenoxyacetic acid3641-{(R)-2-[5-(2-Amino-Boc-D-Pipecolic Acid, N-379.5pyridin-4-yl)-2H-Amino-2-Amino-[1,2,4]triazol-3-yl]-piperidin-isonicotinamidine and1-yl}-2-phenoxy-ethanonephenoxyacetic acid3655-(3-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, N-446.7acetyl)-piperidin-2-yl]-1H-Amino-3-(5-Oxo-4,5-dihydro-[1,2,4]triazol-3-yl}-phenyl)-[1,3,4]oxadiazol-2-yl)-3H-[1,3,4]oxadiazol-2-onebenzamidine and phenoxyaceticacid3661-{(R)-2-[5-(3-Boc-D-Pipecolic Acid, N-430.7[1,3,4]Oxadiazol-2-yl-phenyl)-Amino-3-[1,3,4]Oxadiazol-2-yl-2H-[1,2,4]triazol-3-yl]-benzamidine and phenoxyaceticpiperidin-1-yl}-2-phenoxy-acidethanone3673-{5-[1-(2-Phenoxy-acetyl)-Boc-D-Pipecolic Acid, N-407.5piperidin-2-yl]-1H-Amino-3-Carbamidoyl-[1,2,4]triazol-3-yl}-phenylboronic acid andphenylboronic acidphenoxyacetic acid

Example 368
6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one

Step 1:

2-Hydrazinocarbonyl-piperidine-1-carboxylic acid tert-butyl ester

3 g of (R)-Piperidine-1,2-dicarboxylic acid 1-tert-butyl ester were dissolved in 30 ml DMF. 5 g HATU and 2.2 ml DIPEA were added and the reaction mixture cooled to 0° C. 4 eq. of Hydrazine-Monohydrate in 30 ml DMF were added and the reaction warmed to rt and stirred for 1 h. The crude product was extracted from ethylacetate/aq. NaHCO3.

MS(ISO): 244.3 (MH+)

Step 2:

6-(5-Piperidin-2-yl-1H-[1,2,4]triazol-3-yl)-4H-benzo[1,4]oxazin-3-one

1.5 mmol of 2-Hydrazinocarbonyl-piperidine-1-carboxylic acid tert-butyl ester were dissolved in 3 ml DMF. 1 eq of 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxamidine and 90 ul acetic acid were added and the reaction mixture heated to 120° C. overnight. The solvent was evaporated and the crude extracted from ethylacetate/water. The resulting oil was taken up in 15 ml DCM and treated with 3 ml TFA. The reaction mixture was reduced to dryness.

Step 3:

6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one

Crude product from step 3 was taken up in DMF and cooled to 0° C. 4 eq. DIPEA and 1 eq of phenoxyacetyl chloride were added dropwise and the reaction mixture warmed to rt and stirred for additional 30 min. The product was isolated via preparative HPLC.

The following compounds were generated in analogy to example 368

MH+ExampleCompound nameStarting materials(found)3691-[(R)-2-(5-Imidazo[1,2-Boc-D-Pipecolic Acid,443.7a]pyridin-6-yl-2H-Imidazo[1,2-a]pyridine-6-[1,2,4]triazol-3-yl)-piperidin-carboxamidine and1-yl]-2-phenoxy-ethanonephenoxyacetic acid3701-{(R)-2-[5-(6-Amino-Boc-D-Pipecolic Acid, 6-379.1pyridin-3-yl)-2H-Amino-nicotinamidineand[1,2,4]triazol-3-yl]-piperidin-phenoxyacetic acid1-yl}-2-phenoxy-ethanone3711-{(R)-2-[5-(1H-Boc-D-Pipecolic Acid, 1H-403.2Benzoimidazol-5-yl)-2H-Benzoimidazole-5-[1,2,4]triazol-3-yl]-piperidin-carboxamidine and1-yl}-2-phenoxy-ethanonephenoxyacetic acid3722-Phenoxy-1-[(R)-2-(5-Boc-D-Pipecolic Acid,364.2pyridin-3-yl-2H-[1,2,4]triazol-Nicotinamidine and3-yl)-piperidin-1-yl]-ethanonephenoxyacetic acid3731-{(R)-2-[5-(3,5-Dimethyl-Boc-D-Pipecolic Acid, 3,5-382.2isoxazol-4-yl)-2H-Dimethyl-isoxazole-4-[1,2,4]triazol-3-yl]-piperidin-carboxamidine and1-yl}-2-phenoxy-ethanonephenoxyacetic acid3742-Phenoxy-1-[(R)-2-(5-Boc-D-Pipecolic Acid,369.1thiophen-2-yl-2H-Thiophene-2-carboxamidine[1,2,4]triazol-3-yl)-piperidin-and phenoxyacetic acid1-yl]-ethanone3752-Phenoxy-1-[(R)-2-(5-Boc-D-Pipecolic Acid,365.1pyrimidin-2-yl-2H-Pyrimidine-2-carboxamidine[1,2,4]triazol-3-yl)-piperidin-and phenoxyacetic acid1-yl]-ethanone3761-{(R)-2-[5-(4-Methyl-oxazol-Boc-D-Pipecolic Acid, 4-368.15-yl)-2H-[1,2,4]triazol-3-yl]-Methyl-oxazole-5-piperidin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid3772-Phenoxy-1-[(R)-2-(5-Boc-D-Pipecolic Acid, Pyrazine-365.1pyrazin-2-yl-2H-[1,2,4]triazol-2-carboxamidine and3-yl)-piperidin-1-yl]-ethanonephenoxyacetic acid3781-{(R)-2-[5-(2-Fluoro-Boc-D-Pipecolic Acid, 2-381.1phenyl)-2H-[1,2,4]triazol-3-Fluoro-benzamidine andyl]-piperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3791-{(R)-2-[5-(3,5-Difluoro-Boc-D-Pipecolic Acid, 3,5-399.1phenyl)-2H-[1,2,4]triazol-3-Difluoro-benzamidine andyl]-piperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3801-{(R)-2-[5-(2-Methyl-Boc-D-Pipecolic Acid, 2-378.1pyridin-4-yl)-2H-Methyl-isonicotinamidine and[1,2,4]triazol-3-yl]-piperidin-phenoxyacetic acid1-yl}-2-phenoxy-ethanone3811-{(R)-2-[5-(3-Fluoro-Boc-D-Pipecolic Acid, 3-381.1phenyl)-2H-[1,2,4]triazol-3-Fluoro-benzamidine andyl]-piperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3821-{(R)-2-[5-(3,4-Difluoro-Boc-D-Pipecolic Acid, 3,4-399.1phenyl)-2H-[1,2,4]triazol-3-Difluoro-benzamidine andyl]-piperidin-1-yl}-2-phenoxy-phenoxyacetic acidethanone3836-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, 2-Oxo-434.5acetyl)-piperidin-2-yl]-1H-1,4-dihydro-2H-[1,2,4]triazol-3-yl}-1,4-benzo[d][1,3]oxazine-6-dihydro-benzo[d][1,3]oxazin-carboxamidine and2-onephenoxyacetic acid3847-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, 2-Oxo-433.5acetyl)-piperidin-2-yl]-1H-1,2,3,4-tetrahydro-quinazoline-[1,2,4]triazol-3-yl}-3,4-7-carboxamidine anddihydro-1H-quinazolin-2-onephenoxyacetic acid3851-(3-{5-[(R)-1-(2-Phenoxy-Boc-D-Pipecolic Acid, 3-(2,4-461.3acetyl)-piperidin-2-yl]-1H-Dioxo-imidazolidin-1-yl)-[1,2,4]triazol-3-yl}-phenyl)-benzamidine and phenoxyaceticimidazolidine-2,4-dioneacid

The following compounds were generated in analogy to example 1

MH+ExampleCompound nameStarting materials(found)3861-{(R)-3-[3-(2-Amino-(R)-Morpholine-3,4-381.6pyridin-4-yl)-[1,2,4]oxadiazol-dicarboxylic acid 4-tert-butyl5-yl]-morpholin-4-yl}-2-ester, 2-Amino-N-hydroxy-phenoxy-ethanoneisonicotinamidine andphenoxyacetyl chloride3871-{(R)-3-[3-(1H-(R)-Morpholine-3,4406.2Benzoimidazol-5-yl)-dicarboxylic acid 4-tert-butyl[1,2,4]oxadiazol-5-yl]-ester, N-Hydroxy-1H-morpholin-4-yl}-2-phenoxy-benzoimidazole-5-ethanonecarboxamidine andphenoxyacetyl chloride3881-{(R)-2-[3-(1H-Piperazine-1,3-dicarboxylic acid405.4Benzoimidazol-5-yl)-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-5-yl]-1H-benzoimidazole-5-piperazin-1-yl}-2-phenoxy-carboxamidine andethanonephenoxyacetic acid3895-{5-[(R)-1-(2-Phenoxy-Piperazine-1,3-dicarboxylic acid420.4acetyl)-piperazin-2-yl]-1-tert-butyl ester, N-Hydroxy-[1,2,4]oxadiazol-3-yl}-1,3-2-oxo-2,3-dihydro-1H-indole-dihydro-indol-2-one5-carboxamidine andphenoxyacetic acid3901-{(R)-2-[3-(2-Amino-Piperazine-1,3-dicarboxylic acid380.6pyridin-4-yl)-[1,2,4]oxadiazol-1-tert-butyl ester, 2-Amino-N-5-yl]-piperazin-1-yl}-2-hydroxy-isonicotinamidine andphenoxy-ethanonephenoxyacetic acid

Example 391
(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetic acid

The title compound was prepared in analogy to example 180 from (3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetic acid methylester. MS: 436.5 (M−H+)

The following compounds were generated in analogy to example 194

MH+ExampleCompound nameStarting materials(found)3922-Phenoxy-1-((R)-2-{5-[3-3-{5-[1-(2-Phenoxy-acetyl)-474.6(piperidine-1-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-ethanoneand piperidine3931-((R)-2-{5-[3-(Morpholine-4-3-{5-[1-(2-Phenoxy-acetyl)-476.6carbonyl)-phenyl]-2H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-piperidin-[1,2,4]triazol-3-yl}-benzoic acid1-yl)-2-phenoxy-ethanoneand morpholine3941-((R-2-{5-[3-(4-Methyl-3-{5-[1-(2-Phenoxy-acetyl)-489.7piperazine-1-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-2-phenoxy-and N-methylpiperazineethanone3954-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-489.6acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-[1,2,4]triazol-3-yl}-benzoic acidpiperazin-2-oneand Piperazin-2-one396N-(2-Methoxy-ethyl)-N-3-{5-[1-(2-Phenoxy-acetyl)-478.6methyl-3-{5-[(R)-1-(2-piperidin-2-yl]-1H-phenoxy-acetyl)-piperidin-2-[1,2,4]triazol-3-yl}-benzoic acidyl]-1H-[1,2,4]triazol-3-yl}-and (2-Methoxy-ethyl)-methyl-benzamideamine3971-((R)-2-{5-[3-(4-Acetyl-3-{5-[1-(2-Phenoxy-acetyl)-517.7piperazine-1-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-2-phenoxy-and 1-Piperazin-1-yl-ethanoneethanone3981-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-518.6acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H[1,2,4]triazol-3-yl}-benzoyl)-[1,2,4]triazol-3-yl}-benzoic acidpiperidine-4-carboxylic acidand Piperidine-4-carboxylicacid3991-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-517.7acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-[1,2,4]triazol-3-yl}-benzoic acidpiperidine-4-carboxylic acidand Piperidine-4-carboxylicamideacid amide4002-Phenoxy-1-((R)-2-{5-[3-3-{5-[1-(2-Phenoxy-acetyl)-478.6(thiazolidine-3-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-ethanoneand Thiazolidine401N-(2-Dimethylamino-ethyl)-3-{5-[1-(2-Phenoxy-acetyl)-491.7N-methyl-3-{5-[(R)-1-(2-piperidin-2-yl]-1H-phenoxy-acetyl)-piperidin-2-[1,2,4]triazol-3-yl}-benzoic acidyl]-1H-[1,2,4]triazol-3-yl}-and N,N,N′-Trimethyl-ethane-benzamide1,2-diamine4022-Phenoxy-1-((R)-2-{5-[3-3-{5-[1-(2-Phenoxy-acetyl)-492.8(thiomorpholine-4-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-ethanoneand thiomorpholine4034-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-547.7acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-[1,2,4]triazol-3-yl}-benzoic acidpiperazine-1-carboxylic acidand Piperazine-1-carboxylicethyl esteracid ethyl ester404N-(2-Hydroxy-ethyl)-3-{5-3-{5-[1-(2-Phenoxy-acetyl)-450.6[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid[1,2,4]triazol-3-yl}-benzamideand aminoethanol405N-Methyl-3-{5-[(R)-1-(2-3-{5-[1-(2-Phenoxy-acetyl)-525.7phenoxy-acetyl)-piperidin-2-piperidin-2-yl]-1H-yl]-1H-[1,2,4]triazol-3-yl}-N-[1,2,4]triazol-3-yl}-benzoic acid(2-pyridin-2-yl-ethyl)-and Methyl-(2-pyridin-2-yl-benzamideethyl)-amine406N-(2-Cyano-ethyl)-N-3-{5-[1-(2-Phenoxy-acetyl)-499.6cyclopropyl-3-{5-[(R)-1-(2-piperidin-2-yl]-1H-phenoxy-acetyl)-piperidin-2-[1,2,4]triazol-3-yl}-benzoic acidyl]-1H-[1,2,4]triazol-3-yl}-and 3-Cyclopropylamino-benzamidepropionitrile4071-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-575.7acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-4-[1,2,4]triazol-3-yl}-benzoic acidphenyl-piperidine-4-and 4-Phenyl-piperidine-4-carbonitrilecarbonitrile4081-((R)-2-{5-[3-(4-Hydroxy-3-{5-[1-(2-Phenoxy-acetyl)-490.6piperidine-1-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-2-phenoxy-and Piperidin-4-olethanone4098-(3-{5-[(R)-1-(2-Phenoxy-3-{5-[1-(2-Phenoxy-acetyl)-558.6acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-[1,2,4]triazol-3-yl}-benzoic acid1,3,8-triaza-spiro[4.5]decane-and 1,3,8-Triaza-2,4-dionespiro[4.5]decane-2,4-dione4101-(2-{5-[3-(Spiro(1-Phtalan)-3-{5-[1-(2-Phenoxy-acetyl)-578.7piperidine-4-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-2-phenoxy-and 4-Spiro(1-Phtalan)-ethanonepiperidine4112-Phenoxy-1-((R)-2-{5-[3-(3-3-{5-[1-(2-Phenoxy-acetyl)-537.7pyridin-4-yl-pyrrolidine-1-piperidin-2-yl]-1H-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-benzoic acid[1,2,4]triazol-3-yl}-piperidin-and 4-Pyrrolidin-3-yl-pyridine1-yl)-ethanone4121-((R)-2-{5-[3-(3-3-{5-[1-(2-Phenoxy-acetyl)-538.6Methanesulfonyl-pyrrolidine-piperidin-2-yl]-1H-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-benzoic acid[1,2,4]triazol-3-yl}-piperidin-and 3-Methanesulfonyl-1-yl)-2-phenoxy-ethanonepyrrolidine4131-((R)-2-{5-[3-((S)-3-Ethoxy-3-{5-[1-(2-Phenoxy-acetyl)-504.6pyrrolidine-1-carbonyl)-piperidin-2-yl]-1H-phenyl]-2H-[1,2,4]triazol-3-[1,2,4]triazol-3-yl}-benzoic acidyl}-piperidin-1-yl)-2-phenoxy-and (S)-3-Ethoxy-pyrrolidineethanone4141-((R)-2-{5-[3-((S)-3-3-{5-[1-(2-Phenoxy-acetyl)-476.6Hydroxy-pyrrolidine-1-piperidin-2-yl]-1H-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-benzoic acid[1,2,4]triazol-3-yl}-piperidin-and (S)-3-Hydroxy-pyrrolidine1-yl)-2-phenoxy-ethanone

The following compounds were generated according to example 231

MH+ExampleCompound nameStarting materials(found)4155-{5-[(R)-1-(2-Phenoxy-5-{5-[1-(2-Phenoxy-acetyl)-407.5acetyl)-piperidin-2-yl]-1H-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-[1,2,4]triazol-3-yl}-nicotinicnicotinamideacid and Rink resin4162-(3-{5-[1-(2-Phenoxy-acetyl)-(3-{5-[1-(2-Phenoxy-acetyl)-437.5piperidin-2-yl]-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetamidephenoxy)-acetic acid and Rink resin

The following compounds were generated according to example 242

MH+ExampleCompound nameStarting materials(found)417N-(3-Fluoro-5-{5-[(R)-1-(2-1-{2-[3-(3-Amino-5-fluoro-439.1phenoxy-acetyl)-piperidin-2-phenyl)-[1,2,4]oxadiazol-5-yl]-yl]-[1,2,4]oxadiazol-3-yl}-piperidin-1-yl}-2-phenoxy-phenyl)-acetamideethanone and acetyl chloride418N-(2-Fluoro-5-{5-[(R)-1-(2-Boc-D-Pipecolic Acid,N-[2-439.1phenoxy-acetyl)-piperidin-2-Fluoro-5-(N-yl]-[1,2,4]oxadiazol-3-yl}-hydroxycarbamidoyl)-phenyl]-phenyl)-acetamideacetamide and phenoxyacetyl chloride419N-(3-{5-[(R)-1-(2-Phenoxy-1-{2-[5-(3-Amino-phenyl)-2H-434.5acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl]-piperidin-1-[1,2,4]triazol-3-yl}-phenyl)-yl}-2-phenoxy-ethanone andpropionamidepropionic acid chloride420N-(3-{5-[(R)-1-(2-Phenoxy-1-{2-[5-(3-Amino-phenyl)-2H-448.6acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl]-piperidin-1-[1,2,4]triazol-3-yl}-phenyl)-yl}-2-phenoxy-ethanone andisobutyramideisobutyric acid chloride

The following compounds were generated according to example 1

MH+ExampleCompound nameStarting materials(found)421N-(4-Fluoro-3-{5-[(R)-1-(2-2-Hydrazinocarbonyl-438.5phenoxy-acetyl)-piperidin-2-piperidine-1-carboxylic acidyl]-1H-[1,2,4]triazol-3-yl}-tert-butyl ester, N-(3-phenyl)-acetamideCarbamidoyl-4-fluoro-phenyl)-acetamide and phenoxyacetic acid422N-(3-Fluoro-5-{5-[(R)-1-(2-2-Hydrazinocarbonyl-348.5phenoxy-acetyl)-piperidin-2-piperidine-1-carboxylic acidyl]-1H-[1,2,4]triazol-3-yl}-tert-butyl ester, N-(3-phenyl)-acetamideCarbamimidoyl-5-fluoro-phenyl)-acetamide andphenoxyacetic acid423N-(2-Fluoro-5-{5-[(R)-1-(2-2-Hydrazinocarbonyl-348.5phenoxy-acetyl)-piperidin-2-piperidine-1-carboxylic acidyl]-1H-[1,2,4]triazol-3-yl}-tert-butyl ester, N-(3-phenyl)-acetamideCarbamimidoyl-6-fluoro-phenyl)-acetamide andphenoxyacetic acid

Example 424
N-(4-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-pyridin-2-yl)-acetamide

The title compound was generated in analogy to example 242 from 1-{2-[5-(2-Amino-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone and acetyl chloride.

MS 421.5 (MH+)

Example 425
1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-azetidin-2-one

75 mg of 1-{2-[5-(3-Amino-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone were dissolved in MDF and 40 ul DIPEA added. 34 mg of 3-Bromo-propionyl chloride were added at 0° C. and the reaction warmed up to rt and stirred for another 30 min. The reaction mixture was heated to 120° C. using microwave heating and the product was isolated via preparative HPLC.

MS(ISO): 432.5 (MH+)

Example 426
1-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-pyrrolidine-2,5-dione

0.1 mmol of 1-{2-[5-(3-Amino-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone were dissolved in 1 ml DMF and 1 eq of succinic anhydride added. The reaction was stirred overnight and the intermediate (N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-succinamic acid) isolated via preparative HPLC. The isolated material was redissolved in DMF and 1 eq of HATU was added. The reaction mixture was heated to 120° C. using microwave heating. The product was isolated via preparative HPLC.

MS(ISO): 460.5 (MH+)

Example 427
2-Phenoxy-1-[(R)-2-(5-pyridazin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone

Step 1:

(R)-2-(N-Hydroxycarbamidoyl)-piperidine-1-carboxylic acid tert-butyl ester

3 g of (R)-N-Boc-2-Cyanopiperidine (14 mmol) were treated with 70 mmol of hydrazine hydrochloride and 35 mmol sodium carbonate in a mixture of ethanol/water (7:3) and heated to 50° C. overnight. The solvent was evaporated and the crude extracted from ethylacetate/water. The organic layer was dried over sodium sulfate. After evaporation a white solid was obtained in quantitative yield.

MS(ISO): 244.5 (MH+)

Step 2:

(R)-2-(5-Pyridazin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidine-1-carboxylic acid tert-butyl ester

0.2 mmol of pyridazine-4-carboxylic acid, HATU and Diisopropylethylamine were dissolved in 1 ml DMF and stirred for 15 min. 0.2 mmol of (R)-2-(N-Hydroxycarbamidoyl)-piperidine-1-carboxylic acid tert-butyl ester were added. The reaction was heated to 80° C. and stirred overnight. The DMF was evaporated and the crude extracted from ethylacetate/water. The crude product was not further characterized.

Step 3:

(R) 4-(3-Piperidin-2-yl-[1,2,4]oxadiazol-5-yl)-pyridazine trifluoroacetate

Crude material from step 3 was treated with neat TFA at room temperature for 1 h. The solvent was evaporated. The crude product was not further characterized.

Step 4:

2-Phenoxy-1-[(R)-2-(5-pyridazin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone

Crude material from step 3 was dissolved in 1 ml DMF and 0.1 mmol DIPEA. Either 0.1 mmol phenoxyacetyl chloride were added and the reaction stirred at room temperature for 30 min, or the corresponding phenoxyacetic acid derivatives were pre-activated with HATU/DIPEA in DMF for 10 min and added to the crude material from step 3. The product was isolated via preparative high performance liquid chromatography (HPLC).

MS(ISO): 366.5 (MH+)

The following compounds were generated in analogy to example 427

MH+ExampleCompound nameStarting materials(found)4284-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-389.3acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-yl}-carboxylic acid tert-butyl ester,benzonitrile4-Cyanobenzoic acid andPhenoxyacetyl chloride4291-{(R)-2-[5-(3-Amino-(R)-2-(N Hydroxycarbamidoyl)-381.3pyrazin-2-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone3-Amino-pyrazine-2-carboxylicacid and phenoxyacetyl chloride4303-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-389.3acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-carboxylic acid tert-butyl ester,benzonitrile3-Cyanobenzoic acid andphenoxyacetyl chloride4311-{(R)-2-[5-(2-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-379.4pyridin-3-yl)-[1,2,4]oxadiazol-piperidine-1-(M − H+)3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone2-Hydroxy-nicotinic andphenoxyacetyl chloride4321-{(R)-2-[5-(5-Amino-(R)-2-(N Hydroxycarbamidoyl)-380.3pyridin-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone5-Amino-nicotinic acid andphenoxyacetyl chloride4331-{(R)-2-[5-(2-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-381.2pyridin-4-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone2-Hydroxy-isonicotinic acid andphenoxyacetyl chloride4341-{(R)-2-[5-(2-Hydroxy-6-(R)-2-(N Hydroxycarbamidoyl)-395.2methyl-pyridin-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-2-Hydroxy-6-methyl-ethanoneisonicotinic acid andphenoxyacetyl chloride4351-{(R)-2-[5-(4-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-381.2pyridin-2-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone4-Hydroxy-pyridine-2-carboxylic acid andphenoxyacetyl chloride4361-{(R)-2-[5-(2-Amino-5-(R)-2-(N Hydroxycarbamidoyl)-415.2chloro-pyrimidin-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-2-Amino-5-chloro-pyrimidine-ethanone4-carboxylic acid andphenoxyacetyl chloride4372-Phenoxy-1-[(R)-2-(5-(R)-2-(N Hydroxycarbamidoyl)-366.2pyrazin-2-yl-[1,2,4]oxadiazol-piperidine-1-3-yl)-piperidin-1-yl]-ethanonecarboxylic acid tert-butyl ester,Pyrazine-2-carboxylic acid andphenoxyacetyl chloride4382-Phenoxy-1-{(R)-2-[5-(4-(R)-2-(N Hydroxycarbamidoyl)-431.2[1,2,4]triazol-1-yl-phenyl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-ethanone4-[1,2,4]Triazol-1-yl-benzoicacid and phenoxyacetyl chloride4392-Phenoxy-1-{(R)-2-[5-(4-(R)-2-(N Hydroxycarbamidoyl)-432.2tetrazol-1-yl-phenyl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-ethanone4-Tetrazol-1-yl-benzoic acidand phenoxyacetyl chloride4401-{(R)-2-[5-(1H-(R)-2-(N Hydroxycarbamidoyl)-404.2Benzoimidazol-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-1H-Benzoimidazole-4-ethanonecarboxylic acid andphenoxyacetyl chloride4411-{(R)-2-[5-(4-Acetyl-phenyl)-(R)-2-(N Hydroxycarbamidoyl)-406.2[1,2,4]oxadiazol-3-yl]-piperidine-1-piperidin-1-yl}-2-phenoxy-carboxylic acid tert-butyl ester,ethanone4-Acetyl-benzoic acid andphenoxyacetyl chloride4421-{(R)-2-[5-(6-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-381.2pyridin-2-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone6-Hydroxy-pyridine-2-carboxylic acid andphenoxyacetyl chloride4431-{(R)-2-[5-(5-Methyl-(R)-2-(N Hydroxycarbamidoyl)-380.2pyrazin-2-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone5-Methyl-pyrazine-2-carboxylicacid and phenoxyacetyl chloride4442-Phenoxy-1-[(R)-2-(5-(R)-2-(N Hydroxycarbamidoyl)-416.2quinoxalin-2-yl-piperidine-1-[1,2,4]oxadiazol-3-yl)-carboxylic acid tert-butyl ester,piperidin-1-yl]-ethanoneQuinoxaline-2-carboxylic acidand phenoxyacetyl chloride4451-{(R)-2-[5-(3-(R)-2-(N Hydroxycarbamidoyl)-442.2Methanesulfonyl-phenyl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-3-Methanesulfonyl-benzoic acidethanoneand phenoxyacetyl chloride4461-{(R)-2-[5-(6-Chloro-(R)-2-(N Hydroxycarbamidoyl)-399.1pyridin-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone6-Chloro-nicotinic acid andphenoxyacetyl chloride4471-[(R)-2-(5-Benzothiazol-6-yl-(R)-2-(N Hydroxycarbamidoyl)-421.2[1,2,4]oxadiazol-3-yl)-piperidine-1-piperidin-1-yl]-2-phenoxy-carboxylic acid tert-butyl ester,ethanoneBenzothiazole-6-carboxylic acidand phenoxyacetyl chloride4482-Phenoxy-1-{(R)-2-[5-(2,4,5-(R)-2-(N Hydroxycarbamidoyl)-418.2trifluoro-phenyl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-ethanone2,4,5-Trifluoro-benzoic acidand phenoxyacetyl chloride4492-Phenoxy-1-{(R)-2-[5-(6-(R)-2-(N Hydroxycarbamidoyl)-433.2trifluoromethyl-pyridin-3-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-ethanone6-Trifluoromethyl-nicotinicacid and phenoxyacetyl chloride4501-[(R)-2-(5-(R)-2-(N Hydroxycarbamidoyl)-422.2Benzo[1,2,3]thiadiazol-5-yl-piperidine-1-[1,2,4]oxadiazol-3-yl)-carboxylic acid tert-butyl ester,piperidin-1-yl]-2-phenoxy-Benzo[1,2,3]thiadiazole-5-ethanonecarboxylic acid andphenoxyacetyl chloride4511-[(R)-2-(5-(R)-2-(N Hydroxycarbamidoyl)-416.2[1,8]Naphthyridin-2-yl-piperidine-1-[1,2,4]oxadiazol-3-yl)-carboxylic acid tert-butyl ester,piperidin-1-yl]-2-phenoxy-[1,8]Naphthyridine-2-ethanonecarboxylic acid andphenoxyacetyl chloride4521-[(R)-2-(5-(R)-2-N Hydroxycarbamidoyl)-416.2[1,6]Naphthyridin-2-yl-piperidine-1-[1,2,4]oxadiazol-3-yl)-carboxylic acid tert-butyl ester,piperidin-1-yl]-2-phenoxy-[1,6]Naphthyridine-2-ethanonecarboxylic acid andphenoxyacetyl chloride4531-[(R)-2-(5-Cinnolin-4-yl-(R)-2-(N Hydroxycarbamidoyl)-416.2[1,2,4]oxadiazol-3-yl)-piperidine-1-piperidin-1-yl]-2-phenoxy-carboxylic acid tert-butyl ester,ethanoneCinnoline-4-carboxylic acid andphenoxyacetyl chloride4541-{(R)-2-[5-(1H-Benzotriazol-(R)-2-(N Hydroxycarbamidoyl)-405.25-yl)-[1,2,4]oxadiazol-3-yl]-piperidine-1-piperidin-1-yl}-2-phenoxy-carboxylic acid tert-butyl ester,ethanone1H-Benzotriazole-5-carboxylicacid and phenoxyacetyl chloride4551-{(R)-2-[5-(1H-(R)-2-(N Hydroxycarbamidoyl)-404.2Benzoimidazol-5-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-1H-Benzoimidazole-5-ethanonecarboxylic acid andphenoxyacetyl chloride4561-{(R)-2-[5-(3,6-Dichloro-(R)-2-(N Hydroxycarbamidoyl)-435.2pyridazin-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-3,6-Dichloro-pyridazine-4-ethanonecarboxylic acid andphenoxyacetyl chloride4576-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-435.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-4H-carboxylic acid tert-butyl ester,benzo[1,4]oxazin-3-one3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylicacid and phenoxyacetyl chloride4581-{(R)-2-[5-(3H-Imidazo[4,5-(R)-2-(N Hydroxycarbamidoyl)-405.1b]pyridin-6-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-3H-Imidazo[4,5-b]pyridine-6-ethanonecarboxylic acid andphenoxyacetyl chloride459N-(4-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-422.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-pyridin-carboxylic acid tert-butyl ester2-yl)-acetamide2-Acetylamino-isonicotinic acidand phenoxyacetic acid4601-{(R)-2-[5-(6-Chloro-3-(R)-2-(N Hydroxycarbamidoyl)-416.1hydroxy-pyridazin-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-6-Chloro-3-hydroxy-ethanonepyridazine-4-carboxylic acidand phenoxyacetyl chloride4616-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-448.1acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-1,4-carboxylic acid tert-butyl ester,dihydro-quinoxaline-2,3-dione2,3-Dioxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acidand phenoxyacetyl chloride4621-{(R)-2-[5-(6-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-381.1pyridin-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone6-Hydroxy-nicotinic acid andphenoxyacetyl chloride4637-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-434.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-3,4-carboxylic acid tert-butyl ester,dihydro-1H-quinoxalin-2-one3-Oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acidand phenoxyacetic acid4641-{(R)-2-[5-(6-Amino-(R)-2-(N Hydroxycarbamidoyl)-380.2pyridin-2-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone6-Amino-pyridine-2-carboxylicacid and phenoxyacetic acid4656-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-390.1acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-carboxylic acid tert-butyl ester,nicotinonitrile5-Cyano-pyridine-2-carboxylicacid and phenoxyacetic acid4665-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-390.1acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-carboxylic acid tert-butyl ester,pyridine-2-carbonitrile6-Cyano-nicotinic acid andphenoxyacetic acid4674-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-420.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-1,2-carboxylic acid tert-butyl ester,dihydro-indazol-3-one3-Oxo-2,3-dihydro-1H-indazole-4-carboxylic acid andphenoxyacetic acid4681-{(R)-2-[5-(2-Amino-(R)-2-(N Hydroxycarbamidoyl)-380.1pyridin-4-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone2-Amino-isonicotinic acid andphenoxyacetic acid4691-{(R)-2-[5-(6-Hydroxy-(R)-2-(N Hydroxycarbamidoyl)-382.1pyrimidin-4-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-6-Hydroxy-pyrimidine-4-ethanonecarboxylic acid andphenoxyacetic acid4704-(3-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-447.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-phenyl)-carboxylic acid tert-butyl ester,2,4-dihydro-[1,2,4]triazol-3-3-(5-Oxo-1,5-dihydro-one[1,2,4]triazol-4-yl)-benzoic acidand phenoxyacetic acid4711-(3-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-462.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-phenyl)-carboxylic acid tert-butyl ester,imidazolidine-2,4-dione3-(2,4-Dioxo-imidazolidin-1-yl)-benzoic acid andphenoxyacetic acid4721-((R)-2-{5-[3-(1,1-Dioxo-(R)-2-(N Hydroxycarbamidoyl)-483.21$$6-isothiazolidin-2-yl)-piperidine-1-phenyl]-[1,2,4]oxadiazol-3-yl}-carboxylic acid tert-butyl ester,piperidin-1-yl)-2-phenoxy-3-(1,1-Dioxo-1$$6-ethanoneisothiazolidin-2-yl)-benzoicacid and phenoxyacetic acid4731-(3-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-447.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-phenyl)-carboxylic acid tert-butyl ester,pyrrolidin-2-one3-(2-Oxo-pyrrolidin-1-yl)-benzoic acid and phenoxyaceticacid4741-(3-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-446.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-phenyl)-carboxylic acid tert-butyl ester,1,3-dihydro-imidazol-2-one3-(2-Oxo-2,3-dihydro-imidazol-1-yl)-benzoic acid andphenoxyacetic acid4753-(3-{3-[(R)-1-(2-Phenoxy-(R)-2-(N Hydroxycarbamidoyl)-462.2acetyl)-piperidin-2-yl]-piperidine-1-[1,2,4]oxadiazol-5-yl}-phenyl)-carboxylic acid tert-butyl ester,imidazolidine-2,4-dione3-(2,5-Dioxo-imidazolidin-1-yl)-benzoic acid andphenoxyacetic acid4761-{(R)-2-[5-(1-Methyl-1H-(R)-2-(N Hydroxycarbamidoyl)-368.2pyrazol-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone1-Methyl-1H-pyrazole-3-carboxylic acid andphenoxyacetic acid4772-Phenoxy-1-{(R)-2-[5-(1H-(R)-2-(N Hydroxycarbamidoyl)-354.1pyrazol-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-ethanonecarboxylic acid tert-butyl ester,1H-Pyrazole-3-carboxylic acidand phenoxyacetic acid4781-{(R)-2-[5-(5-Methyl-(R)-2-(N Hydroxycarbamidoyl)-369.1isoxazol-3-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-5-Methyl-isoxazole-3-carboxylicethanoneacid and phenoxyacetic acid4791-{(R)-2-[5-(2,5-Dimethyl-(R)-2-(N Hydroxycarbamidoyl)-382.22H-pyrazol-3-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-2,5-Dimethyl-2H-pyrazole-3-ethanonecarboxylic acid andphenoxyacetic acid4801-{(R)-2-[5-(5-Methyl-2H-(R)-2-(N Hydroxycarbamidoyl)-368.2pyrazol-3-yl)-[1,2,4]oxadiazol-piperidine-1-3-yl]-piperidin-1-yl}-2-carboxylic acid tert-butyl ester,phenoxy-ethanone5-Methyl-2H-pyrazole-3-carboxylic acid andphenoxyacetic acid4811-{(R)-2-[5-(3-Methyl-(R)-2-(N Hydroxycarbamidoyl)-369.1isoxazol-5-yl)-piperidine-1-[1,2,4]oxadiazol-3-yl]-carboxylic acid tert-butyl ester,piperidin-1-yl}-2-phenoxy-3-Methyl-isoxazole-5-carboxylicethanoneacid and phenoxyacetic acid

The following intermediate compounds were prepared in analogy to example 256

ExampleIntermediate nameStarting materials482N-Hydroxy-2-imidazol-1-yl-2-Imidazol-1-yl-isonicotinonitrileisonicotinamidineand hydroxylamine483N-Hydroxy-4-(3H-imidazol-4-yl)-4-(3H-Imidazol-4-yl)-benzonitrilebenzamidineand hydroxylamine484N-Hydroxy-4-(2-methyl-imidazol-1-4-(2-Methyl-imidazol-1-yl)-yl)-benzamidinebenzonitrile and hydroxylamine485N-Hydroxy-2-pyrazol-1-yl-2-Pyrazol-1-yl-isonicotinonitrileisonicotinamidineand hydroxylamine4865-(N-Hydroxycarbamidoyl)-nicotinic5-Cyano-nicotinic acid ethyl esteracid ethyl esterand hydroxylamine487N-Hydroxy-4-piperidin-1-yl-4-Piperidin-1-yl-benzonitrile andbenzamidinehydroxylamine488N-Hydroxy-4-morpholin-1-yl-4-Morpholin-1-yl-benzonitrile andbenzamidinehydroxylamine489N-Hydroxy-6-imidazol-1-yl-6-Imidazol-1-yl-nicotinonitrile andnicotinamidinehydroxylamine490N-[3-(N-Hydroxycarbamidoyl)-N-(3-Cyano-phenyl)-acetamidephenyl]-acetamideand hydroxylamine4914-(N-Hydroxycarbamidoyl)-benzoicN-(3-Cyano-phenyl)-4-Cyano-acid benzyl esterbenzoic acid benzyl ester andhydroxylamine4925-(N-Hydroxycarbamidoyl)-pyridine-5-Cyano-pyridine-2-carboxylic acid2-carboxylic acid methyl estermethyl ester and hydroxylamine4932-Fluoro-4-(N-hydroxycarbamidoyl)-4-Cyano-2-fluoro-benzoic acidbenzoic acid ethyl esterethyl ester and hydroxylamine4944-(N-Hydroxycarbamidoyl)-benzoic4-Cyano-benzoic acid methyl esteracid methyl esterand hydroxylamine495[3-(N-Hydroxycarbamidoyl)-(3-Cyano-phenoxy)-acetic acidphenoxy]-acetic acid methyl estermethyl ester and hydroxylamine496N-Hydroxy-2-methyl-1H-2-Methyl-1H-benzoimidazole-5-benzoimidazole-5-carboxamidinecarbonitrile and hydroxylamine4972-Amino-N-hydroxy-2-Amino-isonicotinonitrile andisonicotinamidinehydroxylamine4983,N-Dihydroxy-benzamidine3-Hydroxy-benzonitrile andhydroxylamine4994,N-Dihydroxy-benzamidine4-Hydroxy-benzonitrile andhydroxylamine5004-(N-Hydroxycarbamimidoyl)-4-Cyano-phenylboronic acid andbenzoic acidhydroxylamine501N-Hydroxy-furan-2-carboxamidineFuran-2-carbonitrile andhydroxylamine502N-Hydroxy-4-methyl-4-Methyl-[1,2,3]thiadiazole-5-[1,2,3]thiadiazole-5-carboxamidinecarbonitrile and hydroxylamine503N-Hydroxy-2,5-dimethyl-2H-2,5-Dimethyl-2H-pyrazole-3-pyrazole-3-carboxamidinecarbonitrile and hydroxylamine504N-Hydroxy-1H-pyrazole-4-1H-Pyrazole-4-carbonitrile andcarboxamidinehydroxylamine505N-Hydroxy-5-methyl-isoxazole-3-5-Methyl-isoxazole-3-carbonitrilecarboxamidineand hydroxylamine506N-Hydroxy-1H-pyrazole-3-1H-Pyrazole-3-carbonitrile andcarboxamidinehydroxylamine507N-Hydroxy-2,4-dioxo-1,2,3,4-2,4-Dioxo-1,2,3,4-tetrahydro-tetrahydro-pyrimidine-5-pyrimidine-5-carbonitrile andcarboxamidinehydroxylamine5086-Amino-N-hydroxy-nicotinamidine6-Amino-nicotinonitrile andhydroxylamine509N-Hydroxy-imidazo[1,2-a]pyridine-Imidazo[1,2-a]pyridine-6-6-carboxamidinecarbonitrile and hydroxylamine510N-[4-Fluoro-3-(N-N-(3-Cyano-4-fluoro-phenyl)-hydroxycarbamimidoyl)-phenyl]-acetamide and hydroxylamineacetamide511N-[5-Fluoro-3-(N-N-(3-Cyano-5-fluoro-phenyl)-hydroxycarbamimidoyl)-phenyl]-acetamide and hydroxylamineacetamide512N-[6-Fluoro-3-(N-N-(3-Cyano-6-fluoro-phenyl)-hydroxycarbamimidoyl)-phenyl]-acetamide and hydroxylamineacetamide513N-Hydroxy-3-oxo-3,4-dihydro-2H-3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxamidinebenzo[1,4]oxazine-6-carbonitrileand hydroxylamine514N-Hydroxy-2-oxo-1,4-dihydro-2H-2-Oxo-1,4-dihydro-2H-benzo[d][1,3]oxazine-6-benzo[d][1,3]oxazine-6-carboxamidinecarbonitrile and hydroxylamine515N-Hydroxy-2-oxo-1,2,3,4-tetrahydro-2-Oxo-1,2,3,4-tetrahydro-quinazoline-7-carboxamidinequinazoline-7-carbonitrile andhydroxylamine5163-(1,1-Dioxo-1□6-isothiazolidin-2-3-(1,1-Dioxo-1□6-isothiazolidin-2-yl)-N-hydroxy-benzamidineyl)-benzonitrile and hydroxylamine517N-Hydroxy-3-(2-oxo-pyrrolidin-1-3-(2-Oxo-pyrrolidin-1-yl)-yl)-benzamidinebenzonitrile and hydroxylamine5183-(2,4-Dioxo-imidazolidin-1-yl)-N-3-(2,4-Dioxo-imidazolidin-1-yl)-hydroxy-benzamidinebenzonitrile and hydroxylamine519N-Hydroxy-3-(5-oxo-1,5-dihydro-3-(5-Oxo-1,5-dihydro-[1,2,4]triazol-4-yl)-benzamidine[1,2,4]triazol-4-yl)-benzonitrile andhydroxylamine

The following compounds were generated according to example 312

ExampleIntermediate nameStarting materials520N-Amino-2-Oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-indole-5-indole-5-carboxamidine hydrochloridecarbonitrile and hydrazine521N-Amino-1H-Indazole-5-1H-Indazole-5-carbonitrile andcarboxamidine hydrochloridehydrazine522N-Amino-1H-Indole-5-1H-Indole-5-carbonitrile andcarboxamidine hydrochloridehydrazine523N-Amino-1H-Benzotriazole-5-1H-Benzotriazole-5-carbonitrilecarboxamidine hydrochlorideand hydrazine524N-Amino-2-Oxo-2,3-dihydro-1H-2-Oxo-2,3-dihydro-1H-benzoimidazole-5-carboxamidinebenzoimidazole-5-carbonitrile andhydrochloridehydrazine525N-Amino-N-Hydroxy-2-methyl-1H-2-Methyl-1H-benzoimidazole-5-benzoimidazole-5-carboxamidinecarbonitrile and hydrazinehydrochloride526N-Amino-2-Amino-2-Amino-isonicotinonitrile andisonicotinamidine hydrochloridehydrazine527N-Amino-3-(5-Oxo-4,5-dihydro-3-(5-Oxo-4,5-dihydro-[1,3,4]oxadiazol-2-yl)-benzamidine[1,3,4]oxadiazol-2-yl)-benzonitrilehydrochlorideand hydrazine528N-Amino-3-[1,3,4]Oxadiazol-2-yl-3-[1,3,4]Oxadiazol-2-yl-benzamidine hydrochloridebenzonitrile and hydrazine529N-Amino-3-Carbamidoyl-3-Cyano-phenylboronic acid andphenylboronic acid hydrochloridehydrazine530N-Amino-2-fluoro-benzamidine2-Fluorobenzonitrile and hydrazinehydrochlorideand hydrazine531N-Amino-6-Amino-nicotinamidine6-Amino-nicotinonitrile andhydrochloridehydrazine532N-Amino-4-Carbamimidoyl-benzoic4-Cyano-benzoic acid methyl esteracid methyl ester hydrochlorideand hydrazine533N-Amino-4-Fluoro-benzamidine4-Fluoro-benzonitrile andhydrochloridehydrazine534N-Amino-3-Fluoro-benzamidine3-Fluoro-benzonitrile andhydrochloridehydrazine

Example 535
N-(5-Cyano-2-fluoro-phenyl)-acetamide

10 mmol of 3-Amino-4-fluoro-benzonitrile were dissolved in 30 ml THF. 1.5 eq of DIPEA were added and the reaction mixture cooled to 0° C. 1.2 eq of acetylchloride were added dropwise, the reaction warmed up to rt and stirred for additional 30 min. The solvent was evaporated and the product isolated via extraction from ethylacetate and saturated NaHCO₃solution.

MS(ISO): 179.2 (MH+)

Example 536
N-(3-Cyano-5-fluoro-phenyl)-acetamide

The title compound was prepared in analogy to example 535 from 3-Amino-5-Fluoro-benzonitril. MS(ISO): 179.2 (MH+)

Example 537
N-(3-Cyano-4-fluoro-phenyl)-acetamide

The title compound was prepared in analogy to example 535 from 5-Amino-2-Fluoro-benzonitril. MS(ISO): 179.2 (MH+)

Example 538
3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carbonitrile

24 mmol of 4-Hydroxy-3-nitrobenzonitrile were dissolved in DMF. 1.1 eq of Cs2CO3 were added and the reaction stirred at rt for 15 min. 1.5 eq of ethylbromo acetate were added and the reaction mixture heated to 50° C. for 2 h. The intermediate was isolated via extraction from ethylacetate/water. The organic layer was separated and dried over Na2SO4. After evaporation the resulting solid was redissolved in MeOH and sat. NH4Cl (1:1). 8 g of Zn powder were added and the suspension stirred at rt for 2 h. The solid was filtered off and the organic layer evaporated. Ethylacetate was added and the organic layer washed with sat. NaHCO3. The organic layer was separated again, dried over Na2SO4 and reduced resulting in a light brown solid. MS(ISO): 175.2 (MH+)

Example 539
2-Oxo-1,4-dihydro-2H-benzo[d][1,3]oxazine-6-carbonitrile

20 mmol of 4-Amino-3-hydroxymethyl-benzonitrile were dissolved in THF. 1.2 eq. of DIPEA were added and the reaction cooled to 0° C. 3.5 eq of ethyl chloroformate were added dropwise and the reaction warmed to rt and stirred for another 15 min. The crude material was extracted form etyhlacetate and sat. NaHCO3. After separation, and drying of the organic layer the solvent was evaporated and the crude taken up in toluene. 2.5 ml of DBU were added and the reaction mixture refluxed for 4 h. The organic layer was extracted with water and the organic layer separated and reduced resulting in a yellow oil. Crude material was not further characterized.

Example 540
2-Oxo-1,2,3,4-tetrahydro-quinazoline-7-carbonitrile

24 mmol of 2-Nitro-4-chloro-benzylamine hydrochloride were dissolved in THF. 2.2 eq of DIPEA were added and the reaction mixture cooled to 0° C. 3.5 eq. of ethyl chloroforamte were added dropwise and the reaction stirred for 15 min. After extraction from ethylacetate/sat. NaHCO3 and evaporation of the organic layer a light brown solid resulted. This was taken up in MeOH/sat. NH4Cl (1:1). 6 g of Zn was added and the suspension stirred at rt for 4 h. The solid was filtered off, the methanol reduced and the product isolated via extraction with ethylacetate. After evaporation a light yellow solid resulted. MS(ISO): 174.2 (MH+)

Example 541
3-(5-Oxo-1,5-dihydro-[1,2,4]triazol-4-yl)-benzonitrile

g of 3-Aminobenzonitril were dissolved in 20 ml MeOH. 1.8 ml of trimethyl orthoformate, hydrazinecarboxylic acid methyl ester and cat. para-toluenesulfonic acid were added. The reaction mixture was heated to 65° C. for 3 h. The suspension was cooled to rt and 9 ml of NaOMe solution were added and the reaction mixture stirred at rt for 2 h. Water was added and the pH adjusted to 1 using aq. HCl (25%). The resulting suspension was filtered off and dried under vacuum. MS(ISO): 187.2 (MH+)

Example 542
3-(2,4-Dioxo-imidazolidin-1-yl)-benzonitrile

g of 3-Aminobenzonitril were dissolved in 60 ml Dioxan and 0.8 ml of Chloro-acetyl isocyanate added. The reaction mixture was stirred at rt for 2 h. 2.5 ml of DBU were added and the reaction mixture stirred at rt for 40 h. The product was extracted with DCM. MS(ISO): 202.2 (MH+)

Example 543
3-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-benzonitrile

1 g of 3-Aminobenzonitril were dissolved in 10 ml DCM and 2.2 ml of DIPEA. 1.3 ml of 3-Chloro-propane-1-sulfonyl chloride were added and the reaction mixture stirred at rt overnight. The organic layer was evaporated, the crude taken up in DMF and 1.5 ml DBU added. The reaction mixture was stirred at rt overnight. DCM was added and the organic phase washed with water. The organic layer was separated, dried over Na2SO4 and evaporated. MS(ISO): 232.2 (MH+)

Example 544
3-(2-Oxo-pyrrolidin-1-yl)-benzonitrile

g of 3-Aminobenzonitril were dissolved in 20 ml DMF and 4.4 ml of DIPEA. The reaction mixture was cooled to 0° C. and 2 ml of 4-chloro-butyryl chloride added. The reaction mixture was stirred at rt for 1 h. 5 ml of DBU were added and the reaction mixture stirred at rt overnight. DCM was added and the organic phase washed with 1N HCL and water. The organic layer was separated, dried over Na2SO4 and evaporated. MS(ISO): 187.2 (MH+)

Example 545
6-Chloro-3-hydroxy-pyridazine-4-carboxylic acid

2 mmol of 3,6-Dichloropyridazine-4-carboxylic acid are treated with 8 ml of aqueous 2N NaOH and refluxed for 1 h. The reaction mixture was acidified to pH=1. The resulting white solid was filtered off and dried under vacuum. MS(ISO): 173.2 (M−H+)

Example 546
3-(5-Oxo-1,5-dihydro-[1,2,4]triazol-4-yl)-benzoic acid

13 mmol of methyl-3-aminobenzoate were dissolved in 20 ml MeOH. 12 mmol of trimethylorthoformiate, 12 mmol methyl hydrazinocarboxylate and 50 mg of p-toluenesulfonic acid were added. The suspension was heated for 48 h to 65° C. 37 mmol of sodium methanolate were added and stirred for additional 2 h. The organic layer was reduced and water was added. The solution was acidified to pH=1 and the resulting solid filtered off to result in 5.7 mmol of product. MS(ISO): 204.2 (M−H+)

Example 547
3-(2,4-Dioxo-imidazolidin-1-yl)-benzoic acid

12 mmol of ethyl-3-aminobenzoate were dissolved in 120 ml Dioxan. 1 eq of chloroacetyl isocyanate were added. The reaction mixture was stirred at rt for 1 h and then heated to 120° C. for an additional 2 h. The reaction was cooled to rt, 2 eq of DBU added and again stirred at rt overnight. The solvent was evaporated and the crude extracted from DCM. The crude material was dissolved in 20 ml MeOH and 4 ml of 4N NaOH were added. The reaction mixture was stirred at rt for 20 h. After evaporation of the organic layer the aqueous phase was acidified to pH=1 and the resulting white solid was filtered off and dried under vacuum. MS(ISO): 219.2 (M−H+)

Example 548
3-(1,1-Dioxo-1λ6-[1,2,5]thiadiazolidin-2-yl)-benzoic acid

13 mmol of methyl-3-aminobenzoate were dissolved in 20 ml DCM and 3 ml of TEA added. 1.6 ml of 3-chloropropanesulfonyl chloride were added slowly under argon atmosphere. The reaction mixture was stirred at rt overnight and washed with 1N HCl. The organic layer was separated, dried over Na2SO4 and reduced under vacuum. The resulting crude was taken up in 16 ml DMF and 2.4 ml of DBU added. The reaction mixture was stirred at rt for 2 h and washed with 1N HCl. The crude material was dissolved in 20 ml MeOH and 4 ml of 2N NaOH were added. The reaction mixture was stirred at rt for 72 h and acidified with HCl to pH=1. The resulting white solid was filtered off and dried under vacuum. MS(ISO): 241.3 (M−H+)

Example 549
3-(2-Oxo-2,3-dihydro-imidazol-1-yl)-benzoic acid

12 mmol of ethyl-3-aminobenzoate were dissolved in 20 ml DCM and 2 ml of TEA added. The reaction mixture was cooled to ° C. and 1.5 ml Diphosgen were added slowly. The reaction mixture was warmed to rt and stirred for an additional 1 h under argon atmosphere. The reaction mixture was poured on ice and the organic layer separated, dried over Na2SO4 and reduced under vacuum. The crude material was taken up in 30 ml DCM and 1.3 ml of aminoacetaldehyde dimethylacetal were added. The reaction mixture was stirred for 3 h at rt. The organic layer was washed with sat. NaHCO3, separated and dried over Na2SO4. After evaporation of the solvent the resulting crude material was purified via Kieselgel chromatography. 200 mg of the product were dissolved in 5 ml MeOH and 2 ml of 2N NaOH added. The reaction mixture was stirred at rt for 2 h, acidified with HCl to pH=1 and the resulting white solid filtered off. MS(ISO): 203.2 (M−H+)

Example 550
3-(2,5-Dioxo-imidazolidin-1-yl)-benzoic acid

13 mmol of methyl-3-aminobenzoate were dissolved in 20 ml DCM and 1.7 ml of ethyl isocyanatoacetate added. The reaction mixture was stirred at rt for 1 h. The solvent was evaporated and the resulting crude taken up in 50 ml acetone. 50 ml of aq. HCl (25%) were added and heated to reflux for 8 h. After evaporation of the organic layer the resulting solid was filtered off, washed with water and dried under vacuum. MS(ISO): 219.2 (M−H+)

Example 551
3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxamidine

8.7 mmol of N-Hydroxy-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxamidine were dissolved in 25 ml acetic acid. 5 eq. of ammonium formiate and 0.05 eq. of Pd/C (10%) were added and the reaction mixture heated to reflux overnight. The reaction mixture was concentrated, cooled to 0° C. and the pH adjusted to 8 using aq. NaOH (28%). The resulting solid was filtered off and washed with water. MS(ISO): 192.2 (M−H+)

The following intermediate compounds were generated in analogy to example 551

ExampleIntermediate nameStarting material552Imidazo[1,2-a]pyridine-6-carboxamidineN-Hydroxy-imidazo[1,2-a]pyridine-6-carboxamidine5531H-Benzoimidazole-5-carboxamidineN-Hydroxy-1H-benzoimidazole-5-carboxamidine554NicotinamidineN-Hydroxy-nicotinamidine5553,5-Dimethyl-isoxazole-4-N-Hydroxy-3,5-dimethyl-carboxamidineisoxazole-4-carboxamidine556Thiophene-2-carboxamidineN-Hydroxy-thiophene-2-carboxamidine556Pyrimidine-2-carboxamidineN-Hydroxy-pyrimidine-2-carboxamidine5574-Methyl-oxazole-5-carboxamidineN-Hydroxy-4-methyl-oxazole-5-carboxamidine558Pyrazine-2-carboxamidineN-Hydroxy-pyrazine-2-carboxamidine5592-Methyl-isonicotinamidineN-Hydroxy-2-methyl-isonicotinamidine5602-Oxo-1,4-dihydro-2H-N-Hydroxy-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazine-6-benzo[d][1,3]oxazine-6-carboxamidinecarboxamidine5612-Oxo-1,2,3,4-tetrahydro-N-Hydroxy-2-oxo-1,2,3,4-quinazoline-6-carboxamidinetetrahydro-quinazoline-6-carboxamidine5623-(2,4-Dioxo-imidazolidin-1-yl)-3-(2,4-Dioxo-imidazolidin-1-yl)-benzamidineN-hydroxy-benzamidine563N-(3-Carbamidoyl-4-fluoro-phenyl)-N-[4-Fluoro-3-(N-acetamidehydroxycarbamidoyl)-phenyl]-acetamide564N-(3-Carbamidoyl-5-fluoro-phenyl)-N-[5-Fluoro-3-(N-acetamidehydroxycarbamidoyl)-phenyl]-acetamide565N-(3-Carbamidoyl-6-fluoro-phenyl)-N-[6-Fluoro-3-(N-acetamidehydroxycarbamidoyl)-phenyl]-acetamide

Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

IngredientsPer tabletKernel:Compound of formula (I)10.0mg200.0mgMicrocrystalline cellulose23.5mg43.5mgLactose hydrous60.0mg70.0mgPovidone K3012.5mg15.0mgSodium starch glycolate12.5mg17.0mgMagnesium stearate1.5mg4.5mg(Kernel Weight)120.0mg350.0mgFilm Coat:Hydroxypropyl methyl cellulose3.5mg7.0mgPolyethylene glycol 60000.8mg1.6mgTalc1.3mg2.6mgIron oxyde (yellow)0.8mg1.6mgTitan dioxide0.8mg1.6mg

The active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

IngredientsPer capsuleCompound of formula (I)25.0mgLactose150.0mgMaize starch20.0mgTalc5.0mg

The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:

Compound of formula (I)3.0mgPolyethylene Glycol 400150.0mgAcetic Acidq.s. ad pH 5.0Water for injection solutionsad 1.0ml

The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.

Example D

Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

Capsule contentsCompound of formula (I)5.0mgYellow wax8.0mgHydrogenated Soya bean oil8.0mgPartially hydrogenated plant oils34.0mgSoya bean oil110.0mgWeight of capsule contents165.0mgGelatin capsuleGelatin75.0mgGlycerol 85%32.0mgKarion 838.0mg (dry matter)Titanium dioxide0.4mgIron oxide yellow1.1mg

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.

Example E

Sachets containing the following ingredients can be manufactured in a conventional manner:

Compound of formula (I)50.0mgLactose, fine powder1015.0mgMicrocristalline cellulose (AVICEL PH 102)1400.0mgSodium carboxymethyl cellulose14.0mgPolyvinylpyrrolidon K 3010.0mgMagnesium stearate10.0mgFlavoring additives1.0mg

The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulste is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

It is to be understood that the invention is not limited to the particular embodiments of the invention described above, as variations of the particular embodiments may be made and still fall within the scope of the appended claims.

Claims

1. A compound of formula (I):
2. The compound according to claim 1, wherein X is C(R8R9), NR10, O, S, S(O), S(O2); R1 is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, hydroxy, lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and CN; R2 is hydrogen or lower-alkyl; R3 and R4 independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R3 and R4 together are ═O to form a carbonyl group together with the carbon atom to which they are attached; R5 and R6 independently from each other are hydrogen, halogen, lower-alkyl or lower-alkoxy, or R5 and R6 together are ═O to form a carbonyl group together with the carbon atom to which they are attached; R7 is an oxadiazolyl or triazolyl, which oxadiazolyl or triazolyl is substituted with R11 and optionally substituted with R12; R8 and R9 independently from each other are hydrogen, halogen, hydroxy, lower-alkyl, lower-alkoxy; or R8 and R9 are bound together and —R8—R9— is —(CH2)2-7— to form a ring together with the carbon atom to which they are attached; R10 is hydrogen, lower-alkyl, lower-alkyl-carbonyl or lower-alkyl-sulfonyl; R11 is aryl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyrimidinyl, pyridinyl-2-one, oxadiazolyl, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl, imidazopyridinyl, triazolepyridinyl,tetrazolepyridinyl and benzimidazolyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O2)R13, C(O)R14, NO2, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower-alkoxy, which imidazolyl is optionally substituted with lower-alkyl and which phenyl-lower-alkoxy is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl; R12 is hydrogen or lower-alkyl; R13 is lower-alkyl, NR17R18 or fluoro-lower-alkyl; R14 is OH, NR19R20, lower-alkoxy or lower-alkenyl-oxy; R15 and R16 independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO2, lower-alkenyl-oxy-carbonyl, NH2-carbonyl, lower-alkyl-NH-carbonyl, (lower-alkyl)2N-carbonyl or phenyl-lower-alkyl, which phenyl-lower-alkyl is optionally substituted with hydroxy, halogen, lower-alkyl, lower-alkoxy or fluoro-lower-alkyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl, piperazinyl and pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl; R17 and R18 independently from each other are hydrogen, lower-alkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or NR17R18 is morpholinyl; R19 and R20 independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl or lower-alkoxy-lower-alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl, pyrrolidinyl and 8-oxa-3-aza-bicyclo[3.2.1]octyl, which heterocyclyl is optionally substituted with hydroxy or lower-alkyl-S(O2); and pharmaceutically acceptable salts and esters thereof.
3. The compound according to claim 1, wherein R1 is phenyl optionally substituted with halogen, hydroxy, hydroxy-lower-alkyl or CN.
4. The compound according to claim 1, wherein R1 is phenyl.
5. The compound according to claim 1, wherein R2 is hydrogen.
6. The compound according to claim 1, wherein R3 is hydrogen.
7. The compound according to claim 1, wherein R4 is hydrogen.
8. The compound according to claim 1, wherein R5 is hydrogen.
9. The compound according to claim 1, wherein R6 is hydrogen.
10. The compound according to claim 1, wherein R7 is
11. The compound according to claim 1, wherein R7 is
12. The compound according to claim 1, wherein R7 is
13. The compound according to claim 1, wherein X is C(R8R9), NR10, O or S, wherein R8, R9 and R10 are as defined in claim 1.
14. The compound according to claim 1, wherein X is C(R8R9) or NR10, wherein R8, R9 and R10 are as defined in claim 1.
15. The compound according to claim 1, wherein R8 is hydrogen.
16. The compound according to claim 1, wherein R9 is hydrogen.
17. The compound according to claim 1, wherein R10 is hydrogen.
18. The compound according to claim 1, wherein R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyrazinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of lower-alkyl, hydroxy-lower-alkyl, fluoro-lower-alkyl, lower-alkoxy, halogen, S(O2)R13, C(O)R14, NO2, NR15R16, imidazolyl, pyrazolyl, tetrazolyl, pyrrolyl, and phenyl-lower-alkoxy, which imidazolyl is optionally substituted with lower-alkyl, wherein R13, R14, R15 and R16 are as defined in claim 1.
19. The compound according to claim 1, wherein R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, pyridinyl-2-one, indazolyl, 1,3-dihydro-benzimidazol-2-one, 1,3-dihydro-indol-2-one, benztriazolyl and benzimidazolyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents selected from the group consisting of fluoro-lower-alkyl, halogen, C(O)R14 and NR15R16, wherein R14, R15 and R16 are as defined in claim 1.
20. The compound according to claim 1, wherein R11 is 1H-Indazol-5-yl, 1H-Indazol-6-yl, 1,3-dihydro-indol-2-one-6-yl, 1,3-dihydro-benzoimidazol-2-one-5-yl, 1,3-dihydro-indol-2-one-5-yl, 1H-Benzotriazol-5-yl, 1H-Benzoimidazol-5-yl, 1H-pyridin-2-one-4-yl, 4-Fluoro-phenyl, 3-trifluoromethyl-phenyl, 1H-Benzoimidazol-5-yl, 3-benzamide, 5-nicotinamide, 3-(N-acetamide)-phenyl or 3-(N-methanesulfonamide)-phenyl.
21. The compound according to claim 1, wherein R11 is phenyl or a heteroaryl selected from the group consisting of 2-oxo-2,3-dihydro-1H-indol-5-yl, pyrimidin-4-one, furanyl, thiadiazolyl, pyrazolyl, isoxazolyl, pyrimidine-2,4-dione, benzooxazin-3-one, 1,4-dihydro-benzooxazin-2-one, indolyl, thiophenyl, oxazolyl, benzooxazin-2-one, 3,4-dihydro-quinazolin-2-one, pyridazinyl, quinoxalinyl, benzothiazolyl, benzothiadiazolyl, naphthyridinyl, cinnolinyl, 1,4-dihydro-quinoxaline-2,3-dione and 1,2-dihydro-indazol-3-one, which phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, B(OH)2, carboxy-lower-alkoxy, carbamoyl-lower-alkoxy, cyano, [1,3,4]oxadiazol-2-one, oxadiazolyl, triazolyl and isoxazolyl, which pyrazolyl is optionally substituted with lower-alkyl, and which isoxazolyl is optionally substituted with lower-alkyl.
22. The compound according to claim 1, wherein R11 is phenyl or a heteroaryl selected from the group consisting of pyridinyl, 1,3-dihydro-indol-2-one, 1H-benzimidazolyl, 3H-pyrimidin-4-one, 1H-pyrazolyl, isoxazolyl and 4H-benzo[1,4]oxazin-3-one, which phenyl or heteroaryl is optionally substituted with 1 to 3 substituents selected from the group consisting of lower-alkyl, hydroxy, halogen and NR15R16, wherein R14 and R15 are as defined in claim 1.
23. The compound according to claim 1, wherein R11 is 2-methyl-3H-pyrimidin-4-one, 5-methyl-isoxazol-3-yl, 1H-pyrazol-3-yl, 6-amino-pyridin-3-yl, 1,3-dihydro-indol-2-one, 2-amino-pyridin-4-yl, 4H-benzo[1,4]oxazin-3-one, 1H-benzimidazol-5-yl, 3-(N-acetamide)-4-fluoro-phenyl or 2-hydroxy-pyridin-4-yl.
24. The compound according to claim 1, wherein R12 is hydrogen.
25. The compound according to claim 1, wherein R13 is lower-alkyl.
26. The compound according to claim 1, wherein R14 is NR19R20, wherein R19 and R20 are as defined in claim 1.
27. The compound according to claim 1, wherein R14 is lower-alkyl.
28. The compound according to claim 1, wherein R15 and R16 independently from each other are hydrogen, lower-alkyl, lower-alkyl-carbonyl, lower-alkyl-SO2, lower-alkanyl-oxy-carbonyl or lower-alkyl-NH-carbonyl; or NR15R16 is a heterocyclyl selected from the group consisting of morpholinyl, thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, piperidin-2-one, piperazin-2-one, piperazinyl and pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl.
29. The compound according to claim 1, wherein R15 and R16 independently from each other are hydrogen, lower-alkyl-carbonyl or lower-alkyl-SO2.
30. The compound according to claim 1, wherein NR15R16 is a heterocyclyl selected from the group consisting of 1,1-dioxo-isothiazolidinyl, pyrrolidin-2-one, imidazolidine-2,4-dione, 2,4-dihydro[1,2,4]triazol-3-one, pyrrolidine-2,5-dione, azetidin-2-one and 1,3-dihydro-imidazol-2-one, which heterocyclyl is optionally substituted with hydroxy-lower-alkyl or lower-alkyl-carbonyl.
31. The compound according to claim 1, wherein R17 and R18 independently from each other are hydrogen or lower-alkyl; or NR17R18 is morpholinyl.
32. The compound according to claim 1, wherein R19 and R20 independently from each other are hydrogen, lower-alkyl, cycloalkyl, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of morpholinyl or pyrrolidinyl, which heterocyclyl is optionally substituted with hydroxy or lower-alkyl-S(O2).
33. The compound according to claim 1, wherein R19 and R20 are hydrogen.
34. The compound according to claim 1, wherein R19 and R20 independently from each other are (lower-alkyl)2N-lower-alkyl, pyridinyl-lower-alkyl or cyano-lower-alkyl; or NR19R20 is a heterocyclyl selected from the group consisting of piperidinyl, piperazinyl, piperazin-2-one, thiazolidinyl, thiomorpholinyl, 1,3,8-triaza-spiro[4,5]decane-2,4-dione and spiro(1-phtalan)-piperidine-4-yl, which heterocyclyl is optionally substituted with hydroxy, lower-alkyl-S(O2), lower-alkyl, lower-alkyl-carbonyl, carboxy, carbamoyl, lower-alkoxy-carbonyl, cyano, phenyl, pyridinyl or lower-alkoxy.
35. The compound according to claim 1, which are R-isomers and which are characterised by formula (Ia)
36. The compound according to claim 1, selected from the group consisting of (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-3-(2-{2-[3-(4-Methoxy-phenyl)[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-oxo-ethoxy)benzonitrile, (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-propan-1-one, (R)-1-{2-[3-(4-Bromo-phenyl)[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-2-(4-Hydroxy-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-(4-Chloro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-(4-Hydroxymnethyl-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-(3-Chloro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-(4-Fluoro-phenoxy)-1-{2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Methane-sulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-2-(4-Fluoro-phenoxy)-1-[2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid methyl ester, (R)-1-{2-[3-(3-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-2-Phenoxy-1-[2-(3-pyrazin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-ethanone, (R)-1-(2-{3-[4-(Morpholine-4-sulfonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(3-Hydroxymethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid allyl ester, (R)-1-{2-[3-(4-Imidazol-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[3-(4-trifluoromethanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-Phenoxy-1-{2-[3-(4-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-1-{2-[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide, (R)-1-{2-[3-(3-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Methoxy-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-N-(2-Hydroxy-ethyl)-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl -benzenesulfonamide, (R)-N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, (R)-1-{2-[3-(2-Morpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[3-(3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-2-Phenoxy-1-{2-[3-(2-thiomorpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-1-{2-[3-(2-Diethylamino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethyl ester, (R)-1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-{2-[3-(2-Imidazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-piperidin-2-one, (R)-1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[4-(2-Methyl-imidazol-1-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[3-(2-pyrazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, (R)-4-(5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-piperazin-2-one, (R)-2-Phenoxy-1-(2-{3-[4-(1H-tetrazol-5-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-ethanone, (R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Indazol-6-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Fluoro-3-trifluoromethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, (R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-(2-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide, (R)-1-{2-[3-(6-Benzyloxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid ethyl ester, (R)-4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, (R)-2-Phenoxy-1-[2-(5-phenyl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone, (R)-1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(3,4-Dimethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(3,4-Dichloro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxyethanone, (R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-ethanone, (R)-1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(3-Nitro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid methyl ester, (R)-1-{2-[5-(4-Fluoro-3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one, 1-{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone, 1-{3-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone, 4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 1-(3-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-morpholin-4-yl)-2-phenoxy-ethanone, N-(4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide, 1-{3-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-morpholin-4-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{3-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-morpholin-4-yl}-ethanone, (R)-4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, 1-{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-thiomorpholin-4-yl}-2-phenoxy-ethanone, 1-{3-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-thiomorpholin-4-yl}-2-phenoxy-ethanone, 4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 2-Phenoxy-1-[3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-thiomorpholin-4-yl]-ethanone, 1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, N-(5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide, 1-{2-[3-(2-Imidazol-1-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 1-{2-[3-(4-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-ethanone, 1-{2-[3-(2,4-Dichloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[2-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-ethanone, 2-Phenoxy-1-[2-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperazin-2-yl]-ethanone, 1-{2-[3-(4-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(3-Hydroxymethyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(4-Diethylamino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-(2-{3-[4-(Morpholine-4-sulfonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 1-{2-[3-(4-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, N-(4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide, 4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid allyl ester, 1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(4-Methoxy-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[3-(4-Chloro-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 3-Fluoro-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid methyl ester, 4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethyl ester, 2-Phenoxy-1-{2-[3-(4-piperidin-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone, 1-{2-[3-(4-Morpholin-4-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-(2-{3-[4-(2-Methyl-imidazol-1-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, 1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, 4-(5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-piperazin-2-one, 1-{2-[3-(6-Imidazol-1-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, 2-Phenoxy-1-{2-[3-(4-pyrrol-1-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone, 2-Phenoxy-1-{2-[3-(4-trifluoromethanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone, 1-{2-[3-(2-Morpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{2-[3-(2-thiomorpholin-4-yl-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-ethanone, 1-(2-{3-[6-(3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, (R)-1-{2-[3-(6-Methoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(6-Morpholin-4-yl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-2-trifluoromethyl-phenyl)-acetamide, (R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Methyl-3-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Morpholin-4-yl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-(2-{3-[4-(3H-Imidazol-4-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[6-(3-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[6-(4-Acetyl-piperazin-1-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide hydrochloride, (R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone hydrochloride, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one, (R)-1-(2-{3-[6-(1,1-Dioxo-thiomorpholin-4-yl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone hydrochloride, (R)-1-{2-[3-(3-Nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, 1-{4-Acetyl-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{4-Acetyl-2-[3-(4-methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 4-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzenesulfonamide, 1-[4-Acetyl-2-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperazin-1-yl]-2-phenoxy-ethanone, 1-{4-Methanesulfonyl-2-[3-(4-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone, 1-{2-[5-(4-Fluoro-3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone, 2-Phenoxy-1-[2-(5-p-tolyl-2H-[1,2,4]triazol-3-yl)-piperazin-1-yl]-ethanone, 2-Phenoxy-1-{2-[5-(4-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-ethanone, 1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(3,4-Dimethoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(3,4-Dichloro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 1-{2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-1-{2-[3-(1H-Indazol-5yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-5-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, (R)-5-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one, (R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{4-Methyl-2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(4-Methoxy-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(4-Methanesulfonyl-phenyl)-2H-[1,2,4]triazol-3-yl]-4-methyl-piperazin-1-yl}-2-phenoxy-ethanone, (R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid methyl ester, (R)-N-(3-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, (R)-N-(3-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-methanesulfonamide, (R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, (R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid, (R)-2-Fluoro-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid, 3-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, 3-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, 4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, 4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3-yl]-[1,2,4]oxadiazol-4-yl}-benzamide, 3-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, 4-{5-[4-Acetyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzoic acid, (R)-4-{5-[4-Methyl-1-(2-phenoxy-acetyl)-piperazin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoic acid, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinic acid, 1-(2-{3-[4-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[4-(3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-N,N-Diethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N,N-Dimethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Ethyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Cyclopropyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-(2-Hydroxy-ethyl)-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-(2-Methoxy-ethyl)-N-methyl-4-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N,N-Dimethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Ethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Cyclopropyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-(2-Hydroxy-ethyl)-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-(2-Methoxy-ethyl)-N-methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-1-(2-{3-[3-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[3-(3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-N,N-Diethyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid methylamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid dimethylamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid ethylamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid diethylamide, (R)-1-(2-{3-[2-(Morpholine-4-carbonyl)-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-1-(2-{3-[2-(3-Methanesulfonyl-pyrrolidine-1-carbonyl)-pyridin-4-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid methylamide, (R)-N-Methyl-3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, 1N,N-Diethyl-4-5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, 1-(2-{3-[4-(Morpholine-4-carbonyl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperazin-1-yl)-2-phenoxy-ethanone, N-Methyl-4-{5-[1-(2-phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-N-Methyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-Ethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-Diethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-Diethyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-(2-Hydroxy-ethyl)-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-(2-Methoxy-ethyl)-N-methyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-Cyclopropyl-5-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-1-(2-{3-[5-(3-Hydroxy-pyrrolidine-1-carbonyl)-pyridin-3-yl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, (R)-4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridine-2-carboxylic acid amide, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, 4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, 4-{5-[4-(2-Phenoxy-acetyl)-thiomorpholin-3yl]-[1,2,4]oxadiazol-3yl}-benzamide, 4-{5-[1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, 5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-1-{2-[3-(3-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(4-Amino-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[5-(3-Amino-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide, (R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide, (R)-N-(5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-pyridin-2-yl)-acetamide, (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-methanesulfonamide, (R)-N-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-methane-sulfonamide, (R)-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-carbamic acid allyl ester, (R)-(4-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-carbamic acid allyl ester, (R)-N-(3-[5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl]-phenyl)-methanesulfonamide, (R)-1-Ethyl-3-(3-{5-[1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-urea, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzonitrile, and (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinonitrile, and pharmaceutically acceptable salts and esters thereof.
37. The compound according to claim 1, selected from the group consisting of (R)-1-{2-[3-(1H-Indazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Indazol-6-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-6-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-benzoimidazol-2-one, (R)-5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, (R)-1-{2-[3-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-4-{5-[4-(2-Phenoxy-acetyl)-morpholin-3-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, (R)-1-{2-[5-(4-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, (R)-2-Phenoxy-1-{2-[5-(3-trifluoromethyl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-ethanone, (R)-1-{2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (R)-3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-benzamide, 5-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-nicotinamide, (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, and (R)-N-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-methanesulfonamide, and pharmaceutically acceptable salts and esters thereof.
38. The compound according to claim 1, selected from the group consisting of 1-{(R)-2-[3-(2-Methyl-1H-benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[3-(3-Hydroxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 4-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyridin-2-one, 1-{(R)-2-[3-(4-Hydroxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenylboronic acid, 4-(2-Oxo-2-{(R)-2-[3-(2-oxo-2,3-dihydro-1H-indol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethoxy)-benzonitrile, 4-(2-{(R)-2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-oxo-ethoxy)-benzonitrile, 2-Methyl-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-3H-pyrimidin-4-one, 1-[(R)-2-(3-Furan-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-[(R)-2-(3-Imidazo[1,2-a]pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-{(R)-2-[3-(4-Methyl-[1,2,3]thiadiazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[3-(2,5-Dimethyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, 1-{(R)-2-[3-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1H-pyrimidine-2,4-dione, 1-{(R)-2-[3-(6-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-[(R)-2-(3-Imidazo[1,2-a]pyridin-6-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-4H-benzo[1,4]oxazin-3-one, 6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 1-((R)-2-{3-[3-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-phenyl]-[1,2,4]oxadiazol-5-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-pyrrolidin-2-one, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-imidazolidine-2,4-dione, 4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one, 1-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-pyrrolidine-2,5-dione, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one, 1-{(R)-2-[5-(1H-Indazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(1H-Indol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(3H-Benzotriazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-benzoimidazol-2-one, 1-{(R)-2-[5-(2-Methyl-1H-benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 5-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-3H-[1,3,4]oxadiazol-2-one, 1-{(R)-2-[5-(3-[1,3,4]Oxadiazol-2-yl-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenylboronic acid, 6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one, 1-[(R)-2-(5-Imidazo[1,2-a]pyridin-6-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-{(R)-2-[5-(6-Amino-pyridin-3-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[(R)-2-(5-pyridin-3-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone, 1-{(R)-2-[5-(3,5-Dimethyl-isoxazol-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[(R)-2-(5-thiophen-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone, 2-Phenoxy-1-[(R)-2-(5-pyrimidin-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone, 1-{(R)-2-[5-(4-Methyl-oxazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[(R)-2-(5-pyrazin-2-yl-2H-[1,2,4]triazol-3-yl)-piperidin-1-yl]-ethanone, 1-{(R)-2-[5-(2-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(3,5-Difluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2-Methyl-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(3-Fluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(3,4-Difluoro-phenyl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,4-dihydro-benzo[d][1,3]oxazin-2-one, 7-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-3,4-dihydro-1H-quinazolin-2-one, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-imidazolidine-2,4-dione, 1-{(R)-3-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone, 1-{(R)-3-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-2-phenoxy-ethanone, 1-{(R)-2-[3-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperazin-2-yl]-[1,2,4]oxadiazol-3-yl}-1,3-dihydro-indol-2-one, 1-{(R)-2-[3-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-5-yl]-piperazin-1-yl}-2-phenoxy-ethanone, (3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetic acid, 2-Phenoxy-1-((R)-2-{5-[3-(piperidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone, 1-((R)-2-{5-[3-(Morpholine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-((R)-2-{5-[3-(4-Methyl-piperazine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperazin-2-one, N-(2-Methoxy-ethyl)-N-methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, 1-((R)-2-{5-[3-(4-Acetyl-piperazine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperidine-4-carboxylic acid, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperidine-4-carboxylic acid amide, 2-Phenoxy-1-((R)-2-{5-[3-(thiazolidine-3-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone, N-(2-Dimethylamino-ethyl)-N-methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, 2-Phenoxy-1-((R)-2-{5-[3-(thiomorpholine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone, 4-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-piperazine-1-carboxylic acid ethyl ester, N-(2-Hydroxy-ethyl)-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, N-Methyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-N-(2-pyridin-2-yl-ethyl)-benzamide, N-(2-Cyano-ethyl)-N-cyclopropyl-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzamide, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-4-phenyl-piperidine-4-carbonitrile, 1-((R)-2-{5-[3-(4-Hydroxy-piperidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 8-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-benzoyl)-1,3,8-triaza-spiro[4.5]decane-2,4-dione, 1-(2-{5-[3-(Spiro(1-Phtalan)-piperidine-4-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 2-Phenoxy-1-((R)-2-{5-[3-(3-pyridin-4-yl-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-ethanone, 1-((R)-2-{5-[3-(3-Methanesulfonyl-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-((R)-2-{5-[3-((S)-3-Ethoxy-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-((R)-2-{5-[3-((S)-3-Hydroxy-pyrrolidine-1-carbonyl)-phenyl]-2H-[1,2,4]triazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-nicotinamide, 2-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenoxy)-acetamide, N-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide, N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-phenyl)-acetamide, N-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-propionamide, N-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-isobutyramide, N-(4-Fluoro-3-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, N-(3-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, N-(4-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-pyridin-2-yl)-acetamide, 1-(3-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-azetidin-2-one, 1-(3-{5-[1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-pyrrolidine-2,5-dione, 2-Phenoxy-1-[(R)-2-(5-pyridazin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone, 4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-benzonitrile, 1-{(R)-2-[5-(3-Amino-pyrazin-2-yi)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-benzonitrile, 1-{(R)-2-[5-(2-Hydroxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(5-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2-Hydroxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2-Hydroxy-6-methyl-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(4-Hydroxy-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2-Amino-5-chloro-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[(R)-2-(5-pyrazin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone, 2-Phenoxy-1-{(R)-2-[5-(4-[1,2,4]triazol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone, 2-Phenoxy-1-{(R)-2-[5-(4-tetrazol-1-yl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone, 1-{(R)-2-[5-(1H-Benzoimidazol-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(4-Acetyl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(6-Hydroxy-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(5-Methyl-pyrazin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-[(R)-2-(5-quinoxalin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-ethanone, 1-{(R)-2-[5-(3-Methanesulfonyl-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(6-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-[(R)-2-(5-Benzothiazol-6-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 2-Phenoxy-1-{(R)-2-[5-(2,4,5-trifluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone, 2-Phenoxy-1-{(R)-2-[5-(6-trifluoromethyl-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone, 1-[(R)-2-(5-Benzo[1,2,3]thiadiazol-5-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-[(R)-2-(5-[1,8]Naphthyridin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-[(R)-2-(5-[1,6]Naphthyridin-2-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-[(R)-2-(5-Cinnolin-4-yl-[1,2,4]oxadiazol-3-yl)-piperidin-1-yl]-2-phenoxy-ethanone, 1-{(R)-2-[5-(1H-Benzotriazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(3,6-Dichloro-pyridazin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-4H-benzo[1,4]oxazin-3-one, 1-{(R)-2-[5-(3H-Imidazo[4,5-b]pyridin-6-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, N-(4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-pyridin-2-yl)-acetamide, 1-{(R)-2-[5-(6-Chloro-3-hydroxy-pyridazin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-1,4-dihydro-quinoxaline-2,3-dione, 1-{(R)-2-[5-(6-Hydroxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 7-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-3,4-dihydro-1H-quinoxalin-2-one, 1-{(R)-2-[5-(6-Amino-pyridin-2-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 6-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-nicotinonitrile, 5-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-pyridine-2-carbonitrile, 4-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-1,2-dihydro-indazol-3-one, 1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(6-Hydroxy-pyrimidin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 4-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one, 1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-imidazolidine-2,4-dione, 1-((R)-2-{5-[3-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-phenyl]-[1,2,4]oxadiazol-3-yl}-piperidin-1-yl)-2-phenoxy-ethanone, 1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-pyrrolidin-2-one, 1-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-1,3-dihydro-imidazol-2-one, 3-(3-{3-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-5-yl}-phenyl)-imidazolidine-2,4-dione, 1-{(R)-2-[5-(1-Methyl-1H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{(R)-2-[5-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-ethanone, 1-{(R)-2-[5-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(2,5-Dimethyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(5-Methyl-2H-pyrazol-3-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, and 1-{(R)-2-[5-(3-Methyl-isoxazol-5-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, and pharmaceutically acceptable salts and esters thereof.
39. The compound according to claim 1, selected from the group consisting of 2-Methyl-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-[1,2,4]oxadiazol-3-yl}-3H-pyrimidin-4-one, 1-{(R)-2-[3-(5-Methyl-isoxazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 2-Phenoxy-1-{(R)-2-[3-(1H-pyrazol-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-ethanone, 1-{(R)-2-[3-(6-Amino-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 5-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-1,3-dihydro-indol-2-one, 1-{(R)-2-[5-(2-Amino-pyridin-4-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 6-{5-[(R)-1-(2-Phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-4H-benzo[1,4]oxazin-3-one, 1-{(R)-2-[5-(6-Amino-pyridin-3-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, 1-{(R)-2-[5-(1H-Benzoimidazol-5-yl)-2H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, N-(2-Fluoro-5-{5-[(R)-1-(2-phenoxy-acetyl)-piperidin-2-yl]-1H-[1,2,4]triazol-3-yl}-phenyl)-acetamide, and 1-{(R)-2-[5-(2-Hydroxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-2-phenoxy-ethanone, and pharmaceutically acceptable salts and esters thereof.
40. A process for the manufacture of a compound according to claim 1, comprising the step of reacting a compound of formula (II)
41. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier and/or adjuvant.
42. A method for the treatment of diseases which are modulated by L-CPT1 inhibitors, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a human being or animal in need thereof.
43. The method according to claim 42, wherein said diseases are hyperglycemia, glucose tolerance disorders, diabetes and associated pathologies, non insulin dependent diabetes mellitus, obesity, hypertension, insulin resistance syndrome, metabolic syndrome, hyperlipidemia, hypercholesterolemia, fatty liver disease, atherosclerosis, congestive heart failure and renal failure.

Priority Claims (1)

Number	Date	Country	Kind
05111560.8	Dec 2005	EP	regional

Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)